Document_and_Entity_Informatio
Document and Entity Information (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Jan. 31, 2014 | Jun. 30, 2013 | |
Document and Entity Information | ' | ' | ' |
Entity Registrant Name | 'ABBOTT LABORATORIES | ' | ' |
Entity Central Index Key | '0000001800 | ' | ' |
Document Type | '10-K | ' | ' |
Document Period End Date | 31-Dec-13 | ' | ' |
Amendment Flag | 'false | ' | ' |
Current Fiscal Year End Date | '--12-31 | ' | ' |
Entity Well-known Seasoned Issuer | 'Yes | ' | ' |
Entity Voluntary Filers | 'No | ' | ' |
Entity Current Reporting Status | 'Yes | ' | ' |
Entity Filer Category | 'Large Accelerated Filer | ' | ' |
Entity Public Float | ' | ' | $52,878,980,567 |
Entity Common Stock, Shares Outstanding | ' | 1,543,070,300 | ' |
Document Fiscal Year Focus | '2013 | ' | ' |
Document Fiscal Period Focus | 'FY | ' | ' |
Consolidated_Statement_of_Earn
Consolidated Statement of Earnings (USD $) | 12 Months Ended | ||
In Millions, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Consolidated Statement of Earnings | ' | ' | ' |
Net Sales | $21,848 | $21,494 | $21,407 |
Cost of products sold | 10,040 | 9,817 | 10,017 |
Amortization of intangible assets | 791 | 795 | 884 |
Research and development | 1,452 | 1,544 | 1,512 |
Selling, general and administrative | 6,936 | 7,444 | 7,365 |
Total Operating Cost and Expenses | 19,219 | 19,600 | 19,778 |
Operating Earnings | 2,629 | 1,894 | 1,629 |
Interest expense | 157 | 347 | 359 |
Interest income | -67 | -59 | -65 |
Net loss on extinguishment of debt | ' | 1,351 | ' |
Net foreign exchange (gain) loss | 50 | -25 | -20 |
Other (income) expense, net | -32 | -25 | 119 |
Earnings from Continuing Operations Before Taxes | 2,521 | 305 | 1,236 |
Taxes on Earnings from Continuing Operations | 138 | -274 | 110 |
Earnings from Continuing Operations | 2,383 | 579 | 1,126 |
Less: Earnings from Discontinued Operations, net of tax | 193 | 5,384 | 3,602 |
Net Earnings | $2,576 | $5,963 | $4,728 |
Basic Earnings Per Common Share | ' | ' | ' |
Continuing Operations (in dollars per share) | $1.52 | $0.36 | $0.72 |
Discontinued Operations (in dollars per share) | $0.12 | $3.40 | $2.31 |
Net Earnings (in dollars per share) | $1.64 | $3.76 | $3.03 |
Diluted Earnings Per Common Share | ' | ' | ' |
Continuing Operations (in dollars per share) | $1.50 | $0.36 | $0.72 |
Discontinued Operations (in dollars per share) | $0.12 | $3.36 | $2.29 |
Net Earnings (in dollars per share) | $1.62 | $3.72 | $3.01 |
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,558 | 1,575 | 1,557 |
Dilutive Common Stock Options and Awards (in shares) | 16 | 17 | 10 |
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options and Awards (in shares) | 1,574 | 1,592 | 1,567 |
Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 1 | 1 | 27 |
Consolidated_Statement_of_Comp
Consolidated Statement of Comprehensive Income (USD $) | 3 Months Ended | 12 Months Ended | |||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Consolidated Statement of Comprehensive Income | ' | ' | ' | ' | ' |
Net Earnings | $589 | $1,053 | $2,576 | $5,963 | $4,728 |
Less: Earnings from Discontinued Operations, net of tax | ' | ' | 193 | 5,384 | 3,602 |
Earnings from Continuing Operations | 589 | -522 | 2,383 | 579 | 1,126 |
Foreign currency translation (loss) adjustments | ' | ' | -239 | -181 | -523 |
Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $393 in 2013, $(253) in 2012 and $(380) in 2011 | ' | ' | 882 | -715 | -503 |
Unrealized (losses) gains on marketable equity securities, net of taxes of $(10) in 2013, $11 in 2012 and $(1) in 2011 | ' | ' | -18 | 19 | -2 |
Net adjustments for derivative instruments designated as cash flow hedges, net of taxes of $(13) in 2013, $(21) in 2012 and $28 in 2011 | ' | ' | -53 | -91 | 111 |
Other Comprehensive Income (Loss) from Continuing Operations | ' | ' | 572 | -968 | -917 |
Comprehensive Income (Loss) from Continuing Operations | ' | ' | 2,955 | -389 | 209 |
Comprehensive Income from Discontinued Operations | ' | ' | 193 | 5,355 | 3,289 |
Comprehensive Income | ' | ' | 3,148 | 4,966 | 3,498 |
Supplemental Accumulated Other Comprehensive Income Information, net of tax as of December 31: | ' | ' | ' | ' | ' |
Cumulative foreign currency translation loss adjustments | -718 | -79 | -718 | -79 | -72 |
Net actuarial (losses) and prior service (cost) and credits | -1,312 | -3,596 | -1,312 | -3,596 | -2,731 |
Cumulative unrealized gains on marketable equity securities | 13 | 31 | 13 | 31 | 38 |
Cumulative gains on derivative instruments designated as cash flow hedges | $5 | $50 | $5 | $50 | $168 |
Consolidated_Statement_of_Comp1
Consolidated Statement of Comprehensive Income (Parenthetical) (USD $) | 12 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Consolidated Statement of Comprehensive Income | ' | ' | ' |
Net actuarial (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, taxes | $393 | ($253) | ($380) |
Unrealized (losses) gains on marketable equity securities, taxes | -10 | 11 | -1 |
Net adjustments for derivative instruments designated as cash flow hedges, taxes | ($13) | ($21) | $28 |
Consolidated_Statement_of_Cash
Consolidated Statement of Cash Flows (USD $) | 12 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Cash Flow From (Used in) Operating Activities: | ' | ' | ' |
Net earnings | $2,576 | $5,963 | $4,728 |
Adjustments to reconcile earnings to net cash from operating activities - | ' | ' | ' |
Depreciation | 928 | 1,363 | 1,395 |
Amortization of intangible assets | 791 | 1,419 | 1,649 |
Share-based compensation | 262 | 433 | 383 |
Acquired in-process and collaborations research and development | ' | 288 | 672 |
Investing and financing (gains) losses, net | 4 | 356 | 142 |
Net loss on extinguishment of debt | ' | 1,351 | ' |
Trade receivables | -113 | 36 | -670 |
Inventories | -154 | -417 | -130 |
Prepaid expenses and other assets | 131 | -35 | 413 |
Trade accounts payable and other liabilities | -436 | -134 | 1,790 |
Income taxes | -665 | -1,309 | -1,402 |
Net Cash From Operating Activities | 3,324 | 9,314 | 8,970 |
Cash Flow From (Used in) Investing Activities: | ' | ' | ' |
Acquisitions of property and equipment | -1,145 | -1,795 | -1,491 |
Acquisitions of businesses and technologies, net of cash acquired | -580 | -706 | -273 |
Purchases of investment securities | -10,064 | -11,998 | -5,110 |
Proceeds from sales of investment securities | 7,839 | 8,936 | 5,649 |
Release of restricted funds | ' | ' | 1,870 |
Other | 21 | 3 | 16 |
Net Cash (Used in) From Investing Activities | -3,929 | -5,560 | 661 |
Cash Flow From (Used in) Financing Activities: | ' | ' | ' |
Proceeds from issuance of (repayments of) short-term debt and other | 2,086 | 784 | -1,965 |
Proceeds from issuance of long-term debt and debt with maturities over 3 months | 9 | 14,700 | 1,000 |
Repayments of long-term debt and debt with maturities over 3 months | -303 | -11,071 | -3,012 |
Acquisition and contingent consideration payments related to business acquisitions | -495 | -521 | -400 |
Transfer of cash and cash equivalents to AbbVie Inc. | -5,901 | ' | ' |
Purchases of common shares | -1,605 | -2,364 | -77 |
Proceeds from stock options exercised, including income tax benefit | 395 | 1,850 | 969 |
Dividends paid | -882 | -3,183 | -2,938 |
Net Cash (Used in) From Financing Activities | -6,696 | 195 | -6,423 |
Effect of exchange rate changes on cash and cash equivalents | -26 | 40 | -43 |
Net (Decrease) Increase in Cash and Cash Equivalents | -7,327 | 3,989 | 3,165 |
Cash and Cash Equivalents, Beginning of Year | 10,802 | 6,813 | 3,648 |
Cash and Cash Equivalents, End of Year | 3,475 | 10,802 | 6,813 |
Supplemental Cash Flow Information: | ' | ' | ' |
Income taxes paid | 1,039 | 1,367 | 1,782 |
Interest paid | $148 | $576 | $545 |
Consolidated_Balance_Sheet
Consolidated Balance Sheet (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Millions, unless otherwise specified | ||
Current Assets: | ' | ' |
Cash and cash equivalents | $3,475 | $10,802 |
Investments, primarily bank time deposits and U.S. treasury bills | 4,623 | 4,372 |
Trade receivables, less allowances of - 2013: $312; 2012: $406 | 3,986 | 7,613 |
Inventories: | ' | ' |
Finished products | 1,866 | 2,346 |
Work in process | 349 | 629 |
Materials | 478 | 818 |
Total inventories | 2,693 | 3,793 |
Deferred income taxes | 2,528 | 2,986 |
Other prepaid expenses and receivables | 1,504 | 1,757 |
Current assets held for disposition | 438 | ' |
Total Current Assets | 19,247 | 31,323 |
Investments | 119 | 274 |
Property and Equipment, at Cost: | ' | ' |
Land | 502 | 605 |
Buildings | 2,994 | 4,259 |
Equipment | 8,506 | 13,111 |
Construction in progress | 868 | 954 |
Property and Equipment, at Cost | 12,870 | 18,929 |
Less: accumulated depreciation and amortization | 6,965 | 10,866 |
Net Property and Equipment | 5,905 | 8,063 |
Intangible Assets, net of amortization | 5,735 | 8,588 |
Goodwill | 9,772 | 15,774 |
Deferred Income Taxes and Other Assets | 2,109 | 3,213 |
Non-current Assets Held for Disposition | 66 | ' |
Total Assets | 42,953 | 67,235 |
Current Liabilities: | ' | ' |
Short-term borrowings | 3,164 | 2,082 |
Trade accounts payable | 1,026 | 1,797 |
Salaries, wages and commissions | 906 | 1,428 |
Other accrued liabilities | 3,500 | 6,788 |
Dividends payable | 341 | 221 |
Income taxes payable | 175 | 655 |
Current portion of long-term debt | 9 | 309 |
Current liabilities held for disposition | 386 | ' |
Total Current Liabilities | 9,507 | 13,280 |
Long-term Debt | 3,388 | 18,085 |
Post-employment Obligations and Other Long-term Liabilities | 4,784 | 9,057 |
Non-current Liabilities Held for Disposition | 7 | ' |
Commitments and Contingencies | 'Â Â | 'Â Â |
Shareholders' Investment: | ' | ' |
Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | 'Â Â | 'Â Â |
Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2013: 1,685,827,096; 2012: 1,675,930,484 | 12,048 | 11,755 |
Common shares held in treasury, at cost - Shares: 2013: 137,728,810; 2012: 99,262,992 | -6,844 | -5,591 |
Earnings employed in the business | 21,979 | 24,151 |
Accumulated other comprehensive income (loss) | -2,012 | -3,594 |
Total Abbott Shareholders' Investment | 25,171 | 26,721 |
Noncontrolling Interests in Subsidiaries | 96 | 92 |
Total Shareholders' Investment | 25,267 | 26,813 |
Total Liabilities and Shareholders' Investment | $42,953 | $67,235 |
Consolidated_Balance_Sheet_Par
Consolidated Balance Sheet (Parenthetical) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Millions, except Share data, unless otherwise specified | ||
Consolidated Balance Sheet | ' | ' |
Trade receivables, allowances (in dollars) | $312 | $406 |
Preferred shares, par value (in dollars per share) | $1 | $1 |
Preferred shares, Authorized shares | 1,000,000 | 1,000,000 |
Preferred shares, issued shares | 0 | 0 |
Common shares, Authorized shares | 2,400,000,000 | 2,400,000,000 |
Common shares, Issued shares | 1,685,827,096 | 1,675,930,484 |
Common shares held in treasury, shares | 137,728,810 | 99,262,992 |
Consolidated_Statement_of_Shar
Consolidated Statement of Shareholders' Investment (USD $) | 3 Months Ended | 12 Months Ended | |||||
In Millions, unless otherwise specified | Dec. 31, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Increase (Decrease) in Shareholders' Investment | ' | ' | ' | ' | ' | ' | ' |
Beginning of Year | ' | $26,813 | ' | ' | $26,813 | ' | ' |
Net earnings | 589 | 545 | 1,053 | 1,242 | 2,576 | 5,963 | 4,728 |
Separation of AbbVie Inc. | ' | ' | ' | ' | 1,010 | ' | ' |
Other comprehensive income (loss) | ' | ' | ' | ' | 572 | -968 | -917 |
End of Year | 25,267 | ' | 26,813 | ' | 25,267 | 26,813 | ' |
Common Shares: | ' | ' | ' | ' | ' | ' | ' |
Increase (Decrease) in Shareholders' Investment | ' | ' | ' | ' | ' | ' | ' |
Beginning of Year | ' | 11,755 | ' | 9,817 | 11,755 | 9,817 | 8,745 |
Issued under incentive stock programs | ' | ' | ' | ' | 393 | 1,854 | 954 |
Share-based compensation | ' | ' | ' | ' | 261 | 435 | 382 |
Issuance of restricted stock awards | ' | ' | ' | ' | -361 | -351 | -264 |
End of Year | 12,048 | ' | 11,755 | ' | 12,048 | 11,755 | 9,817 |
Common Shares Held in Treasury: | ' | ' | ' | ' | ' | ' | ' |
Increase (Decrease) in Shareholders' Investment | ' | ' | ' | ' | ' | ' | ' |
Beginning of Year | ' | -5,591 | ' | -3,688 | -5,591 | -3,688 | -3,917 |
Issued under incentive stock programs | ' | ' | ' | ' | 310 | 363 | 250 |
Purchased | ' | ' | ' | ' | -1,563 | -2,266 | -21 |
End of Year | -6,844 | ' | -5,591 | ' | -6,844 | -5,591 | -3,688 |
Earnings Employed in the Business: | ' | ' | ' | ' | ' | ' | ' |
Increase (Decrease) in Shareholders' Investment | ' | ' | ' | ' | ' | ' | ' |
Beginning of Year | ' | 24,151 | ' | 20,907 | 24,151 | 20,907 | 19,216 |
Net earnings | ' | ' | ' | ' | 2,576 | 5,963 | 4,728 |
Separation of AbbVie Inc. | ' | ' | ' | ' | -3,735 | ' | ' |
Cash dividends declared on common shares (per share - 2013: $0.64; 2012: $1.67; 2011: $1.92) | ' | ' | ' | ' | -1,002 | -2,650 | -3,012 |
Effect of common and treasury share transactions | ' | ' | ' | ' | -11 | -69 | -25 |
End of Year | 21,979 | ' | 24,151 | ' | 21,979 | 24,151 | 20,907 |
Accumulated Other Comprehensive Income (Loss): | ' | ' | ' | ' | ' | ' | ' |
Increase (Decrease) in Shareholders' Investment | ' | ' | ' | ' | ' | ' | ' |
Beginning of Year | ' | -3,594 | ' | -2,597 | -3,594 | -2,597 | -1,367 |
Separation of AbbVie Inc. | ' | ' | ' | ' | 1,010 | ' | ' |
Other comprehensive income (loss) | ' | ' | ' | ' | 572 | -997 | -1,230 |
End of Year | -2,012 | ' | -3,594 | ' | -2,012 | -3,594 | -2,597 |
Noncontrolling Interests in Subsidiaries: | ' | ' | ' | ' | ' | ' | ' |
Increase (Decrease) in Shareholders' Investment | ' | ' | ' | ' | ' | ' | ' |
Beginning of Year | ' | 92 | ' | 86 | 92 | 86 | 88 |
Noncontrolling Interests' share of income, business combinations, net of distributions and share repurchases | ' | ' | ' | ' | 4 | 6 | -2 |
End of Year | $96 | ' | $92 | ' | $96 | $92 | $86 |
Consolidated_Statement_of_Shar1
Consolidated Statement of Shareholders' Investment (Parenthetical) (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Common Shares: | ' | ' | ' |
Increase (Decrease) in Shareholders' Investment | ' | ' | ' |
Balance Beginning of Year (in shares) | 1,675,930,484 | 1,638,870,201 | 1,619,689,876 |
Issued under incentive stock programs (in shares) | 9,896,612 | 37,060,283 | 19,180,325 |
Balance End of Year (in shares) | 1,685,827,096 | 1,675,930,484 | 1,638,870,201 |
Common Shares Held in Treasury: | ' | ' | ' |
Increase (Decrease) in Shareholders' Investment | ' | ' | ' |
Balance Beginning of Year (in shares) | 99,262,992 | 68,491,382 | 72,705,928 |
Issued under incentive stock programs (in shares) | 5,718,575 | 6,691,748 | 4,638,841 |
Purchased: treasury shares (in shares) | 44,184,393 | 37,463,358 | 424,295 |
Balance End of Year (in shares) | 137,728,810 | 99,262,992 | 68,491,382 |
Earnings Employed in the Business: | ' | ' | ' |
Increase (Decrease) in Shareholders' Investment | ' | ' | ' |
Cash Dividends Declared Per Common Share (in dollars per share) | 0.64 | 1.67 | 1.92 |
Summary_of_Significant_Account
Summary of Significant Accounting Policies | 12 Months Ended | ||
Dec. 31, 2013 | |||
Summary of Significant Accounting Policies | ' | ||
Summary of Significant Accounting Policies | ' | ||
Note 1 — Summary of Significant Accounting Policies | |||
        NATURE OF BUSINESS — Abbott's principal business is the discovery, development, manufacture and sale of a broad line of health care products. | |||
        CHANGES IN PRESENTATION DUE TO ABBVIE SEPARATION — On January 1, 2013, Abbott completed the separation of AbbVie Inc., which was formed to hold Abbott's research-based proprietary pharmaceuticals business. The historical operating results of the research-based proprietary pharmaceuticals business prior to separation are excluded from Earnings from Continuing Operations and are presented on the Earnings from Discontinued Operations line in Abbott's Consolidated Statement of Earnings. The assets, liabilities, and cash flows of the research-based proprietary pharmaceuticals business are included in Abbott's Consolidated Balance Sheet and its Consolidated Statements of Cash Flows for periods prior to January 1, 2013. See Note 2 for additional information. | |||
        BASIS OF CONSOLIDATION AND CHANGE IN ACCOUNTING PRINCIPLE — The consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions. Prior to January 1, 2011, the accounts of foreign subsidiaries were consolidated based on a fiscal year ended November 30 due to the time needed to consolidate these subsidiaries. Effective January 1, 2011, the one month lag in the consolidation of the accounts of foreign subsidiaries was eliminated and the year-end of foreign subsidiaries was changed to December 31. Abbott believes that the change in accounting principle related to the elimination of the one month reporting lag is preferable because it results in more contemporaneous reporting of the results of foreign subsidiaries. In accordance with applicable accounting literature, a change in subsidiaries' year-end is treated as a change in accounting principle and requires retrospective application. The impact of the change was not material to the results of operations for the previously reported annual and interim periods after January 1, 2009, and thus, those results have not been revised. A charge of $137 million was recorded in 2011 to recognize the cumulative immaterial impacts to 2009 and 2010 of which $37 million is recognized in the results of discontinued operations. | |||
        The Consolidated Statements of Cash Flows for 2012 and 2011 have been appropriately revised to reflect acquisition and contingent consideration payments related to certain business acquisitions as cash flow used in financing activities. The amounts had been previously reflected as cash flow used in investing activities. | |||
        USE OF ESTIMATES — The financial statements have been prepared in accordance with generally accepted accounting principles in the United States and necessarily include amounts based on estimates and assumptions by management. Actual results could differ from those amounts. Significant estimates include amounts for sales rebates, income taxes, pension and other post-employment benefits, valuation of intangible assets, litigation, derivative financial instruments, and inventory and accounts receivable exposures. | |||
        FOREIGN CURRENCY TRANSLATION — The statements of earnings of foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using average exchange rates for the period. The net assets of foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using exchange rates as of the balance sheet date. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in equity as a component of accumulated other comprehensive income (loss). Transaction gains and losses are recorded in earnings and were not significant for any of the periods presented. | |||
        REVENUE RECOGNITION — Revenue from product sales is recognized upon passage of title and risk of loss to customers. Provisions for discounts, rebates and sales incentives to customers, and returns and other adjustments are provided for in the period the related sales are recorded. Sales incentives to customers are not material. Historical data is readily available and reliable, and is used for estimating the amount of the reduction in gross sales. Revenue from the launch of a new product, from an improved version of an existing product, or for shipments in excess of a customer's normal requirements are recorded when the conditions noted above are met. In those situations, management records a returns reserve for such revenue, if necessary. In certain of Abbott's businesses, primarily within diagnostics and medical optics, Abbott participates in selling arrangements that include multiple deliverables (e.g., instruments, reagents, procedures, and service agreements). Under these arrangements, Abbott recognizes revenue upon delivery of the product or performance of the service and allocates the revenue based on the relative selling price of each deliverable, which is based primarily on vendor specific objective evidence. Sales of product rights for marketable products are recorded as revenue upon disposition of the rights. Revenue from license of product rights, or for performance of research or selling activities, is recorded over the periods earned. | |||
        INCOME TAXES — Deferred income taxes are provided for the tax effect of differences between the tax bases of assets and liabilities and their reported amounts in the financial statements at the enacted statutory rate to be in effect when the taxes are paid. U.S. income taxes are provided on those earnings of foreign subsidiaries which are intended to be remitted to the parent company. Deferred income taxes are not provided on undistributed earnings reinvested indefinitely in foreign subsidiaries as working capital and plant and equipment. Interest and penalties on income tax obligations are included in taxes on income. | |||
        EARNINGS PER SHARE — Unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings from Continuing Operations allocated to common shares in 2013, 2012 and 2011 were $2.366 billion, $575 million and $1.123 billion, respectively. Net earnings allocated to common shares in 2013, 2012 and 2011 were $2.558 billion, $5.917 billion and $4.714 billion, respectively. | |||
        PENSION AND POST-EMPLOYMENT BENEFITS — Abbott accrues for the actuarially determined cost of pension and post-employment benefits over the service attribution periods of the employees. Abbott must develop long-term assumptions, the most significant of which are the health care cost trend rates, discount rates and the expected return on plan assets. Differences between the expected long-term return on plan assets and the actual return are amortized over a five-year period. Actuarial losses and gains are amortized over the remaining service attribution periods of the employees under the corridor method. | |||
        FAIR VALUE MEASUREMENTS — For assets and liabilities that are measured using quoted prices in active markets, total fair value is the published market price per unit multiplied by the number of units held without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs are valued by reference to similar assets or liabilities, adjusted for contract restrictions and other terms specific to that asset or liability. For these items, a significant portion of fair value is derived by reference to quoted prices of similar assets or liabilities in active markets. For all remaining assets and liabilities, fair value is derived using a fair value model, such as a discounted cash flow model or Black-Scholes model. Purchased intangible assets are recorded at fair value. The fair value of significant purchased intangible assets is based on independent appraisals. Abbott uses a discounted cash flow model to value intangible assets. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital, terminal values and market participants. Intangible assets, goodwill and indefinite-lived intangible assets are reviewed for impairment at least on a quarterly and annual basis, respectively. | |||
        SHARE-BASED COMPENSATION — The value of stock options and restricted stock awards and units are amortized over their service period, which could be shorter than the vesting period if an employee is retirement eligible, with a charge to compensation expense. | |||
        LITIGATION — Abbott accounts for litigation losses in accordance with FASB ASC No. 450, "Contingencies." Under ASC No. 450, loss contingency provisions are recorded for probable losses at management's best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. Legal fees are recorded as incurred. | |||
        CASH, CASH EQUIVALENTS AND INVESTMENTS — Cash equivalents consist of bank time deposits and U.S. treasury bills with original maturities of three months or less. Investments in marketable equity securities are classified as available-for-sale and are recorded at fair value with any unrealized holding gains or losses, net of tax, included in Accumulated other comprehensive income (loss). Investments in equity securities that are not traded on public stock exchanges are recorded at cost. Investments in debt securities are classified as held-to-maturity, as management has both the intent and ability to hold these securities to maturity, and are reported at cost, net of any unamortized premium or discount. Income relating to these securities is reported as interest income. | |||
        Abbott reviews the carrying value of investments each quarter to determine whether an other than temporary decline in market value exists. Abbott considers factors affecting the investee, factors affecting the industry the investee operates in and general equity market trends. Abbott considers the length of time an investment's market value has been below carrying value and the near-term prospects for recovery to carrying value. When Abbott determines that an other than temporary decline has occurred, the investment is written down with a charge to Other (income) expense, net. | |||
        TRADE RECEIVABLE VALUATIONS — Accounts receivable are stated at their net realizable value. The allowance against gross trade receivables reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. Accounts receivable are charged off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted. | |||
        INVENTORIES — Inventories are stated at the lower of cost (first-in, first-out basis) or market. Cost includes material and conversion costs. | |||
        PROPERTY AND EQUIPMENT — Depreciation and amortization are provided on a straight-line basis over the estimated useful lives of the assets. The following table shows estimated useful lives of property and equipment: | |||
Classification | Estimated Useful Lives | ||
Buildings | 10 to 50Â years (average 27Â years) | ||
Equipment | 3 to 20Â years (average 11Â years) | ||
        PRODUCT LIABILITY — Abbott accrues for product liability claims when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. The liabilities are adjusted quarterly as additional information becomes available. Receivables for insurance recoveries for product liability claims are recorded as assets, on an undiscounted basis, when it is probable that a recovery will be realized. Product liability losses are self-insured. | |||
        RESEARCH AND DEVELOPMENT COSTS — Internal research and development costs are expensed as incurred. Clinical trial costs incurred by third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are achieved. | |||
        ACQUIRED IN-PROCESS AND COLLABORATIONS RESEARCH AND DEVELOPMENT (IPR&D) — The initial costs of rights to IPR&D projects obtained in an asset acquisition are expensed as IPR&D unless the project has an alternative future use. These costs include initial payments incurred prior to regulatory approval in connection with research and development collaboration agreements that provide rights to develop, manufacture, market and/or sell pharmaceutical products. The fair value of IPR&D projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets. | |||
        CONCENTRATION OF RISK AND GUARANTEES — Due to the nature of its operations, Abbott is not subject to significant concentration risks relating to customers, products or geographic locations. Governmental accounts in Italy, Spain, Greece and Portugal accounted for 12 percent and 16 percent of total net trade receivables as of December 31, 2013 and 2012 respectively. Product warranties are not significant. | |||
        Abbott has no material exposures to off-balance sheet arrangements; no special purpose entities; nor activities, that include non-exchange-traded contracts accounted for at fair value. Abbott has periodically entered into agreements in the ordinary course of business, such as assignment of product rights, with other companies, which has resulted in Abbott becoming secondarily liable for obligations that Abbott was previously primarily liable. Since Abbott no longer maintains a business relationship with the other parties, Abbott is unable to develop an estimate of the maximum potential amount of future payments, if any, under these obligations. Based upon past experience, the likelihood of payments under these agreements is remote. Abbott periodically acquires a business or product rights in which Abbott agrees to pay contingent consideration based on attaining certain thresholds or based on the occurrence of certain events. | |||
        RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS — In February 2013, the FASB issued a standard pertaining to the reporting of amounts reclassified out of accumulated other comprehensive income (AOCI). The standard requires that an entity provide, by component, information regarding the amounts reclassified out of AOCI and the line items in the statement of operations to which the amounts were reclassified. This guidance is effective prospectively for reporting periods beginning after December 15, 2012. Abbott's adoption of this guidance in the first quarter of 2013 did not have a material impact on our results of operations or financial position. | |||
Separation_of_AbbVie_Inc
Separation of AbbVie Inc. | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Separation of AbbVie Inc. | ' | |||||||
Separation of AbbVie Inc. | ' | |||||||
Note 2 — Separation of AbbVie Inc. | ||||||||
        On November 28, 2012, Abbott's board of directors declared a special dividend distribution of all of the outstanding shares of common stock of AbbVie Inc. (AbbVie), the company formed to hold Abbott's research-based proprietary pharmaceuticals business. For each Abbott common share held at the close of business on December 12, 2012, Abbott shareholders received one share of AbbVie stock on January 1, 2013. Abbott has received a ruling from the Internal Revenue Service that the separation qualifies as a tax-free distribution to Abbott and its U.S. shareholders for U.S. federal income tax purposes. | ||||||||
        The historical operating results of the research-based proprietary pharmaceuticals business prior to separation are excluded from Earnings from Continuing Operations and are presented on the Earnings from Discontinued Operations line. Discontinued operations include the results of AbbVie's business except for certain corporate overhead costs and certain costs associated with transition services that will be provided by Abbott to AbbVie. Discontinued operations also includes other costs incurred by Abbott to separate AbbVie as well as an allocation of interest assuming a uniform ratio of consolidated debt to equity for all of Abbott's historical operations. The assets, liabilities, and cash flows of the research-based proprietary pharmaceuticals business are included in Abbott's Consolidated Balance Sheet and its Consolidated Statements of Cash Flows for periods prior to January 1, 2013. | ||||||||
        The following is a summary of the assets and liabilities transferred to AbbVie as part of the separation on January 1, 2013: | ||||||||
(in billions) | ||||||||
Assets: | ||||||||
Cash and cash equivalents | $ | 5.9 | ||||||
Investments | 2.2 | |||||||
Trade receivables, less allowances | 3.2 | |||||||
Inventories | 0.7 | |||||||
Prepaid expenses, deferred income taxes, and other current receivables | 2.9 | |||||||
Net property and equipment | 2.2 | |||||||
Intangible assets, net of amortization | 2.3 | |||||||
Goodwill | 6.1 | |||||||
Deferred income taxes and other assets | 1.1 | |||||||
​ | ​ | ​ | ​ | ​ | ||||
26.6 | ||||||||
​ | ​ | ​ | ​ | ​ | ||||
Liabilities: | ||||||||
Short-term borrowings | 1 | |||||||
Trade accounts payable and other current liabilities | 5.2 | |||||||
Long-term debt | 14.6 | |||||||
Post-employment obligations, deferred income taxes and other long-term liabilities | 3.1 | |||||||
​ | ​ | ​ | ​ | ​ | ||||
23.9 | ||||||||
​ | ​ | ​ | ​ | ​ | ||||
Net Assets Transferred to AbbVie Inc. | $ | 2.7 | ||||||
​ | ​ | ​ | ​ | ​ | ||||
​ | ​ | ​ | ​ | ​ | ||||
        In addition, approximately $1 billion of accumulated other comprehensive losses, net of income taxes, primarily related to the pension and other benefit plan net liabilities as well as foreign translation was transferred to AbbVie. | ||||||||
        In 2013, there are no operating results related to discontinued operations other than a favorable adjustment to tax expense of $193 million as a result of the resolution of various tax positions related to AbbVie's operations prior to separation. Summarized financial information for discontinued operations for 2012 and 2011 is as follows: | ||||||||
Year Ended | ||||||||
December 31 | ||||||||
(in millions) | 2012 | 2011 | ||||||
Net sales | $ | 18,380 | $ | 17,444 | ||||
Earnings before taxes | 5,958 | 3,963 | ||||||
Taxes on earnings | 574 | 361 | ||||||
Net earnings | 5,384 | 3,602 | ||||||
        Abbott and AbbVie entered into transitional services agreements prior to the separation pursuant to which Abbott and AbbVie are providing various services to each other on an interim transitional basis. Transition services may be provided for up to 24 months with an option for a one-year extension by the recipient. Services being provided by Abbott include certain information technology and back office support. Billings by Abbott under these transitional services agreements are recorded as a reduction of the costs to provide the respective service in the applicable expense category in the Consolidated Statement of Earnings. This transitional support will enable AbbVie to establish its stand-alone processes for various activities that were previously provided by Abbott and does not constitute significant continuing support of AbbVie's operations. | ||||||||
        For a small portion of AbbVie's operations, the legal transfer of AbbVie's assets (net of liabilities) did not occur with the separation of AbbVie on January 1, 2013 due to the time required to transfer marketing authorizations and other regulatory requirements in each of these countries. Under the terms of the separation agreement with Abbott, AbbVie is subject to the risks and entitled to the benefits generated by these operations and assets. The majority of these operations were transferred to AbbVie in 2013 with the remainder transferring in 2014. These assets and liabilities have been presented as held for disposition in the Consolidated Balance Sheet. At December 31, 2013, the assets and liabilities held for disposition consist of inventories of $243 million, trade accounts receivable of $163 million, other current assets of $32 million, equipment of $28 million, other assets of $38 million, trade accounts payable and accrued liabilities of $386 million and other liabilities of $7 million. Abbott's obligation to transfer the net assets held for disposition to AbbVie of $111 million is included in Other accrued liabilities. | ||||||||
        Abbott has retained all liabilities for all U.S. federal and foreign income taxes on income prior to the separation, as well as certain non-income taxes attributable to AbbVie's business. AbbVie generally will be liable for all other taxes attributable to its business. In connection with the separation, Abbott has adjusted its employee stock compensation awards and separated its defined benefit programs for pensions and post-employment medical and dental benefit plans. See notes 8 and 12 for additional information. | ||||||||
Supplemental_Financial_Informa
Supplemental Financial Information | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Supplemental Financial Information | ' | |||||||
Supplemental Financial Information | ' | |||||||
Note 3 — Supplemental Financial Information | ||||||||
        Other (income) expense, net, for 2013 primarily relates to gains from the sales of equity securities. The loss on the extinguishment of debt of $1.35 billion in 2012 relates to the early redemption of $7.7 billion of long-term notes. The loss consists of the premium paid on the notes and the write off of deferred financing costs totaling $1.83 billion and was partially offset by a gain of $479 million related to the unwinding of interest rate swaps related to a portion of the debt. As discussed in Note 1, Other (income) expense, net, for 2011 includes a charge of $100 million to recognize the cumulative immaterial impacts to 2009 and 2010 relating to the change in year end for foreign subsidiaries. | ||||||||
        The detail of various balance sheet components is as follows: | ||||||||
2013 | 2012 | |||||||
(in millions) | ||||||||
Long-term Investments: | ||||||||
Equity securities | $ | 93 | $ | 213 | ||||
Other | 26 | 61 | ||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total | $ | 119 | $ | 274 | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
        The reduction in long-term investments from December 31, 2012 to December 31, 2013 is due primarily to the separation of AbbVie on January 1, 2013. | ||||||||
2013 | 2012 | |||||||
(in millions) | ||||||||
Other Accrued Liabilities: | ||||||||
Accrued rebates payable to government agencies | $ | 136 | $ | 1,020 | ||||
Accrued other rebates (a) | 220 | 1,079 | ||||||
All other (b) | 3,144 | 4,689 | ||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total | $ | 3,500 | $ | 6,788 | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
(a) | ||||||||
Accrued wholesaler chargeback rebates of approximately $90 millon and $300 million at December 31, 2013 and 2012, respectively, are netted in trade receivables because Abbott's customers are invoiced at a higher catalog price but only remit to Abbott their contract price for the products. The reduction in the chargeback rebates from December 31, 2012 to December 31, 2013 is primarily due to the separation of AbbVie on January 1, 2013. | ||||||||
(b) | ||||||||
2013 and 2012 includes acquisition consideration payable of approximately $400Â million related primarily to the acquisition of Piramal Healthcare Limited's Healthcare Solutions business. | ||||||||
2013 | 2012 | |||||||
(in millions) | ||||||||
Post-employment Obligations and Other Long-term Liabilities: | ||||||||
Defined benefit pension plans and post-employment medical and dental plans for significant plans | $ | 1,818 | $ | 4,871 | ||||
Deferred income taxes | 466 | 710 | ||||||
All other (c) | 2,500 | 3,476 | ||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total | $ | 4,784 | $ | 9,057 | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
(c) | ||||||||
2013 includes $1.3Â billion of gross unrecognized tax benefits, as well as $70Â million of acquisition consideration payable. 2012 includes $1.4Â billion of gross unrecognized tax benefits, as well as acquisition consideration payable of $385Â million related to the acquisition of Piramal Healthcare Limited's Healthcare Solutions business. | ||||||||
Accumulated_Other_Comprehensiv
Accumulated Other Comprehensive Income | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Accumulated Other Comprehensive Income | ' | ||||||||||||||||
Accumulated Other Comprehensive Income | ' | ||||||||||||||||
Note 4 — Accumulated Other Comprehensive Income | |||||||||||||||||
        The components of the changes in accumulated other comprehensive income from continuing operation, net of income taxes, are as follows: (in millions) | |||||||||||||||||
Cumulative | Net | Cumulative | Cumulative | Total | |||||||||||||
Foreign | Actuarial | Unrealized | Gains on | ||||||||||||||
Currency | Losses and | Gains on | Derivative | ||||||||||||||
Translation | Prior | Marketable | Instruments | ||||||||||||||
Adjustments | Service | Equity | Designated as | ||||||||||||||
Costs and | Securities | Cash Flow | |||||||||||||||
Credits | Hedges | ||||||||||||||||
Balance at December 31, 2012 | $ | (79 | ) | $ | (3,596 | ) | $ | 31 | $ | 50 | $ | (3,594 | ) | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Separation of AbbVie | (400 | ) | 1,402 | — | 8 | 1,010 | |||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Other comprehensive income (loss) before reclassifications | (239 | ) | 771 | 22 | (23 | ) | 531 | ||||||||||
Income (loss) amounts reclassified from accumulated other comprehensive income (a) | — | 111 | (40 | ) | (30 | ) | 41 | ||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Net current period comprehensive income (loss) from continuing operations | (239 | ) | 882 | (18 | ) | (53 | ) | 572 | |||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Balance at December 31, 2013 | $ | (718 | ) | $ | (1,312 | ) | $ | 13 | $ | 5 | $ | (2,012 | ) | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
(a) | |||||||||||||||||
Reclassified amounts for foreign currency translation are recorded in the Consolidated Statement of Earnings as Net Foreign exchange loss (gain); gains on marketable equity securities are recorded as Other (income) expense and gains/losses related to cash flow hedges are recorded as Cost of product sold. Net actuarial losses and prior service cost is included as a component of net periodic benefit plan cost — see Note 12 for additional information. | |||||||||||||||||
Business_Acquisitions
Business Acquisitions | 12 Months Ended |
Dec. 31, 2013 | |
Business Acquisitions | ' |
Business Acquisitions | ' |
Note 5 — Business Acquisitions | |
        In August 2013, Abbott acquired 100 percent of IDEV Technologies, net of debt, for $310 million, in cash. The acquisition of IDEV Technologies expands Abbott's endovascular portfolio. The allocation of the fair value of the acquisition resulted in non-deductible acquired in-process research and development of approximately $170 million which is accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation, non-deductible definite-lived intangible assets of approximately $66 million, non-deductible goodwill of approximately $123 million and net deferred tax liabilities of $56 million. Acquired intangible assets consist of developed technology and are being amortized over 11 years. | |
        In August 2013, Abbott acquired 100 percent of OptiMedica for $260 million, in cash, plus additional payments up to $150 million to be made upon completion of certain development, regulatory and sales milestones. The acquisition of OptiMedica provides Abbott with an immediate entry point into the laser assisted cataract surgery market. The allocation of the fair value of the acquisition resulted in non-deductible definite-lived intangible assets of approximately $160 million; non-deductible acquired in-process research and development of approximately $60 million, which is accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation; non-deductible goodwill of approximately $151 million, net deferred tax liabilities of $70 million and contingent consideration of approximately $70 million. The fair value of the contingent consideration was determined based on an independent appraisal. Acquired intangible assets consist primarily of developed technology that is being amortized over 18 years. | |
        The preliminary allocations of fair value of these acquisitions will be finalized when valuations are completed. Had the above acquisitions taken place on January 1 of the previous year, consolidated net sales and income would not have been significantly different from reported amounts. | |
Goodwill_and_Intangible_Assets
Goodwill and Intangible Assets | 12 Months Ended |
Dec. 31, 2013 | |
Goodwill and Intangible Assets | ' |
Goodwill and Intangible Assets | ' |
Note 6 — Goodwill and Intangible Assets | |
        Abbott recorded goodwill of approximately $274 million in 2013 related to the acquisitions of IDEV Technologies and OptiMedica. Goodwill related to the IDEV acquisition was allocated to the Vascular Products segment and goodwill related to OptiMedica was allocated to a non-reportable segment. Foreign currency translation and other adjustments decreased goodwill in 2013 and 2011 by $168 million and $225 million, respectively, and increased goodwill in 2012 by $69 million. In addition, in connection with the separation of AbbVie on January 1, 2013, Abbott transferred approximately $6.1 billion of goodwill to AbbVie. The amount of goodwill related to reportable segments at December 31, 2013 was $2.9 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $444 million for the Diagnostic Products segment, and $3.1 billion for the Vascular Products segment. Other than the effects of the separation of AbbVie, there were no reductions of goodwill relating to the disposal of all or a portion of a business. There was no reduction of goodwill relating to impairments. | |
        The gross amount of amortizable intangible assets, primarily product rights and technology was $12.2 billion and $17.6 billion as of December 31, 2013 and 2012, respectively, and accumulated amortization was $6.8 billion and $9.7 billion as of December 31, 2013 and 2012, respectively. Indefinite-lived intangible assets, which relate to in-process research and development acquired in a business combination, were approximately $266 million and $691 million at December 31, 2013 and 2012, respectively. Gross amortizable intangible assets, accumulated amortization and indefinite-lived intangible assets of $5.7 billion, $3.8 billion and $417 million, respectively, were transferred to AbbVie as part of the separation on January 1, 2013. In 2012 and 2011, Abbott recorded impairment charges of $69 million and $125 million, respectively, for certain research and development assets due to changes in the projected development and regulatory timelines for the projects. The charges relate to non-reportable segments. Discounted cash flow analysis was used to analyze fair value and the charges are included in research and development expenses. | |
        The estimated annual amortization expense for intangible assets recorded at December 31, 2013 is approximately $711 million in 2014, $652 million in 2015, $636 million in 2016, $635 million in 2017 and $505 million in 2018. Amortizable intangible assets are amortized over 2 to 20 years (average 11 years). | |
Restructuring_Plans
Restructuring Plans | 12 Months Ended | ||||
Dec. 31, 2013 | |||||
Restructuring Plans | ' | ||||
Restructuring Plans | ' | ||||
Note 7 — Restructuring Plans | |||||
        In 2013, Abbott management approved a plan to reduce costs and improve efficiencies across various functional areas as well as a plan to streamline certain manufacturing operations in order to reduce costs and improve efficiencies in Abbott's established pharmaceuticals business. In addition, in 2012, Abbott management approved plans to streamline various commercial operations in order to reduce costs and improve efficiencies in Abbott's core diagnostics, established pharmaceutical and nutritionals businesses. Abbott recorded employee related severance charges of approximately $78 million in 2013 and $167 million in 2012. Additional charges of approximately $4 million in 2013 and $22 million in 2012 were also recorded primarily for asset impairments. Approximately $35 million in 2013 and $70 million in 2012 are recorded in Cost of products sold and approximately $47 million in 2013 and $119 million as Selling, general and administrative expense in 2012. No significant cash payments were made during 2012 relating to the 2012 actions. The following summarizes the activity for these restructurings: (in millions) | |||||
Restructuring charges recorded in 2012 | $ | 167 | |||
Restructuring charges recorded in 2013 | 78 | ||||
Payments and other adjustments | (97 | ) | |||
​ | ​ | ​ | ​ | ​ | |
Accrued balance at December 31, 2013 | $ | 148 | |||
​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | |
        In 2013 and prior years, Abbott management approved plans to realign its worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and research and development operations in order to reduce costs. In 2013, Abbott recorded employee severance charges of approximately $11 million. In 2011, Abbott recorded charges of approximately $194 million reflecting the impairment of manufacturing facilities and other assets, employee severance and other related charges. Approximately $11 million in 2013 and $18 million in 2011 are classified as Cost of products sold. The remaining 2011 charge of $176 million related to businesses transferred to AbbVie and is being recognized in the results of discontinued operations. | |||||
        The following summarizes the activity for these restructurings: (in millions) | |||||
Accrued balance at January 1, 2011 | $ | 77 | |||
2011 restructuring charges | 194 | ||||
Payments, impairments and other adjustments | (94 | ) | |||
​ | ​ | ​ | ​ | ​ | |
Accrued balance at December 31, 2011 | 177 | ||||
Payments, impairments and other adjustments | (48 | ) | |||
​ | ​ | ​ | ​ | ​ | |
Accrued balance at December 31, 2012 | 129 | ||||
Transfer of liability to AbbVie | (62 | ) | |||
Restructuring charges | 11 | ||||
Payments and other adjustments | (58 | ) | |||
​ | ​ | ​ | ​ | ​ | |
Accrued balance at December 31, 2013 | $ | 20 | |||
​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | |
        An additional $41 million, $110 million and $25 million were recorded in 2013, 2012 and 2011, respectively, relating to these restructurings, primarily for accelerated depreciation. | |||||
        In 2012 and 2010, Abbott management approved restructuring plans primarily related to the acquisition of Solvay's pharmaceuticals business. These plans streamline operations, improve efficiencies and reduce costs in certain Solvay sites and functions as well as in certain Abbott and Solvay commercial organizations in various countries. In 2012, Abbott recorded a charge of approximately $150 million for employee severance and contractual obligations, primarily related to the exit from a research and development facility. These charges are related to businesses transferred to AbbVie and are being recognized in the results of discontinued operations. The accrued restructuring reserves of $115 million at December 31, 2012 related to these actions were transferred to AbbVie on January 1, 2013 as part of the separation. As such, there are no remaining accruals being reported in Abbott's balance sheet as of December 31, 2013. | |||||
        In 2011 and 2008, Abbott management approved plans to streamline global manufacturing operations, reduce overall costs, and improve efficiencies in Abbott's core diagnostic business. In 2011, a charge of $28 million was recorded in Cost of products sold. The following summarizes the activity for these restructurings: (in millions) | |||||
Accrued balance at January 1, 2011 | $ | 88 | |||
2011 restructuring charge | 28 | ||||
Payments and other adjustments | (37 | ) | |||
​ | ​ | ​ | ​ | ​ | |
Accrued balance at December 31, 2011 | 79 | ||||
Payments and other adjustments | (23 | ) | |||
​ | ​ | ​ | ​ | ​ | |
Accrued balance at December 31, 2012 | 56 | ||||
Payments and other adjustments | (15 | ) | |||
​ | ​ | ​ | ​ | ​ | |
Accrued balance at December 31, 2013 | $ | 41 | |||
​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | |
        In addition, charges of approximately $16 million and $42 million were recorded in 2012 and 2011, primarily for accelerated depreciation and product transfer costs. | |||||
Incentive_Stock_Program
Incentive Stock Program | 12 Months Ended | |||||||||||||||||||
Dec. 31, 2013 | ||||||||||||||||||||
Incentive Stock Program | ' | |||||||||||||||||||
Incentive Stock Program | ' | |||||||||||||||||||
Note 8 — Incentive Stock Program | ||||||||||||||||||||
        The 2009 Incentive Stock Program authorizes the granting of nonqualified stock options, restricted stock awards, restricted stock units, performance awards, foreign benefits and other share-based awards. Stock options, replacement stock options and restricted stock awards and units comprise the majority of benefits that have been granted and are currently outstanding under this program and a prior program. In 2013, Abbott granted 4,733,378 stock options, 918,819 replacement stock options, 848,674 restricted stock awards and 6,412,867 restricted stock units under this program. | ||||||||||||||||||||
        The purchase price of shares under option must be at least equal to the fair market value of the common stock on the date of grant, and the maximum term of an option is 10 years. Options generally vest equally over three years. Restricted stock awards generally vest between 3 and 5 years and for restricted stock awards that vest over 5 years, no more than one-third of the award vests in any one year upon Abbott reaching a minimum return on equity target. Restricted stock units vest over three years and upon vesting, the recipient receives one share of Abbott stock for each vested restricted stock unit. The aggregate fair market value of restricted stock awards and units is recognized as expense over the service period. Restricted stock awards and settlement of vested restricted stock units are issued out of treasury shares. Abbott generally issues new shares for exercises of stock options. Abbott does not have a policy of purchasing its shares relating to its share-based programs. | ||||||||||||||||||||
        In connection with the separation of AbbVie on January 1, 2013, Abbott modified its outstanding equity awards granted under incentive stock programs for its employees. The awards were generally modified such that immediately following the separation, the awardees held the same number of awards in Abbott stock and an equal number of awards in AbbVie stock. The exercise price on outstanding Abbott options was adjusted and the exercise price on the AbbVie options granted under this modification was established with the intention of generally preserving the value of the awards immediately prior to the separation. This modification did not result in additional compensation expense. | ||||||||||||||||||||
        At December 31, 2013, approximately 130 million shares were reserved for future grants. Subsequent to year-end, the reserve was reduced by approximately 22 million shares for stock options and restricted stock awards and units granted by the Board of Directors. | ||||||||||||||||||||
        The number of restricted stock awards and units outstanding and the weighted-average grant-date fair value at December 31, 2013 and January 1, 2013 was 14,385,221 and $30.13 and 15,728,503 and $25.51, respectively. The number of restricted stock awards and units, and the weighted-average grant-date fair value, that were granted, vested and lapsed during 2013 were 7,261,541 and $34.92, 7,821,999 and $25.36 and 782,824 and $29.34, respectively. The fair market value of restricted stock awards and units vested in 2013, 2012 and 2011 was $274 million, $385 million and $237 million, respectively. | ||||||||||||||||||||
Options Outstanding | Exercisable Options | |||||||||||||||||||
Shares | Weighted | Weighted | Shares | Weighted | Weighted | |||||||||||||||
Average | Average | Average | Average | |||||||||||||||||
Exercise | Remaining | Exercise | Remaining | |||||||||||||||||
Price | Life (Years) | Price | Life (Years) | |||||||||||||||||
December 31, 2012 (a) | 48,685,273 | $ | 24.97 | 4 | 43,511,651 | $ | 24.68 | 3.7 | ||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Granted | 5,652,197 | 34.91 | ||||||||||||||||||
Exercised | (11,370,121 | ) | 25.37 | |||||||||||||||||
Lapsed | (210,009 | ) | 31.82 | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
December 31, 2013 | 42,757,340 | $ | 26.15 | 4 | 36,185,039 | $ | 25.02 | 3.1 | ||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
(a) | ||||||||||||||||||||
The amount of options outstanding and the weighted average exercise price have been revised to reflect the impact of the AbbVie separation. | ||||||||||||||||||||
        The aggregate intrinsic value of options outstanding and exercisable at December 31, 2013 was $525 million and $487 million, respectively. The total intrinsic value of options exercised in 2013, 2012 and 2011 was $120 million, $528 million and $94 million, respectively. The total unrecognized compensation cost related to all share-based compensation plans at December 31, 2013 amounted to approximately $153 million, which is expected to be recognized over the next three years. | ||||||||||||||||||||
        Total non-cash compensation expense charged against income from continuing operations in 2013, 2012 and 2011 for share-based plans totaled approximately $262 million, $284 million and $256 million, respectively, and the tax benefit recognized was approximately $84 million, $87 million and $71 million, respectively. Compensation cost capitalized as part of inventory is not significant. | ||||||||||||||||||||
        The fair value of an option granted in 2013, 2012 and 2011 was $5.77, $6.80, and $6.23, respectively. The fair value of an option grant was estimated using the Black-Scholes option-pricing model with the following assumptions | ||||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||||
Risk-free interest rate | 1.1 | % | 1.2 | % | 2.7 | % | ||||||||||||||
Average life of options (years) | 6 | 6 | 6 | |||||||||||||||||
Volatility | 20 | % | 21 | % | 21 | % | ||||||||||||||
Dividend yield | 1.6 | % | 3.6 | % | 4.1 | % | ||||||||||||||
        The risk-free interest rate is based on the rates available at the time of the grant for zero-coupon U.S. government issues with a remaining term equal to the option's expected life. The average life of an option is based on both historical and projected exercise and lapsing data. Expected volatility is based on implied volatilities from traded options on Abbott's stock and historical volatility of Abbott's stock over the expected life of the option. Dividend yield is based on the option's exercise price and annual dividend rate at the time of grant. | ||||||||||||||||||||
Debt_and_Lines_of_Credit
Debt and Lines of Credit | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Debt and Lines of Credit | ' | |||||||
Debt and Lines of Credit | ' | |||||||
Note 9 — Debt and Lines of Credit | ||||||||
        The following is a summary of long-term debt at December 31: (in millions) | ||||||||
2013 | 2012 | |||||||
1.2% Notes, due 2015 (1) | $ | — | $ | 3,500 | ||||
Variable Rate Notes, due 2015 (1) | — | 500 | ||||||
1.75% Notes, due 2017 (1) | — | 4,000 | ||||||
2.0% Notes, due 2018 (1) | — | 1,000 | ||||||
5.125% Notes, due 2019 | 947 | 947 | ||||||
4.125% Notes, due 2020 | 597 | 597 | ||||||
2.9% Notes, due 2022 (1) | — | 3,100 | ||||||
6.15% Notes, due 2037 | 547 | 547 | ||||||
6.0% Notes, due 2039 | 515 | 515 | ||||||
5.3% Notes, due 2040 | 694 | 694 | ||||||
4.4% Notes, due 2042 (1) | — | 2,600 | ||||||
Other, including fair value adjustments relating to interest rate hedge contracts designated as fair value hedges | 88 | 85 | ||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total, net of current maturities | 3,388 | 18,085 | ||||||
Current maturities of long-term debt | 9 | 309 | ||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total carrying amount | $ | 3,397 | $ | 18,394 | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
-1 | ||||||||
These notes were issued by AbbVie Inc. in November 2012. With the separation of AbbVie on January 1, 2013, Abbott no longer has any obligations related to this debt. | ||||||||
        In 2012, Abbott redeemed $7.7 billion of its outstanding notes. Abbott incurred a cost of $1.35 billion to extinguish this debt, net of gains from the unwinding of interest rate swaps related to the debt. In 2012, AbbVie Inc., a wholly owned subsidiary of Abbott, issued $14.7 billion of long-term debt with maturities ranging from 3 to 30 years. The debt issued by AbbVie Inc. was guaranteed by Abbott with the guarantee expiring when AbbVie Inc. separated from Abbott on January 1, 2013. | ||||||||
        Principal payments required on long-term debt outstanding at December 31, 2013 are $9 million in 2014, $10 million in 2015, $3 million in 2016, $1 million in 2017, $1 million in 2018 and $3.3 billion in 2019 and thereafter. | ||||||||
        At December 31, 2013, Abbott's long-term debt rating was A+ by Standard & Poor's Corporation and A1 by Moody's Investors Service. Abbott has readily available financial resources, including unused lines of credit of $5.0 billion that support commercial paper borrowing arrangements which expire in 2017. Abbott's weighted-average interest rate on short-term borrowings was 0.2% at December 31, 2013 and 0.4% at December 31, 2012 and 2011. | ||||||||
Financial_Instruments_Derivati
Financial Instruments, Derivatives and Fair Value Measures | 12 Months Ended | ||||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||||
Financial Instruments, Derivatives and Fair Value Measures | ' | ||||||||||||||||||||
Financial Instruments, Derivatives and Fair Value Measures | ' | ||||||||||||||||||||
Note 10 — Financial Instruments, Derivatives and Fair Value Measures | |||||||||||||||||||||
        Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, totaling $137 million at December 31, 2013, and $1.6 billion at December 31, 2012, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Contracts totaling $1.0 billion were transferred to AbbVie as part of the separation on January 1, 2013. Accumulated gains and losses as of December 31, 2013 will be included in Cost of products sold at the time the products are sold, generally through the next twelve months. The amount of hedge ineffectiveness was not significant in 2013, 2012 and 2011. | |||||||||||||||||||||
        Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies and Japanese yen, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar, European currencies and Japanese yen. At December 31, 2013, 2012 and 2011, Abbott held $13.8 billion, $18.2 billion and $15.7 billion, respectively, of such foreign currency forward exchange contracts. Contracts totaling $4.3 billion were transferred to AbbVie as part of the separation on January 1, 2013. | |||||||||||||||||||||
        Abbott has designated foreign denominated short-term debt as a hedge of the net investment in a foreign subsidiary of approximately $505 million, $615 million and $680 million as of December 31, 2013, 2012 and 2011, respectively. Accordingly, changes in the fair value of this debt due to changes in exchange rates are recorded in Accumulated other comprehensive income (loss), net of tax. | |||||||||||||||||||||
        Abbott is a party to interest rate hedge contracts totaling $1.5 billion, $9.5 billion and $6.8 billion at December 31, 2013, 2012 and 2011, respectively, to manage its exposure to changes in the fair value of fixed-rate debt. $8.0 billion of the contracts outstanding at December 31, 2012 related to debt issued by AbbVie Inc. in the fourth quarter of 2012 and were transferred to AbbVie as part of the separation on January 1, 2013. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. No hedge ineffectiveness was recorded in income in 2013, 2012 and 2011 for these hedges. | |||||||||||||||||||||
        Gross unrealized holding gains on available-for-sale equity securities totaled $22 million, $51 million and $64 million at December 31, 2013, 2012 and 2011, respectively. | |||||||||||||||||||||
        The following table summarizes the amounts and location of certain derivative financial instruments as of December 31: | |||||||||||||||||||||
Fair Value — Assets | Fair Value — Liabilities | ||||||||||||||||||||
2013 | 2012 | Balance Sheet Caption | 2013 | 2012 | Balance Sheet Caption | ||||||||||||||||
(in millions) | |||||||||||||||||||||
Interest rate swaps designated as fair value hedges | $ | 87 | $ | 185 | Deferred income taxes and other assets | $ | — | $ | 80 | Post-employment obligations and other long-term liabilities | |||||||||||
Foreign currency forward exchange contracts — | |||||||||||||||||||||
Hedging instruments | 14 | 22 | Other prepaid expenses and receivables | — | 11 | Other accrued liabilities | |||||||||||||||
Others not designated as hedges | 70 | 98 | 75 | 135 | |||||||||||||||||
Debt designated as a hedge of net investment in a foreign subsidiary | — | — | n/a | 505 | 615 | Short-term borrowings | |||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||
$ | 171 | $ | 305 | $ | 580 | $ | 841 | ||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||
        The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and the amounts and location of income (expense) and gain (loss) reclassified into income and for certain other derivative financial instruments. The amount of hedge ineffectiveness was not significant in 2013, 2012 and 2011 for these hedges. | |||||||||||||||||||||
Gain (loss) Recognized in | Income (expense) and | ||||||||||||||||||||
Other Comprehensive | Gain (loss) Reclassified | ||||||||||||||||||||
Income (loss) | into Income | ||||||||||||||||||||
2013 | 2012 | 2011 | 2013 | 2012 | 2011 | Income Statement Caption | |||||||||||||||
(in millions) | |||||||||||||||||||||
Foreign currency forward exchange contracts designated as cash flow hedges | $ | 35 | $ | 13 | $ | 67 | $ | 47 | $ | 114 | $ | (44 | ) | Cost of products sold | |||||||
Debt designated as a hedge of net investment in a foreign subsidiary | 110 | 65 | (30 | ) | — | — | — | n/a | |||||||||||||
Interest rate swaps designated as fair value hedges | n/a | n/a | n/a | (98 | ) | 62 | 488 | Interest expense | |||||||||||||
Foreign currency forward exchange contracts not designated as hedges | n/a | n/a | n/a | 88 | 131 | (41 | ) | Net foreign exchange (gain) loss | |||||||||||||
        The interest rate swaps are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The hedged debt is marked to market, offsetting the effect of marking the interest rate swaps to market. | |||||||||||||||||||||
        The carrying values and fair values of certain financial instruments as of December 31 are shown in the table below. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from nonperformance by these counterparties. | |||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||
Carrying | Fair | Carrying | Fair | ||||||||||||||||||
Value | Value | Value | Value | ||||||||||||||||||
(in millions) | |||||||||||||||||||||
Long-term Investment Securities: | |||||||||||||||||||||
Equity securities | $ | 93 | $ | 93 | $ | 213 | $ | 213 | |||||||||||||
Other | 26 | 24 | 61 | 56 | |||||||||||||||||
Total Long-term Debt | (3,397 | ) | (3,930 | ) | (18,394 | ) | (19,588 | ) | |||||||||||||
Foreign Currency Forward Exchange Contracts: | |||||||||||||||||||||
Receivable position | 84 | 84 | 120 | 120 | |||||||||||||||||
(Payable) position | (75 | ) | (75 | ) | (146 | ) | (146 | ) | |||||||||||||
Interest Rate Hedge Contracts: | |||||||||||||||||||||
Receivable position | 87 | 87 | 185 | 185 | |||||||||||||||||
(Payable) position | — | — | (80 | ) | (80 | ) | |||||||||||||||
        The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet: | |||||||||||||||||||||
Basis of Fair Value Measurement | |||||||||||||||||||||
Outstanding | Quoted | Significant Other | Significant | ||||||||||||||||||
Balances | Prices in | Observable | Unobservable | ||||||||||||||||||
Active Markets | Inputs | Inputs | |||||||||||||||||||
(in millions) | |||||||||||||||||||||
December 31, 2013: | |||||||||||||||||||||
Equity securities | $ | 26 | $ | 26 | $ | — | $ | — | |||||||||||||
Interest rate swap financial instruments | 87 | — | 87 | — | |||||||||||||||||
Foreign currency forward exchange contracts | 84 | — | 84 | — | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
Total Assets | $ | 197 | $ | 26 | $ | 171 | $ | — | |||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
Fair value of hedged long-term debt | $ | 1,623 | $ | — | $ | 1,623 | $ | — | |||||||||||||
Foreign currency forward exchange contracts | 75 | — | 75 | — | |||||||||||||||||
Contingent consideration related to business combinations | 208 | — | — | 208 | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
Total Liabilities | $ | 1,906 | $ | — | $ | 1,698 | $ | 208 | |||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
December 31, 2012: | |||||||||||||||||||||
Equity securities | $ | 76 | $ | 76 | $ | — | $ | — | |||||||||||||
Interest rate swap financial instruments | 185 | — | 185 | — | |||||||||||||||||
Foreign currency forward exchange contracts | 120 | — | 120 | — | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
Total Assets | $ | 381 | $ | 76 | $ | 305 | $ | — | |||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
Fair value of hedged long-term debt | $ | 9,632 | $ | — | $ | 9,632 | $ | — | |||||||||||||
Interest rate swap financial instruments | 80 | — | 80 | — | |||||||||||||||||
Foreign currency forward exchange contracts | 146 | — | 146 | — | |||||||||||||||||
Contingent consideration related to business combinations | 323 | — | — | 323 | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
Total Liabilities | $ | 10,181 | $ | — | $ | 9,858 | $ | 323 | |||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
        The fair value of the debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on an independent appraisal adjusted for the time value of money, exchange and other changes in fair value. | |||||||||||||||||||||
Litigation_and_Environmental_M
Litigation and Environmental Matters | 12 Months Ended |
Dec. 31, 2013 | |
Litigation and Environmental Matters | ' |
Litigation and Environmental Matters | ' |
Note 11 — Litigation and Environmental Matters | |
        Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $15 million. | |
        Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $70 million to $90 million. The recorded accrual balance at December 31, 2013 for these proceedings and exposures was approximately $80 million. This accrual represents management's best estimate of probable loss, as defined by FASB ASC No. 450, "Contingencies." Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott's financial position, cash flows, or results of operations. | |
PostEmployment_Benefits
Post-Employment Benefits | 12 Months Ended | |||||||||||||||||||
Dec. 31, 2013 | ||||||||||||||||||||
Post-Employment Benefits | ' | |||||||||||||||||||
Post-Employment Benefits | ' | |||||||||||||||||||
Note 12 — Post-Employment Benefits | ||||||||||||||||||||
        Retirement plans consist of defined benefit, defined contribution and medical and dental plans. Information for Abbott's major defined benefit plans and post-employment medical and dental benefit plans is as follows: | ||||||||||||||||||||
Defined Benefit | Medical and | |||||||||||||||||||
Plans | Dental Plans | |||||||||||||||||||
(in millions) | 2013 | 2012 | 2013 | 2012 | ||||||||||||||||
Projected benefit obligations, January 1 | $ | 11,322 | $ | 9,212 | $ | 1,889 | $ | 1,657 | ||||||||||||
Service cost — benefits earned during the year | 303 | 389 | 43 | 61 | ||||||||||||||||
Interest cost on projected benefit obligations | 276 | 460 | 59 | 81 | ||||||||||||||||
(Gains) losses, primarily changes in discount rates, plan design changes, law changes and differences between actual and estimated health care costs | (650 | ) | 1,461 | (156 | ) | 148 | ||||||||||||||
Benefits paid | (185 | ) | (308 | ) | (60 | ) | (63 | ) | ||||||||||||
Separation of AbbVie Inc. | (4,654 | ) | — | (450 | ) | — | ||||||||||||||
Other, including foreign currency translation | 20 | 108 | (28 | ) | 5 | |||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Projected benefit obligations, December 31 | $ | 6,432 | $ | 11,322 | $ | 1,297 | $ | 1,889 | ||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Plan assets at fair value, January 1 | $ | 7,949 | $ | 6,961 | $ | 417 | $ | 389 | ||||||||||||
Actual return on plans' assets | 727 | 878 | 61 | 48 | ||||||||||||||||
Company contributions | 724 | 379 | 40 | 40 | ||||||||||||||||
Benefits paid | (185 | ) | (302 | ) | (56 | ) | (60 | ) | ||||||||||||
Separation of AbbVie Inc. | (3,107 | ) | — | — | — | |||||||||||||||
Other, primarily foreign currency translation | 15 | 33 | — | — | ||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Plan assets at fair value, December 31 | $ | 6,123 | $ | 7,949 | $ | 462 | $ | 417 | ||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Projected benefit obligations greater than plan assets, December 31 | $ | (309 | ) | $ | (3,373 | ) | $ | (835 | ) | $ | (1,472 | ) | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Long-term assets | $ | 685 | $ | 69 | $ | — | $ | — | ||||||||||||
Short-term liabilities | (11 | ) | (43 | ) | — | — | ||||||||||||||
Long-term liabilities | (983 | ) | (3,399 | ) | (835 | ) | (1,472 | ) | ||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Net liability | $ | (309 | ) | $ | (3,373 | ) | $ | (835 | ) | $ | (1,472 | ) | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Amounts Recognized in Accumulated Other Comprehensive Income (loss): | ||||||||||||||||||||
Actuarial losses, net | $ | 1,791 | $ | 4,923 | $ | 334 | $ | 701 | ||||||||||||
Prior service cost (credits) | 20 | 61 | (252 | ) | (322 | ) | ||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Total | $ | 1,811 | $ | 4,984 | $ | 82 | $ | 379 | ||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
        In connection with separation of AbbVie on January 1, 2013, Abbott transferred to AbbVie Accumulated other comprehensive losses, net of income taxes, of approximately $1.4 billion. The projected benefit obligations for non-U.S. defined benefit plans was $2.0 billion and $3.1 billion at December 31, 2013 and 2012, respectively. The accumulated benefit obligations for all defined benefit plans were $5.5 billion and $9.6 billion at December 31, 2013 and 2012, respectively. | ||||||||||||||||||||
        For plans where the accumulated benefit obligations exceeded plan assets at December 31, 2013 and 2012, the aggregate accumulated benefit obligations, the projected benefit obligations and the aggregate plan assets were as follows: | ||||||||||||||||||||
(in millions) | 2013 | 2012 | ||||||||||||||||||
Accumulated benefit obligation | $ | 408 | $ | 8,100 | ||||||||||||||||
Projected benefit obligation | 505 | 9,619 | ||||||||||||||||||
Fair value of plan assets | — | 6,243 | ||||||||||||||||||
        In 2011, $776 million of assets and liabilities of a plan sponsored by Abbott Healthcare BV, a Dutch subsidiary of Abbott Laboratories, were irrevocably transferred to a Dutch insurance company in full settlement of that plan. The assets were used to purchase an annuity contract to fulfill the plan's obligations. | ||||||||||||||||||||
        The components of the net periodic benefit cost were as follows: | ||||||||||||||||||||
Defined Benefit Plans | Medical and | |||||||||||||||||||
Dental Plans | ||||||||||||||||||||
2013 | 2012 | 2011 | 2013 | 2012 | 2011 | |||||||||||||||
(in millions) | ||||||||||||||||||||
Service cost — benefits earned during the year | $ | 303 | $ | 389 | $ | 332 | $ | 43 | $ | 61 | $ | 55 | ||||||||
Interest cost on projected benefit obligations | 276 | 460 | 446 | 59 | 81 | 88 | ||||||||||||||
Expected return on plans' assets | (396 | ) | (611 | ) | (608 | ) | (36 | ) | (33 | ) | (34 | ) | ||||||||
Settlement | — | — | 40 | — | — | — | ||||||||||||||
Amortization of actuarial losses | 169 | 244 | 163 | 34 | 34 | 38 | ||||||||||||||
Amortization of prior service cost (credits) | 3 | 2 | 4 | (35 | ) | (42 | ) | (42 | ) | |||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total cost | 355 | 484 | 377 | 65 | 101 | 105 | ||||||||||||||
Less: Discontinued operations | — | (206 | ) | (176 | ) | — | (48 | ) | (49 | ) | ||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Net cost — continuing operations | $ | 355 | $ | 278 | $ | 201 | $ | 65 | $ | 53 | $ | 56 | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
        Other comprehensive income (loss) for each respective year includes the amortization of actuarial losses and prior service costs (credits) as noted in the previous table. Other comprehensive income (loss) for each respective year also includes: net actuarial gains and prior service credits of $995 million for defined benefit plans and $201 million for medical and dental plans in 2013; net actuarial losses of $1.2 billion for defined benefit plans and net actuarial losses of $134 million for medical and dental plans in 2012; and net actuarial losses of $1.1 billion for defined benefit plans and net actuarial gains of $66 million for medical and dental plans in 2011. The actuarial losses for 2012 and 2011 related to the businesses transferred to AbbVie as part of the separation were $167 million and $19 million, respectively; prior service costs were not significant. | ||||||||||||||||||||
        The pretax amount of actuarial losses and prior service cost (credits) included in Accumulated other comprehensive income (loss) at December 31, 2013 that is expected to be recognized in the net periodic benefit cost in 2014 is $102 million and $2 million of expense, respectively, for defined benefit pension plans and $17 million of expense and $37 million of income, respectively, for medical and dental plans. | ||||||||||||||||||||
        The weighted average assumptions used to determine benefit obligations for defined benefit plans and medical and dental plans are as follows: | ||||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||||
Discount rate | 4.9 | % | 4.3 | % | 5 | % | ||||||||||||||
Expected aggregate average long-term change in compensation | 5 | % | 5.3 | % | 5.3 | % | ||||||||||||||
        The weighted average assumptions used to determine the net cost for defined benefit plans and medical and dental plans are as follows: | ||||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||||
Discount rate | 4.2 | % | 5 | % | 5.4 | % | ||||||||||||||
Expected return on plan assets | 7.8 | % | 8 | % | 7.8 | % | ||||||||||||||
Expected aggregate average long-term change in compensation | 5 | % | 5.3 | % | 5.1 | % | ||||||||||||||
        The assumed health care cost trend rates for medical and dental plans at December 31 were as follows: | ||||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||||
Health care cost trend rate assumed for the next year | 7 | % | 7 | % | 7 | % | ||||||||||||||
Rate that the cost trend rate gradually declines to | 5 | % | 5 | % | 5 | % | ||||||||||||||
Year that rate reaches the assumed ultimate rate | 2019 | 2019 | 2019 | |||||||||||||||||
        The discount rates used to measure liabilities were determined based on high-quality fixed income securities that match the duration of the expected retiree benefits. The health care cost trend rates represent Abbott's expected annual rates of change in the cost of health care benefits and is a forward projection of health care costs as of the measurement date. A one-percentage point increase/(decrease) in the assumed health care cost trend rate would increase/(decrease) the accumulated post-employment benefit obligations as of December 31, 2013, by $177 million /$(146) million, and the total of the service and interest cost components of net post-employment health care cost for the year then ended by approximately $18 million/$(14) million. | ||||||||||||||||||||
        The following table summarizes the bases used to measure the defined benefit and medical and dental plan assets at fair value: | ||||||||||||||||||||
Basis of Fair Value Measurement | ||||||||||||||||||||
Outstanding | Quoted | Significant | Significant | |||||||||||||||||
Balances | Prices in | Other | Unobservable | |||||||||||||||||
Active Markets | Observable | Inputs | ||||||||||||||||||
Inputs | ||||||||||||||||||||
(in millions) | ||||||||||||||||||||
December 31, 2013: | ||||||||||||||||||||
Equities: | ||||||||||||||||||||
U.S. large cap (a) | $ | 1,618 | $ | 741 | $ | 877 | $ | — | ||||||||||||
U.S. mid cap (b) | 409 | 134 | 275 | — | ||||||||||||||||
International (c) | 1,319 | 608 | 711 | — | ||||||||||||||||
Fixed income securities: | ||||||||||||||||||||
U.S. government securities (d) | 453 | 61 | 392 | — | ||||||||||||||||
Corporate debt instruments (e) | 378 | 108 | 270 | — | ||||||||||||||||
Non-U.S. government securities (f) | 536 | 305 | 231 | — | ||||||||||||||||
Other (g) | 77 | 69 | 8 | — | ||||||||||||||||
Absolute return funds (h) | 1,474 | 197 | 791 | 486 | ||||||||||||||||
Commodities (i) | 170 | 6 | 97 | 67 | ||||||||||||||||
Other (j) | 151 | 149 | — | 2 | ||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
$ | 6,585 | $ | 2,378 | $ | 3,652 | $ | 555 | |||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
December 31, 2012: | ||||||||||||||||||||
Equities: | ||||||||||||||||||||
U.S. large cap (a) | $ | 1,831 | $ | 1,058 | $ | 773 | $ | — | ||||||||||||
U.S. mid cap (b) | 491 | 133 | 358 | — | ||||||||||||||||
International (c) | 1,607 | 657 | 950 | — | ||||||||||||||||
Fixed income securities: | ||||||||||||||||||||
U.S. government securities (d) | 899 | 172 | 727 | — | ||||||||||||||||
Corporate debt instruments (e) | 736 | 355 | 381 | — | ||||||||||||||||
Non-U.S. government securities (f) | 374 | 83 | 291 | — | ||||||||||||||||
Other (g) | 24 | — | 24 | — | ||||||||||||||||
Absolute return funds (h) | 2,070 | 85 | 1,246 | 739 | ||||||||||||||||
Commodities (i) | 222 | 9 | 172 | 41 | ||||||||||||||||
Other (j) | 112 | 109 | — | 3 | ||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
$ | 8,366 | $ | 2,661 | $ | 4,922 | $ | 783 | |||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Prior year amounts have been revised to conform with the current year's asset classifications. | ||||||||||||||||||||
(a) | ||||||||||||||||||||
A mix of index funds that track the S&PÂ 500 (60Â percent in 2013 and 50Â percent in 2012) and separate actively managed equity accounts that are benchmarked to the Russell 1000 (40Â percent in 2013 and 50Â percent in 2012). | ||||||||||||||||||||
(b) | ||||||||||||||||||||
A mix of index funds (70Â percent in 2013 and 75Â percent in 2012) and separate actively managed equity accounts (30Â percent in 2013 and 25Â percent in 2012) that track or are benchmarked to the S&PÂ 400 midcap index. | ||||||||||||||||||||
(c) | ||||||||||||||||||||
Primarily separate actively managed pooled investment accounts that are benchmarked to the MSCI and MSCI emerging market indices. | ||||||||||||||||||||
(d) | ||||||||||||||||||||
Index funds not actively managed (50Â percent in 2013 and 2012) and separate actively managed accounts (50Â percent in 2013 and 2012). | ||||||||||||||||||||
(e) | ||||||||||||||||||||
Index funds not actively managed (40Â percent in 2013 and 20Â percent in 2012) and separate actively managed accounts (60Â percent in 2013 and 80Â percent in 2012). | ||||||||||||||||||||
(f) | ||||||||||||||||||||
Primarily United Kingdom, Japan and Irish government-issued bonds. | ||||||||||||||||||||
(g) | ||||||||||||||||||||
Primarily mortgage backed securities. | ||||||||||||||||||||
(h) | ||||||||||||||||||||
Primarily funds invested by managers that have a global mandate with the flexibility to allocate capital broadly across a wide range of asset classes and strategies including, but not limited to equities, fixed income, commodities, interest rate futures, currencies and other securities to outperform an agreed upon benchmark with specific return and volatility targets. | ||||||||||||||||||||
(i) | ||||||||||||||||||||
Primarily investments in liquid commodity future contracts and private energy funds. | ||||||||||||||||||||
(j) | ||||||||||||||||||||
Primarily cash and cash equivalents. | ||||||||||||||||||||
        Equities that are valued using quoted prices are valued at the published market prices. Equities in a common collective trust or a registered investment company that are valued using significant other observable inputs are valued at the net asset value (NAV) provided by the fund administrator. The NAV is based on the value of the underlying assets owned by the fund minus its liabilities. Fixed income securities that are valued using significant other observable inputs are valued at prices obtained from independent financial service industry-recognized vendors. Absolute return funds and commodities are valued at the NAV provided by the fund administrator. Private energy funds are valued at the NAV provided by the partnership on a one-quarter lag adjusted for known cash flows and significant events through the reporting date. | ||||||||||||||||||||
        The following table summarizes the change in the value of assets that are measured using significant unobservable inputs: | ||||||||||||||||||||
2013 | 2012 | |||||||||||||||||||
(in millions) | ||||||||||||||||||||
January 1 | $ | 783 | $ | 682 | ||||||||||||||||
Transfers in (out of) from other categories | 6 | 6 | ||||||||||||||||||
Separation of AbbVie, Inc. | (165 | ) | — | |||||||||||||||||
Actual return on plan assets: | ||||||||||||||||||||
Assets on hand at year end | 29 | 59 | ||||||||||||||||||
Assets sold during the year | 51 | (4 | ) | |||||||||||||||||
Purchases, sales and settlements, net | (149 | ) | 40 | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||
December 31 | $ | 555 | $ | 783 | ||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||
        The investment mix of equity securities, fixed income and other asset allocation strategies is based upon achieving a desired return, balancing higher return, more volatile equity securities, and lower return, less volatile fixed income securities. Investment allocations are made across a range of markets, industry sectors, capitalization sizes, and in the case of fixed income securities, maturities and credit quality. The plans do not directly hold any securities of Abbott. There are no known significant concentrations of risk in the plans' assets. Abbott's medical and dental plans' assets are invested in a similar mix as the pension plan assets. The actual asset allocation percentages at year end are consistent with the company's targeted asset allocation percentages. | ||||||||||||||||||||
        The plans' expected return on assets, as shown above is based on management's expectations of long-term average rates of return to be achieved by the underlying investment portfolios. In establishing this assumption, management considers historical and expected returns for the asset classes in which the plans are invested, as well as current economic and capital market conditions. | ||||||||||||||||||||
        Abbott funds its domestic pension plans according to IRS funding limitations. International pension plans are funded according to similar regulations. Abbott funded $724 million in 2013 and $379 million in 2012 to defined pension plans. Abbott expects to contribute approximately $400 million to its pension plans in 2014, of which approximately $300 million relates to its main domestic pension plan. | ||||||||||||||||||||
        Total benefit payments expected to be paid to participants, which includes payments funded from company assets, as well as paid from the plans, are as follows: | ||||||||||||||||||||
(in millions) | Defined | Medical and | ||||||||||||||||||
Benefit Plans | Dental Plans | |||||||||||||||||||
2014 | $ | 186 | $ | 71 | ||||||||||||||||
2015 | 198 | 73 | ||||||||||||||||||
2016 | 213 | 74 | ||||||||||||||||||
2017 | 229 | 76 | ||||||||||||||||||
2018 | 249 | 77 | ||||||||||||||||||
2019 to 2023 | 1,578 | 417 | ||||||||||||||||||
        The Abbott Stock Retirement Plan is the principal defined contribution plan. Abbott's contributions to this plan were $86 million in 2013, $150 million in 2012 and $151 million in 2011. The contribution amounts in 2012 and 2011 include amounts associated with the businesses transferred to AbbVie. | ||||||||||||||||||||
Taxes_on_Earnings_from_Continu
Taxes on Earnings from Continuing Operations | 12 Months Ended | ||||||||||
Dec. 31, 2013 | |||||||||||
Taxes on Earnings from Continuing Operations | ' | ||||||||||
Taxes on Earnings from Continuing Operations | ' | ||||||||||
Note 13 — Taxes on Earnings from Continuing Operations | |||||||||||
        Taxes on earnings from continuing operations reflect the annual effective rates, including charges for interest and penalties. Deferred income taxes reflect the tax consequences on future years of differences between the tax bases of assets and liabilities and their financial reporting amounts. | |||||||||||
        In 2013, taxes on earnings from continuing operations reflect the recognition of $234 million of tax benefits as a result of the favorable resolution of various tax positions pertaining to prior years. Earnings from discontinued operations in 2013 include the recognition of $193 million of tax benefits as a result of the resolution of various tax positions related to AbbVie's operations prior to the separation. In addition, as a result of the American Taxpayer Relief Act of 2012 signed into law in January 2013, Abbott recognized a tax benefit in the tax provision related to continuing operations of approximately $103 million for the retroactive extension of the research tax credit and the look-through rules of section 954(c)(6) of the Internal Revenue Code to the beginning of 2012. The $1.515 billion domestic loss before taxes in 2012 includes $1.29 billion of net loss on the early extinguishment of debt. | |||||||||||
        U.S. income taxes are provided on those earnings of foreign subsidiaries which are intended to be remitted to the parent company. Abbott does not record deferred income taxes on earnings reinvested indefinitely in foreign subsidiaries. Undistributed earnings reinvested indefinitely in foreign subsidiaries as working capital and plant and equipment aggregated $24.0 billion at December 31, 2013. It is not practicable to determine the amount of deferred income taxes not provided on these earnings. In the U.S., Abbott's federal income tax returns through 2010 are settled except for three items, and the income tax returns for years after 2010 are open. There are numerous other income tax jurisdictions for which tax returns are not yet settled, none of which are individually significant. Reserves for interest and penalties are not significant. | |||||||||||
        Earnings from continuing operations before taxes, and the related provisions for taxes on earnings from continuing operations, were as follows: | |||||||||||
(in millions) | 2013 | 2012 | 2011 | ||||||||
Earnings (Loss) From Continuing Operations Before Taxes: | |||||||||||
Domestic | $ | 529 | $ | (1,515 | ) | $ | (593 | ) | |||
Foreign | 1,992 | 1,820 | 1,829 | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total | $ | 2,521 | $ | 305 | $ | 1,236 | |||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
(in millions) | 2013 | 2012 | 2011 | ||||||||
Taxes on Earnings From Continuing Operations: | |||||||||||
Current: | |||||||||||
Domestic | $ | 16 | $ | (21 | ) | $ | (888 | ) | |||
Foreign | 555 | 979 | 797 | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total current | 571 | 958 | (91 | ) | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Deferred: | |||||||||||
Domestic | (308 | ) | (572 | ) | 360 | ||||||
Foreign | (125 | ) | (660 | ) | (159 | ) | |||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total deferred | (433 | ) | (1,232 | ) | 201 | ||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total | $ | 138 | $ | (274 | ) | $ | 110 | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
        Differences between the effective income tax rate and the U.S. statutory tax rate were as follows: | |||||||||||
2013 | 2012 | 2011 | |||||||||
Statutory tax rate on earnings from continuing operations | 35 | % | 35 | % | 35 | % | |||||
Benefit of lower tax rates and tax exemptions on foreign income | (18.0 | ) | (75.7 | ) | (14.9 | ) | |||||
Resolution of certain tax positions pertaining to prior years | (9.3 | ) | (69.4 | ) | (14.0 | ) | |||||
Effect of retroactive legislation | (4.1 | ) | — | — | |||||||
State taxes, net of federal benefit | 1.7 | 3.4 | (0.3 | ) | |||||||
All other, net | 0.2 | 17 | 3.1 | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Effective tax rate on earnings from continuing operations | 5.5 | % | (89.7 | )% | 8.9 | % | |||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
        The tax effect of the differences that give rise to deferred tax assets and liabilities were as follows: | |||||||||||
(in millions) | 2013 | 2012 | |||||||||
Deferred tax assets: | |||||||||||
Compensation and employee benefits | $ | 862 | $ | 1,936 | |||||||
Other, primarily reserves not currently deductible, and NOL's and credit carryforwards        | 2,908 | 3,278 | |||||||||
Trade receivable reserves | 155 | 557 | |||||||||
Inventory reserves | 137 | 211 | |||||||||
Deferred intercompany profit | 274 | 1,095 | |||||||||
State income taxes | 196 | 197 | |||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
Total deferred tax assets | 4,532 | 7,274 | |||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
Deferred tax liabilities: | |||||||||||
Depreciation | (72 | ) | (75 | ) | |||||||
Other, primarily the excess of book basis over tax basis of intangible assets | (1,774 | ) | (2,447 | ) | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
Total deferred tax liabilities | (1,846 | ) | (2,522 | ) | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
Total net deferred tax assets | $ | 2,686 | $ | 4,752 | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
        Abbott has incurred losses in a foreign jurisdiction where realization of the future economic benefit is so remote that the benefit is not reflected as a deferred tax asset. Valuation allowances for recorded deferred tax assets were not significant. | |||||||||||
        The following table summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled: | |||||||||||
(in millions) | 2013 | 2012 | |||||||||
January 1 | $ | 2,257 | $ | 2,123 | |||||||
Increase due to current year tax positions | 244 | 673 | |||||||||
Increase due to prior year tax positions | 152 | 62 | |||||||||
Decrease due to prior year tax positions | (541 | ) | (438 | ) | |||||||
Lapse of statute | (23 | ) | — | ||||||||
Settlements | (124 | ) | (163 | ) | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
December 31 | $ | 1,965 | $ | 2,257 | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
        The total amount of unrecognized tax benefits that, if recognized, would impact the effective tax rate is approximately $1.7 billion. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease by $350 million to $425 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. | |||||||||||
Segment_and_Geographic_Area_In
Segment and Geographic Area Information | 12 Months Ended | ||||||||||||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||||||||||||
Segment and Geographic Area Information | ' | ||||||||||||||||||||||||||||
Segment and Geographic Area Information | ' | ||||||||||||||||||||||||||||
Note 14 — Segment and Geographic Area Information | |||||||||||||||||||||||||||||
        Abbott's principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott's products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices and government agencies throughout the world. As a result of the separation of AbbVie, Abbott no longer has a Proprietary Pharmaceutical Products segment and this business has been removed from the 2012 and 2011 historical information presented below. Abbott's reportable segments are as follows: | |||||||||||||||||||||||||||||
        Established Pharmaceutical Products —  International sales of a broad line of branded generic pharmaceutical products. | |||||||||||||||||||||||||||||
        Nutritional Products —  Worldwide sales of a broad line of adult and pediatric nutritional products. | |||||||||||||||||||||||||||||
        Diagnostic Products —  Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions are aggregated and reported as the Diagnostic Products segment. | |||||||||||||||||||||||||||||
        Vascular Products —  Worldwide sales of coronary, endovascular, structural heart, vessel closure and other medical device products. | |||||||||||||||||||||||||||||
        Non-reportable segments include the Diabetes Care and Medical Optics segments. | |||||||||||||||||||||||||||||
        Abbott's underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, effective January 1, 2013, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment's assets. The segment information below for 2012 and 2011 has been adjusted to exclude intangible asset amortization from operating earnings and intangible assets and goodwill from the total segment asset information. The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and are not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements. | |||||||||||||||||||||||||||||
Net Sales to External Customers (a) | Operating Earnings (a) | ||||||||||||||||||||||||||||
(in millions) | 2013 | 2012 | 2011 | 2013 | 2012 | 2011 | |||||||||||||||||||||||
Established Pharmaceuticals | $ | 4,974 | $ | 5,121 | $ | 5,355 | $ | 1,182 | $ | 1,237 | $ | 1,254 | |||||||||||||||||
Nutritionals | 6,740 | 6,461 | 5,989 | 1,263 | 1,020 | 792 | |||||||||||||||||||||||
Diagnostics | 4,545 | 4,292 | 4,126 | 1,008 | 825 | 794 | |||||||||||||||||||||||
Vascular | 3,012 | 3,071 | 3,333 | 962 | 1,020 | 1,111 | |||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
Total Reportable Segments | 19,271 | 18,945 | 18,803 | $ | 4,415 | $ | 4,102 | $ | 3,951 | ||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
Other | 2,577 | 2,549 | 2,604 | ||||||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
Total | $ | 21,848 | $ | 21,494 | $ | 21,407 | |||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
(a) | |||||||||||||||||||||||||||||
Net sales and operating earnings were unfavorably affected by the relatively stronger U.S. dollar in 2013 and 2012 and were favorably affected by the relatively weaker U.S. dollar in 2011. | |||||||||||||||||||||||||||||
2013 | 2012 | 2011 | |||||||||||||||||||||||||||
(in millions) | |||||||||||||||||||||||||||||
Total Reportable Segment Operating Earnings | $ | 4,415 | $ | 4,102 | $ | 3,951 | |||||||||||||||||||||||
Corporate functions and benefit plans costs | (514 | ) | (598 | ) | (529 | ) | |||||||||||||||||||||||
Non-reportable segments | 423 | 443 | 457 | ||||||||||||||||||||||||||
Net interest expense | (90 | ) | (288 | ) | (294 | ) | |||||||||||||||||||||||
Net loss on extinguishment of debt | — | (1,351 | ) | — | |||||||||||||||||||||||||
Share-based compensation | (262 | ) | (284 | ) | (256 | ) | |||||||||||||||||||||||
Amortization of intangible assets | (791 | ) | (795 | ) | (884 | ) | |||||||||||||||||||||||
Other, net (b) | (660 | ) | (924 | ) | (1,209 | ) | |||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||||||||
Earnings from Continuing Operations before Taxes | $ | 2,521 | $ | 305 | $ | 1,236 | |||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||||||||
(b) | |||||||||||||||||||||||||||||
Other, net includes: charges for cost reduction initiatives of approximately $350Â million in 2013 and $430Â million in 2012; and charges of $240Â million in 2011 for cost reduction initiatives and integration. | |||||||||||||||||||||||||||||
Depreciation | Additions to | Total Assets | |||||||||||||||||||||||||||
Long-term Assets | |||||||||||||||||||||||||||||
(in millions) | 2013 | 2012 | 2011 | 2013 | 2012 | 2011 | 2013 | 2012 | 2011 | ||||||||||||||||||||
Established Pharmaceuticals | $ | 84 | $ | 156 | $ | 169 | $ | 128 | $ | 237 | $ | 122 | $ | 2,637 | $ | 2,805 | $ | 4,348 | |||||||||||
Nutritionals | 190 | 175 | 167 | 340 | 428 | 205 | 3,518 | 3,211 | 2,939 | ||||||||||||||||||||
Diagnostics | 368 | 295 | 313 | 394 | 349 | 394 | 3,312 | 3,286 | 3,218 | ||||||||||||||||||||
Vascular | 122 | 76 | 99 | 62 | 69 | 109 | 1,711 | 1,834 | 1,400 | ||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total Reportable Segments | 764 | 702 | 748 | 924 | 1,083 | 830 | $ | 11,178 | $ | 11,136 | $ | 11,905 | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Other | 164 | 661 | 647 | 982 | 902 | 845 | |||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total | $ | 928 | $ | 1,363 | $ | 1,395 | $ | 1,906 | $ | 1,985 | $ | 1,675 | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
2013 | 2012 | 2011 | |||||||||||||||||||||||||||
(in millions) | |||||||||||||||||||||||||||||
Total Reportable Segment Assets | $ | 11,178 | $ | 11,136 | $ | 11,905 | |||||||||||||||||||||||
Cash, investments and restricted funds (c) | 8,217 | 15,448 | 8,476 | ||||||||||||||||||||||||||
Current deferred income taxes (c) | 2,528 | 2,986 | 2,701 | ||||||||||||||||||||||||||
Non-reportable segments | 1,181 | 1,167 | 1,148 | ||||||||||||||||||||||||||
Goodwill and intangible assets (c) | 15,507 | 24,362 | 25,695 | ||||||||||||||||||||||||||
All other (c) | 4,342 | 12,136 | 10,352 | ||||||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||||||||
Total Assets | $ | 42,953 | $ | 67,235 | $ | 60,277 | |||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||||||||
(c) | |||||||||||||||||||||||||||||
In 2012 and 2011, the reported amounts include assets associated with the businesses transferred to AbbVie as part of the separation. | |||||||||||||||||||||||||||||
Net Sales to External | Long-term Assets (e) | ||||||||||||||||||||||||||||
Customers (d) | |||||||||||||||||||||||||||||
2013 | 2012 | 2011 | 2013 | 2012 | 2011 | ||||||||||||||||||||||||
(in millions) | |||||||||||||||||||||||||||||
United States | $ | 6,269 | $ | 6,349 | $ | 6,302 | $ | 7,884 | $ | 15,244 | $ | 15,867 | |||||||||||||||||
Japan | 1,442 | 1,723 | 1,726 | 902 | 1,169 | 1,225 | |||||||||||||||||||||||
Germany | 1,070 | 984 | 1,058 | 1,040 | 6,173 | 5,909 | |||||||||||||||||||||||
The Netherlands | 960 | 1,107 | 1,204 | 560 | 532 | 462 | |||||||||||||||||||||||
China | 1,083 | 859 | 625 | 356 | 259 | 127 | |||||||||||||||||||||||
India | 922 | 919 | 917 | 3,080 | 3,467 | 3,160 | |||||||||||||||||||||||
Brazil | 470 | 448 | 470 | 216 | 200 | 186 | |||||||||||||||||||||||
Switzerland | 792 | 693 | 591 | 1,117 | 1,214 | 1,045 | |||||||||||||||||||||||
Canada | 734 | 753 | 652 | 368 | 352 | 237 | |||||||||||||||||||||||
Italy | 726 | 719 | 761 | 100 | 222 | 229 | |||||||||||||||||||||||
France | 680 | 667 | 781 | 213 | 220 | 214 | |||||||||||||||||||||||
Russia | 525 | 485 | 427 | 30 | 37 | 21 | |||||||||||||||||||||||
Spain | 413 | 417 | 447 | 326 | 314 | 293 | |||||||||||||||||||||||
United Kingdom | 479 | 497 | 475 | 1,380 | 1,345 | 1,273 | |||||||||||||||||||||||
All Other Countries | 5,283 | 4,874 | 4,971 | 6,133 | 5,164 | 6,260 | |||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
Consolidated | $ | 21,848 | $ | 21,494 | $ | 21,407 | $ | 23,705 | $ | 35,912 | $ | 36,508 | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
(d) | |||||||||||||||||||||||||||||
Sales by country are based on the country that sold the product. | |||||||||||||||||||||||||||||
(e) | |||||||||||||||||||||||||||||
Amounts reported in 2012 and 2011 include assets associated with businesses transferred to AbbVie as part of the separation. | |||||||||||||||||||||||||||||
Quarterly_Results_Unaudited
Quarterly Results (Unaudited) | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Quarterly Results (Unaudited) | ' | |||||||
Quarterly Results (Unaudited) | ' | |||||||
Note 15 — Quarterly Results (Unaudited) | ||||||||
(in millions except per share data) | ||||||||
2013 | 2012 | |||||||
First Quarter | ||||||||
Continuing Operations: | ||||||||
Net Sales | $ | 5,378 | $ | 5,284 | ||||
Gross Profit | 2,747 | 2,716 | ||||||
Earnings from Continuing Operations | 545 | 351 | ||||||
Basic Earnings per Common Share | 0.35 | 0.22 | ||||||
Diluted Earnings per Common Share | 0.34 | 0.22 | ||||||
Net Earnings | 545 | 1,242 | ||||||
Basic Earnings Per Common Share (a) | 0.35 | 0.79 | ||||||
Diluted Earnings Per Common Share (a) | 0.34 | 0.78 | ||||||
Market Price Per Share-High (b) | 35.34 | 29.42 | ||||||
Market Price Per Share-Low (b) | 31.64 | 25.82 | ||||||
Second Quarter | ||||||||
Continuing Operations: | ||||||||
Net Sales | $ | 5,446 | $ | 5,313 | ||||
Gross Profit | 2,704 | 2,748 | ||||||
Earnings from Continuing Operations | 476 | 411 | ||||||
Basic Earnings per Common Share | 0.3 | 0.26 | ||||||
Diluted Earnings per Common Share | 0.3 | 0.26 | ||||||
Net Earnings | 476 | 1,725 | ||||||
Basic Earnings Per Common Share (a) | 0.3 | 1.09 | ||||||
Diluted Earnings Per Common Share (a) | 0.3 | 1.08 | ||||||
Market Price Per Share-High (b) | 38.77 | 30.85 | ||||||
Market Price Per Share-Low (b) | 34.69 | 28.25 | ||||||
Third Quarter | ||||||||
Continuing Operations: | ||||||||
Net Sales | $ | 5,369 | $ | 5,265 | ||||
Gross Profit | 2,722 | 2,581 | ||||||
Earnings from Continuing Operations | 773 | 339 | ||||||
Basic Earnings per Common Share | 0.5 | 0.21 | ||||||
Diluted Earnings per Common Share | 0.49 | 0.21 | ||||||
Net Earnings | 966 | 1,943 | ||||||
Basic Earnings Per Common Share (a) | 0.62 | 1.22 | ||||||
Diluted Earnings Per Common Share (a) | 0.61 | 1.21 | ||||||
Market Price Per Share-High (b) | 37.16 | 33.69 | ||||||
Market Price Per Share-Low (b) | 32.7 | 30.39 | ||||||
Fourth Quarter | ||||||||
Continuing Operations: | ||||||||
Net Sales | $ | 5,655 | $ | 5,632 | ||||
Gross Profit | 2,844 | 2,837 | ||||||
Earnings (loss)Â from Continuing Operations | 589 | (522 | ) | |||||
Basic Earnings per Common Share | 0.38 | (0.33 | ) | |||||
Diluted Earnings per Common Share | 0.37 | (0.33 | ) | |||||
Net Earnings | 589 | 1,053 | ||||||
Basic Earnings Per Common Share (a) | 0.38 | 0.66 | ||||||
Diluted Earnings Per Common Share (a) | 0.37 | 0.66 | ||||||
Market Price Per Share-High (b) | 38.81 | 34.67 | ||||||
Market Price Per Share-Low (b) | 32.75 | 29.96 | ||||||
(a) | ||||||||
The sum of the four quarters' of earnings per share for 2013 and 2012 may not add to the full year earnings per share amount due to rounding and/or the use of quarter-to-date weighted average shares to calculate the earnings per share amount in each respective quarter. | ||||||||
(b) | ||||||||
The 2012 market prices per share reflect historical share prices that have been adjusted to reflect the separation of AbbVie. | ||||||||
SCHEDULE_II_VALUATION_AND_QUAL
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS | 12 Months Ended | |||||||||||||
Dec. 31, 2013 | ||||||||||||||
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS | ' | |||||||||||||
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS | ' | |||||||||||||
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS | ||||||||||||||
FOR THE YEARS ENDED DECEMBER 31, 2013, 2012, AND 2011 | ||||||||||||||
(in millions of dollars) | ||||||||||||||
Allowances for Doubtful | Balance | Provisions/ | Amounts | Balance at | ||||||||||
Accounts and Product Returns | at Beginning | Charges | Charged Off | End of Year | ||||||||||
of Year | to Income | and Other | ||||||||||||
Deductions | ||||||||||||||
2013 | $ | 406 | $ | 163 | $ | (257 | )(1) | $ | 312 | |||||
2012 | 421 | 343 | (358 | ) | 406 | |||||||||
2011 | 389 | 430 | (398 | ) | 421 | |||||||||
-1 | ||||||||||||||
Includes $178 million transferred to AbbVie as part of the separation on January 1, 2013. | ||||||||||||||
Summary_of_Significant_Account1
Summary of Significant Accounting Policies (Policies) | 12 Months Ended | ||
Dec. 31, 2013 | |||
Summary of Significant Accounting Policies | ' | ||
CHANGES IN PRESENTATION DUE TO ABBVIE SEPARATION | ' | ||
 CHANGES IN PRESENTATION DUE TO ABBVIE SEPARATION — On January 1, 2013, Abbott completed the separation of AbbVie Inc., which was formed to hold Abbott's research-based proprietary pharmaceuticals business. The historical operating results of the research-based proprietary pharmaceuticals business prior to separation are excluded from Earnings from Continuing Operations and are presented on the Earnings from Discontinued Operations line in Abbott's Consolidated Statement of Earnings. The assets, liabilities, and cash flows of the research-based proprietary pharmaceuticals business are included in Abbott's Consolidated Balance Sheet and its Consolidated Statements of Cash Flows for periods prior to January 1, 2013. See Note 2 for additional information. | |||
BASIS OF CONSOLIDATION AND CHANGE IN ACCOUNTING PRINCIPLE | ' | ||
 BASIS OF CONSOLIDATION AND CHANGE IN ACCOUNTING PRINCIPLE — The consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions. Prior to January 1, 2011, the accounts of foreign subsidiaries were consolidated based on a fiscal year ended November 30 due to the time needed to consolidate these subsidiaries. Effective January 1, 2011, the one month lag in the consolidation of the accounts of foreign subsidiaries was eliminated and the year-end of foreign subsidiaries was changed to December 31. Abbott believes that the change in accounting principle related to the elimination of the one month reporting lag is preferable because it results in more contemporaneous reporting of the results of foreign subsidiaries. In accordance with applicable accounting literature, a change in subsidiaries' year-end is treated as a change in accounting principle and requires retrospective application. The impact of the change was not material to the results of operations for the previously reported annual and interim periods after January 1, 2009, and thus, those results have not been revised. A charge of $137 million was recorded in 2011 to recognize the cumulative immaterial impacts to 2009 and 2010 of which $37 million is recognized in the results of discontinued operation. | |||
        The Consolidated Statements of Cash Flows for 2012 and 2011 have been appropriately revised to reflect acquisition and contingent consideration payments related to certain business acquisitions as cash flow used in financing activities. The amounts had been previously reflected as cash flow used in investing activities. | |||
USE OF ESTIMATES | ' | ||
 USE OF ESTIMATES — The financial statements have been prepared in accordance with generally accepted accounting principles in the United States and necessarily include amounts based on estimates and assumptions by management. Actual results could differ from those amounts. Significant estimates include amounts for sales rebates, income taxes, pension and other post-employment benefits, valuation of intangible assets, litigation, derivative financial instruments, and inventory and accounts receivable exposures. | |||
FOREIGN CURRENCY TRANSLATION | ' | ||
 FOREIGN CURRENCY TRANSLATION — The statements of earnings of foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using average exchange rates for the period. The net assets of foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using exchange rates as of the balance sheet date. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in equity as a component of accumulated other comprehensive income (loss). Transaction gains and losses are recorded in earnings and were not significant for any of the periods presented. | |||
REVENUE RECOGNITION | ' | ||
  REVENUE RECOGNITION — Revenue from product sales is recognized upon passage of title and risk of loss to customers. Provisions for discounts, rebates and sales incentives to customers, and returns and other adjustments are provided for in the period the related sales are recorded. Sales incentives to customers are not material. Historical data is readily available and reliable, and is used for estimating the amount of the reduction in gross sales. Revenue from the launch of a new product, from an improved version of an existing product, or for shipments in excess of a customer's normal requirements are recorded when the conditions noted above are met. In those situations, management records a returns reserve for such revenue, if necessary. In certain of Abbott's businesses, primarily within diagnostics and medical optics, Abbott participates in selling arrangements that include multiple deliverables (e.g., instruments, reagents, procedures, and service agreements). Under these arrangements, Abbott recognizes revenue upon delivery of the product or performance of the service and allocates the revenue based on the relative selling price of each deliverable, which is based primarily on vendor specific objective evidence. Sales of product rights for marketable products are recorded as revenue upon disposition of the rights. Revenue from license of product rights, or for performance of research or selling activities, is recorded over the periods earned. | |||
INCOME TAXES | ' | ||
 INCOME TAXES — Deferred income taxes are provided for the tax effect of differences between the tax bases of assets and liabilities and their reported amounts in the financial statements at the enacted statutory rate to be in effect when the taxes are paid. U.S. income taxes are provided on those earnings of foreign subsidiaries which are intended to be remitted to the parent company. Deferred income taxes are not provided on undistributed earnings reinvested indefinitely in foreign subsidiaries as working capital and plant and equipment. Interest and penalties on income tax obligations are included in taxes on income. | |||
EARNINGS PER SHARE | ' | ||
 EARNINGS PER SHARE — Unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings from Continuing Operations allocated to common shares in 2013, 2012 and 2011 were $2.366 billion, $575 million and $1.123 billion, respectively. Net earnings allocated to common shares in 2013, 2012 and 2011 were $2.558 billion, $5.917 billion and $4.714 billion, respectively. | |||
PENSION AND POST-EMPLOYMENT BENEFITS | ' | ||
PENSION AND POST-EMPLOYMENT BENEFITS — Abbott accrues for the actuarially determined cost of pension and post-employment benefits over the service attribution periods of the employees. Abbott must develop long-term assumptions, the most significant of which are the health care cost trend rates, discount rates and the expected return on plan assets. Differences between the expected long-term return on plan assets and the actual return are amortized over a five-year period. Actuarial losses and gains are amortized over the remaining service attribution periods of the employees under the corridor method. | |||
FAIR VALUE MEASUREMENTS | ' | ||
FAIR VALUE MEASUREMENTS — For assets and liabilities that are measured using quoted prices in active markets, total fair value is the published market price per unit multiplied by the number of units held without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs are valued by reference to similar assets or liabilities, adjusted for contract restrictions and other terms specific to that asset or liability. For these items, a significant portion of fair value is derived by reference to quoted prices of similar assets or liabilities in active markets. For all remaining assets and liabilities, fair value is derived using a fair value model, such as a discounted cash flow model or Black-Scholes model. Purchased intangible assets are recorded at fair value. The fair value of significant purchased intangible assets is based on independent appraisals. Abbott uses a discounted cash flow model to value intangible assets. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital, terminal values and market participants. Intangible assets, goodwill and indefinite-lived intangible assets are reviewed for impairment at least on a quarterly and annual basis, respectively. | |||
SHARE-BASED COMPENSATION | ' | ||
 SHARE-BASED COMPENSATION — The value of stock options and restricted stock awards and units are amortized over their service period, which could be shorter than the vesting period if an employee is retirement eligible, with a charge to compensation expense. | |||
LITIGATION | ' | ||
 LITIGATION — Abbott accounts for litigation losses in accordance with FASB ASC No. 450, "Contingencies." Under ASC No. 450, loss contingency provisions are recorded for probable losses at management's best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. Legal fees are recorded as incurred. | |||
CASH, CASH EQUIVALENTS AND INVESTMENTS | ' | ||
CASH, CASH EQUIVALENTS AND INVESTMENTS — Cash equivalents consist of bank time deposits and U.S. treasury bills with original maturities of three months or less. Investments in marketable equity securities are classified as available-for-sale and are recorded at fair value with any unrealized holding gains or losses, net of tax, included in Accumulated other comprehensive income (loss). Investments in equity securities that are not traded on public stock exchanges are recorded at cost. Investments in debt securities are classified as held-to-maturity, as management has both the intent and ability to hold these securities to maturity, and are reported at cost, net of any unamortized premium or discount. Income relating to these securities is reported as interest income. | |||
        Abbott reviews the carrying value of investments each quarter to determine whether an other than temporary decline in market value exists. Abbott considers factors affecting the investee, factors affecting the industry the investee operates in and general equity market trends. Abbott considers the length of time an investment's market value has been below carrying value and the near-term prospects for recovery to carrying value. When Abbott determines that an other than temporary decline has occurred, the investment is written down with a charge to Other (income) expense, net. | |||
TRADE RECEIVABLE VALUATIONS | ' | ||
 TRADE RECEIVABLE VALUATIONS — Accounts receivable are stated at their net realizable value. The allowance against gross trade receivables reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. Accounts receivable are charged off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted. | |||
INVENTORIES | ' | ||
 INVENTORIES — Inventories are stated at the lower of cost (first-in, first-out basis) or market. Cost includes material and conversion costs. | |||
PROPERTY AND EQUIPMENT | ' | ||
PROPERTY AND EQUIPMENT — Depreciation and amortization are provided on a straight-line basis over the estimated useful lives of the assets. The following table shows estimated useful lives of property and equipment: | |||
Classification | Estimated Useful Lives | ||
Buildings | 10 to 50Â years (average 27Â years) | ||
Equipment | 3 to 20Â years (average 11Â years) | ||
PRODUCT LIABILITY | ' | ||
PRODUCT LIABILITY — Abbott accrues for product liability claims when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. The liabilities are adjusted quarterly as additional information becomes available. Receivables for insurance recoveries for product liability claims are recorded as assets, on an undiscounted basis, when it is probable that a recovery will be realized. Product liability losses are self-insured. | |||
RESEARCH AND DEVELOPMENT COSTS | ' | ||
 RESEARCH AND DEVELOPMENT COSTS — Internal research and development costs are expensed as incurred. Clinical trial costs incurred by third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are achieved. | |||
ACQUIRED IN-PROCESS AND COLLABORATIONS RESEARCH AND DEVELOPMENT (IPR&D) | ' | ||
ACQUIRED IN-PROCESS AND COLLABORATIONS RESEARCH AND DEVELOPMENT (IPR&D) — The initial costs of rights to IPR&D projects obtained in an asset acquisition are expensed as IPR&D unless the project has an alternative future use. These costs include initial payments incurred prior to regulatory approval in connection with research and development collaboration agreements that provide rights to develop, manufacture, market and/or sell pharmaceutical products. The fair value of IPR&D projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets. | |||
CONCENTRATION OF RISK AND GUARANTEES | ' | ||
CONCENTRATION OF RISK AND GUARANTEES — Due to the nature of its operations, Abbott is not subject to significant concentration risks relating to customers, products or geographic locations. Governmental accounts in Italy, Spain, Greece and Portugal accounted for 12 percent and 16 percent of total net trade receivables as of December 31, 2013 and 2012 respectively. Product warranties are not significant. | |||
        Abbott has no material exposures to off-balance sheet arrangements; no special purpose entities; nor activities, that include non-exchange-traded contracts accounted for at fair value. Abbott has periodically entered into agreements in the ordinary course of business, such as assignment of product rights, with other companies, which has resulted in Abbott becoming secondarily liable for obligations that Abbott was previously primarily liable. Since Abbott no longer maintains a business relationship with the other parties, Abbott is unable to develop an estimate of the maximum potential amount of future payments, if any, under these obligations. Based upon past experience, the likelihood of payments under these agreements is remote. Abbott periodically acquires a business or product rights in which Abbott agrees to pay contingent consideration based on attaining certain thresholds or based on the occurrence of certain events. | |||
RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS | ' | ||
RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS — In February 2013, the FASB issued a standard pertaining to the reporting of amounts reclassified out of accumulated other comprehensive income (AOCI). The standard requires that an entity provide, by component, information regarding the amounts reclassified out of AOCI and the line items in the statement of operations to which the amounts were reclassified. This guidance is effective prospectively for reporting periods beginning after December 15, 2012. Abbott's adoption of this guidance in the first quarter of 2013 did not have a material impact on our results of operations or financial position. |
Summary_of_Significant_Account2
Summary of Significant Accounting Policies (Tables) | 12 Months Ended | ||
Dec. 31, 2013 | |||
Summary of Significant Accounting Policies | ' | ||
Estimated useful lives of property and equipment | ' | ||
Classification | Estimated Useful Lives | ||
Buildings | 10 to 50Â years (average 27Â years) | ||
Equipment | 3 to 20Â years (average 11Â years) |
Separation_of_AbbVie_Inc_Table
Separation of AbbVie Inc. (Tables) | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Separation of AbbVie Inc. | ' | |||||||
Summary of the assets and liabilities transferred to AbbVie as part of the separation | ' | |||||||
 The following is a summary of the assets and liabilities transferred to AbbVie as part of the separation on January 1, 2013: | ||||||||
(in billions) | ||||||||
Assets: | ||||||||
Cash and cash equivalents | $ | 5.9 | ||||||
Investments | 2.2 | |||||||
Trade receivables, less allowances | 3.2 | |||||||
Inventories | 0.7 | |||||||
Prepaid expenses, deferred income taxes, and other current receivables | 2.9 | |||||||
Net property and equipment | 2.2 | |||||||
Intangible assets, net of amortization | 2.3 | |||||||
Goodwill | 6.1 | |||||||
Deferred income taxes and other assets | 1.1 | |||||||
​ | ​ | ​ | ​ | ​ | ||||
26.6 | ||||||||
​ | ​ | ​ | ​ | ​ | ||||
Liabilities: | ||||||||
Short-term borrowings | 1 | |||||||
Trade accounts payable and other current liabilities | 5.2 | |||||||
Long-term debt | 14.6 | |||||||
Post-employment obligations, deferred income taxes and other long-term liabilities | 3.1 | |||||||
​ | ​ | ​ | ​ | ​ | ||||
23.9 | ||||||||
​ | ​ | ​ | ​ | ​ | ||||
Net Assets Transferred to AbbVie Inc. | $ | 2.7 | ||||||
​ | ​ | ​ | ​ | ​ | ||||
​ | ​ | ​ | ​ | ​ | ||||
Summary of financial information for discontinued operations | ' | |||||||
Year Ended | ||||||||
December 31 | ||||||||
(in millions) | 2012 | 2011 | ||||||
Net sales | $ | 18,380 | $ | 17,444 | ||||
Earnings before taxes | 5,958 | 3,963 | ||||||
Taxes on earnings | 574 | 361 | ||||||
Net earnings | 5,384 | 3,602 |
Supplemental_Financial_Informa1
Supplemental Financial Information (Tables) | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Supplemental Financial Information | ' | |||||||
Components of long-term investments | ' | |||||||
2013 | 2012 | |||||||
(in millions) | ||||||||
Long-term Investments: | ||||||||
Equity securities | $ | 93 | $ | 213 | ||||
Other | 26 | 61 | ||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total | $ | 119 | $ | 274 | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Other Accrued Liabilities | ' | |||||||
2013 | 2012 | |||||||
(in millions) | ||||||||
Other Accrued Liabilities: | ||||||||
Accrued rebates payable to government agencies | $ | 136 | $ | 1,020 | ||||
Accrued other rebates (a) | 220 | 1,079 | ||||||
All other (b) | 3,144 | 4,689 | ||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total | $ | 3,500 | $ | 6,788 | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
(a) | ||||||||
Accrued wholesaler chargeback rebates of approximately $90 millon and $300 million at December 31, 2013 and 2012, respectively, are netted in trade receivables because Abbott's customers are invoiced at a higher catalog price but only remit to Abbott their contract price for the products. The reduction in the chargeback rebates from December 31, 2012 to December 31, 2013 is primarily due to the separation of AbbVie on January 1, 2013. | ||||||||
(b) | ||||||||
2013 and 2012 includes acquisition consideration payable of approximately $400Â million related primarily to the acquisition of Piramal Healthcare Limited's Healthcare Solutions business. | ||||||||
Post employment Obligations and Other Long term Liabilities | ' | |||||||
2013 | 2012 | |||||||
(in millions) | ||||||||
Post-employment Obligations and Other Long-term Liabilities: | ||||||||
Defined benefit pension plans and post-employment medical and dental plans for significant plans | $ | 1,818 | $ | 4,871 | ||||
Deferred income taxes | 466 | 710 | ||||||
All other (c) | 2,500 | 3,476 | ||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total | $ | 4,784 | $ | 9,057 | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
(c) | ||||||||
2013 includes $1.3Â billion of gross unrecognized tax benefits, as well as $70Â million of acquisition consideration payable. 2012 includes $1.4Â billion of gross unrecognized tax benefits, as well as acquisition consideration payable of $385Â million related to the acquisition of Piramal Healthcare Limited's Healthcare Solutions business. | ||||||||
Accumulated_Other_Comprehensiv1
Accumulated Other Comprehensive Income (Tables) | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Accumulated Other Comprehensive Income | ' | ||||||||||||||||
Schedule of the components of the changes in accumulated other comprehensive income from continuing operations, net of income taxes | ' | ||||||||||||||||
(in millions) | |||||||||||||||||
Cumulative | Net | Cumulative | Cumulative | Total | |||||||||||||
Foreign | Actuarial | Unrealized | Gains on | ||||||||||||||
Currency | Losses and | Gains on | Derivative | ||||||||||||||
Translation | Prior | Marketable | Instruments | ||||||||||||||
Adjustments | Service | Equity | Designated as | ||||||||||||||
Costs and | Securities | Cash Flow | |||||||||||||||
Credits | Hedges | ||||||||||||||||
Balance at December 31, 2012 | $ | (79 | ) | $ | (3,596 | ) | $ | 31 | $ | 50 | $ | (3,594 | ) | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Separation of AbbVie | (400 | ) | 1,402 | — | 8 | 1,010 | |||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Other comprehensive income (loss) before reclassifications | (239 | ) | 771 | 22 | (23 | ) | 531 | ||||||||||
Income (loss) amounts reclassified from accumulated other comprehensive income (a) | — | 111 | (40 | ) | (30 | ) | 41 | ||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Net current period comprehensive income (loss) from continuing operations | (239 | ) | 882 | (18 | ) | (53 | ) | 572 | |||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Balance at December 31, 2013 | $ | (718 | ) | $ | (1,312 | ) | $ | 13 | $ | 5 | $ | (2,012 | ) | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
(a) | |||||||||||||||||
Reclassified amounts for foreign currency translation are recorded in the Consolidated Statement of Earnings as Net Foreign exchange loss (gain); gains on marketable equity securities are recorded as Other (income) expense and gains/losses related to cash flow hedges are recorded as Cost of product sold. Net actuarial losses and prior service cost is included as a component of net periodic benefit plan cost — see Note 12 for additional information. | |||||||||||||||||
Restructuring_Plans_Tables
Restructuring Plans (Tables) | 12 Months Ended | ||||
Dec. 31, 2013 | |||||
Restructuring Plan 2012 | ' | ||||
Restructuring costs | ' | ||||
Schedule of restructuring activity | ' | ||||
(in millions) | |||||
Accrued balance at January 1, 2011 | $ | 77 | |||
2011 restructuring charges | 194 | ||||
Payments, impairments and other adjustments | (94 | ) | |||
​ | ​ | ​ | ​ | ​ | |
Accrued balance at December 31, 2011 | 177 | ||||
Payments, impairments and other adjustments | (48 | ) | |||
​ | ​ | ​ | ​ | ​ | |
Accrued balance at December 31, 2012 | 129 | ||||
Transfer of liability to AbbVie | (62 | ) | |||
Restructuring charges | 11 | ||||
Payments and other adjustments | (58 | ) | |||
​ | ​ | ​ | ​ | ​ | |
Accrued balance at December 31, 2013 | $ | 20 | |||
​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | |
Restructuring Plan 2013 and Prior Years | ' | ||||
Restructuring costs | ' | ||||
Schedule of restructuring activity | ' | ||||
(in millions) | |||||
Restructuring charges recorded in 2012 | $ | 167 | |||
Restructuring charges recorded in 2013 | 78 | ||||
Payments and other adjustments | (97 | ) | |||
​ | ​ | ​ | ​ | ​ | |
Accrued balance at December 31, 2013 | $ | 148 | |||
​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | |
Restructuring Plan 2011 and 2008 | ' | ||||
Restructuring costs | ' | ||||
Schedule of restructuring activity | ' | ||||
(in millions) | |||||
Accrued balance at January 1, 2011 | $ | 88 | |||
2011 restructuring charge | 28 | ||||
Payments and other adjustments | (37 | ) | |||
​ | ​ | ​ | ​ | ​ | |
Accrued balance at December 31, 2011 | 79 | ||||
Payments and other adjustments | (23 | ) | |||
​ | ​ | ​ | ​ | ​ | |
Accrued balance at December 31, 2012 | 56 | ||||
Payments and other adjustments | (15 | ) | |||
​ | ​ | ​ | ​ | ​ | |
Accrued balance at December 31, 2013 | $ | 41 | |||
​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | |
Incentive_Stock_Program_Tables
Incentive Stock Program (Tables) | 12 Months Ended | |||||||||||||||||||
Dec. 31, 2013 | ||||||||||||||||||||
Incentive Stock Program | ' | |||||||||||||||||||
Options outstanding and exercisable | ' | |||||||||||||||||||
Options Outstanding | Exercisable Options | |||||||||||||||||||
Shares | Weighted | Weighted | Shares | Weighted | Weighted | |||||||||||||||
Average | Average | Average | Average | |||||||||||||||||
Exercise | Remaining | Exercise | Remaining | |||||||||||||||||
Price | Life (Years) | Price | Life (Years) | |||||||||||||||||
December 31, 2012 (a) | 48,685,273 | $ | 24.97 | 4 | 43,511,651 | $ | 24.68 | 3.7 | ||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Granted | 5,652,197 | 34.91 | ||||||||||||||||||
Exercised | (11,370,121 | ) | 25.37 | |||||||||||||||||
Lapsed | (210,009 | ) | 31.82 | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
December 31, 2013 | 42,757,340 | $ | 26.15 | 4 | 36,185,039 | $ | 25.02 | 3.1 | ||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
(a) | ||||||||||||||||||||
The amount of options outstanding and the weighted average exercise price have been revised to reflect the impact of the AbbVie separation. | ||||||||||||||||||||
Fair value assumptions | ' | |||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||||
Risk-free interest rate | 1.1 | % | 1.2 | % | 2.7 | % | ||||||||||||||
Average life of options (years) | 6 | 6 | 6 | |||||||||||||||||
Volatility | 20 | % | 21 | % | 21 | % | ||||||||||||||
Dividend yield | 1.6 | % | 3.6 | % | 4.1 | % |
Debt_and_Lines_of_Credit_Table
Debt and Lines of Credit (Tables) | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Debt and Lines of Credit | ' | |||||||
Summary of long-term debt | ' | |||||||
(in millions) | ||||||||
2013 | 2012 | |||||||
1.2% Notes, due 2015 (1) | $ | — | $ | 3,500 | ||||
Variable Rate Notes, due 2015 (1) | — | 500 | ||||||
1.75% Notes, due 2017 (1) | — | 4,000 | ||||||
2.0% Notes, due 2018 (1) | — | 1,000 | ||||||
5.125% Notes, due 2019 | 947 | 947 | ||||||
4.125% Notes, due 2020 | 597 | 597 | ||||||
2.9% Notes, due 2022 (1) | — | 3,100 | ||||||
6.15% Notes, due 2037 | 547 | 547 | ||||||
6.0% Notes, due 2039 | 515 | 515 | ||||||
5.3% Notes, due 2040 | 694 | 694 | ||||||
4.4% Notes, due 2042 (1) | — | 2,600 | ||||||
Other, including fair value adjustments relating to interest rate hedge contracts designated as fair value hedges | 88 | 85 | ||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total, net of current maturities | 3,388 | 18,085 | ||||||
Current maturities of long-term debt | 9 | 309 | ||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total carrying amount | $ | 3,397 | $ | 18,394 | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
-1 | ||||||||
These notes were issued by AbbVie Inc. in November 2012. With the separation of AbbVie on January 1, 2013, Abbott no longer has any obligations related to this debt. | ||||||||
Financial_Instruments_Derivati1
Financial Instruments, Derivatives and Fair Value Measures (Tables) | 12 Months Ended | ||||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||||
Financial Instruments, Derivatives and Fair Value Measures | ' | ||||||||||||||||||||
Summary of the amounts and location of certain derivative financial instruments | ' | ||||||||||||||||||||
Fair Value — Assets | Fair Value — Liabilities | ||||||||||||||||||||
2013 | 2012 | Balance Sheet Caption | 2013 | 2012 | Balance Sheet Caption | ||||||||||||||||
(in millions) | |||||||||||||||||||||
Interest rate swaps designated as fair value hedges | $ | 87 | $ | 185 | Deferred income taxes and other assets | $ | — | $ | 80 | Post-employment obligations and other long-term liabilities | |||||||||||
Foreign currency forward exchange contracts — | |||||||||||||||||||||
Hedging instruments | 14 | 22 | Other prepaid expenses and receivables | — | 11 | Other accrued liabilities | |||||||||||||||
Others not designated as hedges | 70 | 98 | 75 | 135 | |||||||||||||||||
Debt designated as a hedge of net investment in a foreign subsidiary | — | — | n/a | 505 | 615 | Short-term borrowings | |||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||
$ | 171 | $ | 305 | $ | 580 | $ | 841 | ||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||
Schedule of derivatives gain (loss) in OCI and earnings | ' | ||||||||||||||||||||
Gain (loss) Recognized in | Income (expense) and | ||||||||||||||||||||
Other Comprehensive | Gain (loss) Reclassified | ||||||||||||||||||||
Income (loss) | into Income | ||||||||||||||||||||
2013 | 2012 | 2011 | 2013 | 2012 | 2011 | Income Statement Caption | |||||||||||||||
(in millions) | |||||||||||||||||||||
Foreign currency forward exchange contracts designated as cash flow hedges | $ | 35 | $ | 13 | $ | 67 | $ | 47 | $ | 114 | $ | (44 | ) | Cost of products sold | |||||||
Debt designated as a hedge of net investment in a foreign subsidiary | 110 | 65 | (30 | ) | — | — | — | n/a | |||||||||||||
Interest rate swaps designated as fair value hedges | n/a | n/a | n/a | (98 | ) | 62 | 488 | Interest expense | |||||||||||||
Foreign currency forward exchange contracts not designated as hedges | n/a | n/a | n/a | 88 | 131 | (41 | ) | Net foreign exchange (gain) loss | |||||||||||||
Schedule of carrying values and fair values of certain financial instruments | ' | ||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||
Carrying | Fair | Carrying | Fair | ||||||||||||||||||
Value | Value | Value | Value | ||||||||||||||||||
(in millions) | |||||||||||||||||||||
Long-term Investment Securities: | |||||||||||||||||||||
Equity securities | $ | 93 | $ | 93 | $ | 213 | $ | 213 | |||||||||||||
Other | 26 | 24 | 61 | 56 | |||||||||||||||||
Total Long-term Debt | (3,397 | ) | (3,930 | ) | (18,394 | ) | (19,588 | ) | |||||||||||||
Foreign Currency Forward Exchange Contracts: | |||||||||||||||||||||
Receivable position | 84 | 84 | 120 | 120 | |||||||||||||||||
(Payable) position | (75 | ) | (75 | ) | (146 | ) | (146 | ) | |||||||||||||
Interest Rate Hedge Contracts: | |||||||||||||||||||||
Receivable position | 87 | 87 | 185 | 185 | |||||||||||||||||
(Payable) position | — | — | (80 | ) | (80 | ) | |||||||||||||||
Schedule of assets and liabilities measured at fair value on a recurring basis | ' | ||||||||||||||||||||
Basis of Fair Value Measurement | |||||||||||||||||||||
Outstanding | Quoted | Significant Other | Significant | ||||||||||||||||||
Balances | Prices in | Observable | Unobservable | ||||||||||||||||||
Active Markets | Inputs | Inputs | |||||||||||||||||||
(in millions) | |||||||||||||||||||||
December 31, 2013: | |||||||||||||||||||||
Equity securities | $ | 26 | $ | 26 | $ | — | $ | — | |||||||||||||
Interest rate swap financial instruments | 87 | — | 87 | — | |||||||||||||||||
Foreign currency forward exchange contracts | 84 | — | 84 | — | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
Total Assets | $ | 197 | $ | 26 | $ | 171 | $ | — | |||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
Fair value of hedged long-term debt | $ | 1,623 | $ | — | $ | 1,623 | $ | — | |||||||||||||
Foreign currency forward exchange contracts | 75 | — | 75 | — | |||||||||||||||||
Contingent consideration related to business combinations | 208 | — | — | 208 | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
Total Liabilities | $ | 1,906 | $ | — | $ | 1,698 | $ | 208 | |||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
December 31, 2012: | |||||||||||||||||||||
Equity securities | $ | 76 | $ | 76 | $ | — | $ | — | |||||||||||||
Interest rate swap financial instruments | 185 | — | 185 | — | |||||||||||||||||
Foreign currency forward exchange contracts | 120 | — | 120 | — | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
Total Assets | $ | 381 | $ | 76 | $ | 305 | $ | — | |||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
Fair value of hedged long-term debt | $ | 9,632 | $ | — | $ | 9,632 | $ | — | |||||||||||||
Interest rate swap financial instruments | 80 | — | 80 | — | |||||||||||||||||
Foreign currency forward exchange contracts | 146 | — | 146 | — | |||||||||||||||||
Contingent consideration related to business combinations | 323 | — | — | 323 | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
Total Liabilities | $ | 10,181 | $ | — | $ | 9,858 | $ | 323 | |||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||
PostEmployment_Benefits_Tables
Post-Employment Benefits (Tables) | 12 Months Ended | |||||||||||||||||||
Dec. 31, 2013 | ||||||||||||||||||||
Post-Employment Benefits | ' | |||||||||||||||||||
Schedule of aggregate accumulated benefit obligations, projected benefit obligations and aggregate plan assets for plans whose accumulated benefit obligation exceeded plan assets | ' | |||||||||||||||||||
Defined Benefit | Medical and | |||||||||||||||||||
Plans | Dental Plans | |||||||||||||||||||
(in millions) | 2013 | 2012 | 2013 | 2012 | ||||||||||||||||
Projected benefit obligations, January 1 | $ | 11,322 | $ | 9,212 | $ | 1,889 | $ | 1,657 | ||||||||||||
Service cost — benefits earned during the year | 303 | 389 | 43 | 61 | ||||||||||||||||
Interest cost on projected benefit obligations | 276 | 460 | 59 | 81 | ||||||||||||||||
(Gains) losses, primarily changes in discount rates, plan design changes, law changes and differences between actual and estimated health care costs | (650 | ) | 1,461 | (156 | ) | 148 | ||||||||||||||
Benefits paid | (185 | ) | (308 | ) | (60 | ) | (63 | ) | ||||||||||||
Separation of AbbVie Inc. | (4,654 | ) | — | (450 | ) | — | ||||||||||||||
Other, including foreign currency translation | 20 | 108 | (28 | ) | 5 | |||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Projected benefit obligations, December 31 | $ | 6,432 | $ | 11,322 | $ | 1,297 | $ | 1,889 | ||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Plan assets at fair value, January 1 | $ | 7,949 | $ | 6,961 | $ | 417 | $ | 389 | ||||||||||||
Actual return on plans' assets | 727 | 878 | 61 | 48 | ||||||||||||||||
Company contributions | 724 | 379 | 40 | 40 | ||||||||||||||||
Benefits paid | (185 | ) | (302 | ) | (56 | ) | (60 | ) | ||||||||||||
Separation of AbbVie Inc. | (3,107 | ) | — | — | — | |||||||||||||||
Other, primarily foreign currency translation | 15 | 33 | — | — | ||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Plan assets at fair value, December 31 | $ | 6,123 | $ | 7,949 | $ | 462 | $ | 417 | ||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Projected benefit obligations greater than plan assets, December 31 | $ | (309 | ) | $ | (3,373 | ) | $ | (835 | ) | $ | (1,472 | ) | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Long-term assets | $ | 685 | $ | 69 | $ | — | $ | — | ||||||||||||
Short-term liabilities | (11 | ) | (43 | ) | — | — | ||||||||||||||
Long-term liabilities | (983 | ) | (3,399 | ) | (835 | ) | (1,472 | ) | ||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Net liability | $ | (309 | ) | $ | (3,373 | ) | $ | (835 | ) | $ | (1,472 | ) | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Amounts Recognized in Accumulated Other Comprehensive Income (loss): | ||||||||||||||||||||
Actuarial losses, net | $ | 1,791 | $ | 4,923 | $ | 334 | $ | 701 | ||||||||||||
Prior service cost (credits) | 20 | 61 | (252 | ) | (322 | ) | ||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Total | $ | 1,811 | $ | 4,984 | $ | 82 | $ | 379 | ||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Schedule of plans where the accumulated benefit obligations exceeded plan assets the aggregate accumulated benefit obligations, the projected benefit obligations and the aggregate plan assets | ' | |||||||||||||||||||
(in millions) | 2013 | 2012 | ||||||||||||||||||
Accumulated benefit obligation | $ | 408 | $ | 8,100 | ||||||||||||||||
Projected benefit obligation | 505 | 9,619 | ||||||||||||||||||
Fair value of plan assets | — | 6,243 | ||||||||||||||||||
Net cost for the entity's major defined benefit plans and post-employment medical and dental benefit plans | ' | |||||||||||||||||||
Defined Benefit Plans | Medical and | |||||||||||||||||||
Dental Plans | ||||||||||||||||||||
2013 | 2012 | 2011 | 2013 | 2012 | 2011 | |||||||||||||||
(in millions) | ||||||||||||||||||||
Service cost — benefits earned during the year | $ | 303 | $ | 389 | $ | 332 | $ | 43 | $ | 61 | $ | 55 | ||||||||
Interest cost on projected benefit obligations | 276 | 460 | 446 | 59 | 81 | 88 | ||||||||||||||
Expected return on plans' assets | (396 | ) | (611 | ) | (608 | ) | (36 | ) | (33 | ) | (34 | ) | ||||||||
Settlement | — | — | 40 | — | — | — | ||||||||||||||
Amortization of actuarial losses | 169 | 244 | 163 | 34 | 34 | 38 | ||||||||||||||
Amortization of prior service cost (credits) | 3 | 2 | 4 | (35 | ) | (42 | ) | (42 | ) | |||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total cost | 355 | 484 | 377 | 65 | 101 | 105 | ||||||||||||||
Less: Discontinued operations | — | (206 | ) | (176 | ) | — | (48 | ) | (49 | ) | ||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Net cost — continuing operations | $ | 355 | $ | 278 | $ | 201 | $ | 65 | $ | 53 | $ | 56 | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Weighted-average assumptions used to determine benefit obligations and net cost for defined benefit plans and medical and dental plans | ' | |||||||||||||||||||
The weighted average assumptions used to determine benefit obligations for defined benefit plans and medical and dental plans are as follows: | ||||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||||
Discount rate | 4.9 | % | 4.3 | % | 5 | % | ||||||||||||||
Expected aggregate average long-term change in compensation | 5 | % | 5.3 | % | 5.3 | % | ||||||||||||||
        The weighted average assumptions used to determine the net cost for defined benefit plans and medical and dental plans are as follows: | ||||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||||
Discount rate | 4.2 | % | 5 | % | 5.4 | % | ||||||||||||||
Expected return on plan assets | 7.8 | % | 8 | % | 7.8 | % | ||||||||||||||
Expected aggregate average long-term change in compensation | 5 | % | 5.3 | % | 5.1 | % | ||||||||||||||
Assumed health care cost trend rates | ' | |||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||||
Health care cost trend rate assumed for the next year | 7 | % | 7 | % | 7 | % | ||||||||||||||
Rate that the cost trend rate gradually declines to | 5 | % | 5 | % | 5 | % | ||||||||||||||
Year that rate reaches the assumed ultimate rate | 2019 | 2019 | 2019 | |||||||||||||||||
Bases used to measure defined benefit plans' assets at fair value | ' | |||||||||||||||||||
Basis of Fair Value Measurement | ||||||||||||||||||||
Outstanding | Quoted | Significant | Significant | |||||||||||||||||
Balances | Prices in | Other | Unobservable | |||||||||||||||||
Active Markets | Observable | Inputs | ||||||||||||||||||
Inputs | ||||||||||||||||||||
(in millions) | ||||||||||||||||||||
December 31, 2013: | ||||||||||||||||||||
Equities: | ||||||||||||||||||||
U.S. large cap (a) | $ | 1,618 | $ | 741 | $ | 877 | $ | — | ||||||||||||
U.S. mid cap (b) | 409 | 134 | 275 | — | ||||||||||||||||
International (c) | 1,319 | 608 | 711 | — | ||||||||||||||||
Fixed income securities: | ||||||||||||||||||||
U.S. government securities (d) | 453 | 61 | 392 | — | ||||||||||||||||
Corporate debt instruments (e) | 378 | 108 | 270 | — | ||||||||||||||||
Non-U.S. government securities (f) | 536 | 305 | 231 | — | ||||||||||||||||
Other (g) | 77 | 69 | 8 | — | ||||||||||||||||
Absolute return funds (h) | 1,474 | 197 | 791 | 486 | ||||||||||||||||
Commodities (i) | 170 | 6 | 97 | 67 | ||||||||||||||||
Other (j) | 151 | 149 | — | 2 | ||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
$ | 6,585 | $ | 2,378 | $ | 3,652 | $ | 555 | |||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
December 31, 2012: | ||||||||||||||||||||
Equities: | ||||||||||||||||||||
U.S. large cap (a) | $ | 1,831 | $ | 1,058 | $ | 773 | $ | — | ||||||||||||
U.S. mid cap (b) | 491 | 133 | 358 | — | ||||||||||||||||
International (c) | 1,607 | 657 | 950 | — | ||||||||||||||||
Fixed income securities: | ||||||||||||||||||||
U.S. government securities (d) | 899 | 172 | 727 | — | ||||||||||||||||
Corporate debt instruments (e) | 736 | 355 | 381 | — | ||||||||||||||||
Non-U.S. government securities (f) | 374 | 83 | 291 | — | ||||||||||||||||
Other (g) | 24 | — | 24 | — | ||||||||||||||||
Absolute return funds (h) | 2,070 | 85 | 1,246 | 739 | ||||||||||||||||
Commodities (i) | 222 | 9 | 172 | 41 | ||||||||||||||||
Other (j) | 112 | 109 | — | 3 | ||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
$ | 8,366 | $ | 2,661 | $ | 4,922 | $ | 783 | |||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||
Prior year amounts have been revised to conform with the current year's asset classifications. | ||||||||||||||||||||
(a) | ||||||||||||||||||||
A mix of index funds that track the S&PÂ 500 (60Â percent in 2013 and 50Â percent in 2012) and separate actively managed equity accounts that are benchmarked to the Russell 1000 (40Â percent in 2013 and 50Â percent in 2012). | ||||||||||||||||||||
(b) | ||||||||||||||||||||
A mix of index funds (70Â percent in 2013 and 75Â percent in 2012) and separate actively managed equity accounts (30Â percent in 2013 and 25Â percent in 2012) that track or are benchmarked to the S&PÂ 400 midcap index. | ||||||||||||||||||||
(c) | ||||||||||||||||||||
Primarily separate actively managed pooled investment accounts that are benchmarked to the MSCI and MSCI emerging market indices. | ||||||||||||||||||||
(d) | ||||||||||||||||||||
Index funds not actively managed (50Â percent in 2013 and 2012) and separate actively managed accounts (50Â percent in 2013 and 2012). | ||||||||||||||||||||
(e) | ||||||||||||||||||||
Index funds not actively managed (40Â percent in 2013 and 20Â percent in 2012) and separate actively managed accounts (60Â percent in 2013 and 80Â percent in 2012). | ||||||||||||||||||||
(f) | ||||||||||||||||||||
Primarily United Kingdom, Japan and Irish government-issued bonds. | ||||||||||||||||||||
(g) | ||||||||||||||||||||
Primarily mortgage backed securities. | ||||||||||||||||||||
(h) | ||||||||||||||||||||
Primarily funds invested by managers that have a global mandate with the flexibility to allocate capital broadly across a wide range of asset classes and strategies including, but not limited to equities, fixed income, commodities, interest rate futures, currencies and other securities to outperform an agreed upon benchmark with specific return and volatility targets. | ||||||||||||||||||||
(i) | ||||||||||||||||||||
Primarily investments in liquid commodity future contracts and private energy funds. | ||||||||||||||||||||
(j) | ||||||||||||||||||||
Primarily cash and cash equivalents. | ||||||||||||||||||||
Change in the value of assets that are measured using significant unobservable inputs | ' | |||||||||||||||||||
2013 | 2012 | |||||||||||||||||||
(in millions) | ||||||||||||||||||||
January 1 | $ | 783 | $ | 682 | ||||||||||||||||
Transfers in (out of) from other categories | 6 | 6 | ||||||||||||||||||
Separation of AbbVie, Inc. | (165 | ) | — | |||||||||||||||||
Actual return on plan assets: | ||||||||||||||||||||
Assets on hand at year end | 29 | 59 | ||||||||||||||||||
Assets sold during the year | 51 | (4 | ) | |||||||||||||||||
Purchases, sales and settlements, net | (149 | ) | 40 | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||
December 31 | $ | 555 | $ | 783 | ||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||
Benefit payments expected to be paid to participants | ' | |||||||||||||||||||
(in millions) | Defined | Medical and | ||||||||||||||||||
Benefit Plans | Dental Plans | |||||||||||||||||||
2014 | $ | 186 | $ | 71 | ||||||||||||||||
2015 | 198 | 73 | ||||||||||||||||||
2016 | 213 | 74 | ||||||||||||||||||
2017 | 229 | 76 | ||||||||||||||||||
2018 | 249 | 77 | ||||||||||||||||||
2019 to 2023 | 1,578 | 417 |
Taxes_on_Earnings_from_Continu1
Taxes on Earnings from Continuing Operations (Tables) | 12 Months Ended | ||||||||||
Dec. 31, 2013 | |||||||||||
Taxes on Earnings from Continuing Operations | ' | ||||||||||
Earnings from continuing operations before taxes | ' | ||||||||||
(in millions) | 2013 | 2012 | 2011 | ||||||||
Earnings (Loss) From Continuing Operations Before Taxes: | |||||||||||
Domestic | $ | 529 | $ | (1,515 | ) | $ | (593 | ) | |||
Foreign | 1,992 | 1,820 | 1,829 | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total | $ | 2,521 | $ | 305 | $ | 1,236 | |||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Components of Income Tax Expense (Benefit), Continuing Operations | ' | ||||||||||
(in millions) | 2013 | 2012 | 2011 | ||||||||
Taxes on Earnings From Continuing Operations: | |||||||||||
Current: | |||||||||||
Domestic | $ | 16 | $ | (21 | ) | $ | (888 | ) | |||
Foreign | 555 | 979 | 797 | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total current | 571 | 958 | (91 | ) | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Deferred: | |||||||||||
Domestic | (308 | ) | (572 | ) | 360 | ||||||
Foreign | (125 | ) | (660 | ) | (159 | ) | |||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total deferred | (433 | ) | (1,232 | ) | 201 | ||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total | $ | 138 | $ | (274 | ) | $ | 110 | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Reconciliation of income taxes at the U.S. federal statutory rate to income tax expense (benefit) | ' | ||||||||||
2013 | 2012 | 2011 | |||||||||
Statutory tax rate on earnings from continuing operations | 35 | % | 35 | % | 35 | % | |||||
Benefit of lower tax rates and tax exemptions on foreign income | (18.0 | ) | (75.7 | ) | (14.9 | ) | |||||
Resolution of certain tax positions pertaining to prior years | (9.3 | ) | (69.4 | ) | (14.0 | ) | |||||
Effect of retroactive legislation | (4.1 | ) | — | — | |||||||
State taxes, net of federal benefit | 1.7 | 3.4 | (0.3 | ) | |||||||
All other, net | 0.2 | 17 | 3.1 | ||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Effective tax rate on earnings from continuing operations | 5.5 | % | (89.7 | )% | 8.9 | % | |||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Schedule of components of net deferred tax assets (liabilities) | ' | ||||||||||
(in millions) | 2013 | 2012 | |||||||||
Deferred tax assets: | |||||||||||
Compensation and employee benefits | $ | 862 | $ | 1,936 | |||||||
Other, primarily reserves not currently deductible, and NOL's and credit carryforwards        | 2,908 | 3,278 | |||||||||
Trade receivable reserves | 155 | 557 | |||||||||
Inventory reserves | 137 | 211 | |||||||||
Deferred intercompany profit | 274 | 1,095 | |||||||||
State income taxes | 196 | 197 | |||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
Total deferred tax assets | 4,532 | 7,274 | |||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
Deferred tax liabilities: | |||||||||||
Depreciation | (72 | ) | (75 | ) | |||||||
Other, primarily the excess of book basis over tax basis of intangible assets | (1,774 | ) | (2,447 | ) | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
Total deferred tax liabilities | (1,846 | ) | (2,522 | ) | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
Total net deferred tax assets | $ | 2,686 | $ | 4,752 | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
Reconciliation of unrecognized tax benefits for the period | ' | ||||||||||
(in millions) | 2013 | 2012 | |||||||||
January 1 | $ | 2,257 | $ | 2,123 | |||||||
Increase due to current year tax positions | 244 | 673 | |||||||||
Increase due to prior year tax positions | 152 | 62 | |||||||||
Decrease due to prior year tax positions | (541 | ) | (438 | ) | |||||||
Lapse of statute | (23 | ) | — | ||||||||
Settlements | (124 | ) | (163 | ) | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
December 31 | $ | 1,965 | $ | 2,257 | |||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||
Segment_and_Geographic_Area_In1
Segment and Geographic Area Information (Tables) | 12 Months Ended | ||||||||||||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||||||||||||
Segment and Geographic Area Information | ' | ||||||||||||||||||||||||||||
Schedule of segment and geographic area information | ' | ||||||||||||||||||||||||||||
Net Sales to External Customers (a) | Operating Earnings (a) | ||||||||||||||||||||||||||||
(in millions) | 2013 | 2012 | 2011 | 2013 | 2012 | 2011 | |||||||||||||||||||||||
Established Pharmaceuticals | $ | 4,974 | $ | 5,121 | $ | 5,355 | $ | 1,182 | $ | 1,237 | $ | 1,254 | |||||||||||||||||
Nutritionals | 6,740 | 6,461 | 5,989 | 1,263 | 1,020 | 792 | |||||||||||||||||||||||
Diagnostics | 4,545 | 4,292 | 4,126 | 1,008 | 825 | 794 | |||||||||||||||||||||||
Vascular | 3,012 | 3,071 | 3,333 | 962 | 1,020 | 1,111 | |||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
Total Reportable Segments | 19,271 | 18,945 | 18,803 | $ | 4,415 | $ | 4,102 | $ | 3,951 | ||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
Other | 2,577 | 2,549 | 2,604 | ||||||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
Total | $ | 21,848 | $ | 21,494 | $ | 21,407 | |||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
(a) | |||||||||||||||||||||||||||||
Net sales and operating earnings were unfavorably affected by the relatively stronger U.S. dollar in 2013 and 2012 and were favorably affected by the relatively weaker U.S. dollar in 2011. | |||||||||||||||||||||||||||||
Schedule of reconciliation of operating earnings by segment | ' | ||||||||||||||||||||||||||||
2013 | 2012 | 2011 | |||||||||||||||||||||||||||
(in millions) | |||||||||||||||||||||||||||||
Total Reportable Segment Operating Earnings | $ | 4,415 | $ | 4,102 | $ | 3,951 | |||||||||||||||||||||||
Corporate functions and benefit plans costs | (514 | ) | (598 | ) | (529 | ) | |||||||||||||||||||||||
Non-reportable segments | 423 | 443 | 457 | ||||||||||||||||||||||||||
Net interest expense | (90 | ) | (288 | ) | (294 | ) | |||||||||||||||||||||||
Net loss on extinguishment of debt | — | (1,351 | ) | — | |||||||||||||||||||||||||
Share-based compensation | (262 | ) | (284 | ) | (256 | ) | |||||||||||||||||||||||
Amortization of intangible assets | (791 | ) | (795 | ) | (884 | ) | |||||||||||||||||||||||
Other, net (b) | (660 | ) | (924 | ) | (1,209 | ) | |||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||||||||
Earnings from Continuing Operations before Taxes | $ | 2,521 | $ | 305 | $ | 1,236 | |||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||||||||
(b) | |||||||||||||||||||||||||||||
Other, net includes: charges for cost reduction initiatives of approximately $350Â million in 2013 and $430Â million in 2012; and charges of $240Â million in 2011 for cost reduction initiatives and integration. | |||||||||||||||||||||||||||||
Schedule of information about long-lived assets by segment | ' | ||||||||||||||||||||||||||||
2013 | 2012 | 2011 | |||||||||||||||||||||||||||
(in millions) | |||||||||||||||||||||||||||||
Total Reportable Segment Assets | $ | 11,178 | $ | 11,136 | $ | 11,905 | |||||||||||||||||||||||
Cash, investments and restricted funds (c) | 8,217 | 15,448 | 8,476 | ||||||||||||||||||||||||||
Current deferred income taxes (c) | 2,528 | 2,986 | 2,701 | ||||||||||||||||||||||||||
Non-reportable segments | 1,181 | 1,167 | 1,148 | ||||||||||||||||||||||||||
Goodwill and intangible assets (c) | 15,507 | 24,362 | 25,695 | ||||||||||||||||||||||||||
All other (c) | 4,342 | 12,136 | 10,352 | ||||||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||||||||
Total Assets | $ | 42,953 | $ | 67,235 | $ | 60,277 | |||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |||||||||||||||||||
(c) | |||||||||||||||||||||||||||||
In 2012 and 2011, the reported amounts include assets associated with the businesses transferred to AbbVie as part of the separation. | |||||||||||||||||||||||||||||
Schedule of reconciliation of total assets by segment | ' | ||||||||||||||||||||||||||||
Depreciation | Additions to | Total Assets | |||||||||||||||||||||||||||
Long-term Assets | |||||||||||||||||||||||||||||
(in millions) | 2013 | 2012 | 2011 | 2013 | 2012 | 2011 | 2013 | 2012 | 2011 | ||||||||||||||||||||
Established Pharmaceuticals | $ | 84 | $ | 156 | $ | 169 | $ | 128 | $ | 237 | $ | 122 | $ | 2,637 | $ | 2,805 | $ | 4,348 | |||||||||||
Nutritionals | 190 | 175 | 167 | 340 | 428 | 205 | 3,518 | 3,211 | 2,939 | ||||||||||||||||||||
Diagnostics | 368 | 295 | 313 | 394 | 349 | 394 | 3,312 | 3,286 | 3,218 | ||||||||||||||||||||
Vascular | 122 | 76 | 99 | 62 | 69 | 109 | 1,711 | 1,834 | 1,400 | ||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total Reportable Segments | 764 | 702 | 748 | 924 | 1,083 | 830 | $ | 11,178 | $ | 11,136 | $ | 11,905 | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Other | 164 | 661 | 647 | 982 | 902 | 845 | |||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Total | $ | 928 | $ | 1,363 | $ | 1,395 | $ | 1,906 | $ | 1,985 | $ | 1,675 | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | |
Schedule of net sales by product type | ' | ||||||||||||||||||||||||||||
In 2012 and 2011, the reported amounts include assets associated with the businesses transferred to AbbVie as part of the separation. | |||||||||||||||||||||||||||||
Net Sales to External | Long-term Assets (e) | ||||||||||||||||||||||||||||
Customers (d) | |||||||||||||||||||||||||||||
2013 | 2012 | 2011 | 2013 | 2012 | 2011 | ||||||||||||||||||||||||
(in millions) | |||||||||||||||||||||||||||||
United States | $ | 6,269 | $ | 6,349 | $ | 6,302 | $ | 7,884 | $ | 15,244 | $ | 15,867 | |||||||||||||||||
Japan | 1,442 | 1,723 | 1,726 | 902 | 1,169 | 1,225 | |||||||||||||||||||||||
Germany | 1,070 | 984 | 1,058 | 1,040 | 6,173 | 5,909 | |||||||||||||||||||||||
The Netherlands | 960 | 1,107 | 1,204 | 560 | 532 | 462 | |||||||||||||||||||||||
China | 1,083 | 859 | 625 | 356 | 259 | 127 | |||||||||||||||||||||||
India | 922 | 919 | 917 | 3,080 | 3,467 | 3,160 | |||||||||||||||||||||||
Brazil | 470 | 448 | 470 | 216 | 200 | 186 | |||||||||||||||||||||||
Switzerland | 792 | 693 | 591 | 1,117 | 1,214 | 1,045 | |||||||||||||||||||||||
Canada | 734 | 753 | 652 | 368 | 352 | 237 | |||||||||||||||||||||||
Italy | 726 | 719 | 761 | 100 | 222 | 229 | |||||||||||||||||||||||
France | 680 | 667 | 781 | 213 | 220 | 214 | |||||||||||||||||||||||
Russia | 525 | 485 | 427 | 30 | 37 | 21 | |||||||||||||||||||||||
Spain | 413 | 417 | 447 | 326 | 314 | 293 | |||||||||||||||||||||||
United Kingdom | 479 | 497 | 475 | 1,380 | 1,345 | 1,273 | |||||||||||||||||||||||
All Other Countries | 5,283 | 4,874 | 4,971 | 6,133 | 5,164 | 6,260 | |||||||||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
Consolidated | $ | 21,848 | $ | 21,494 | $ | 21,407 | $ | 23,705 | $ | 35,912 | $ | 36,508 | |||||||||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ||||||||||
(d) | |||||||||||||||||||||||||||||
Sales by country are based on the country that sold the product. | |||||||||||||||||||||||||||||
(e) | |||||||||||||||||||||||||||||
Amounts reported in 2012 and 2011 include assets associated with businesses transferred to AbbVie as part of the separation. | |||||||||||||||||||||||||||||
Quarterly_Results_Unaudited_Ta
Quarterly Results (Unaudited) (Tables) | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Quarterly Results (Unaudited) | ' | |||||||
Quarterly Results (Unaudited) | ' | |||||||
(in millions except per share data) | ||||||||
2013 | 2012 | |||||||
First Quarter | ||||||||
Continuing Operations: | ||||||||
Net Sales | $ | 5,378 | $ | 5,284 | ||||
Gross Profit | 2,747 | 2,716 | ||||||
Earnings from Continuing Operations | 545 | 351 | ||||||
Basic Earnings per Common Share | 0.35 | 0.22 | ||||||
Diluted Earnings per Common Share | 0.34 | 0.22 | ||||||
Net Earnings | 545 | 1,242 | ||||||
Basic Earnings Per Common Share (a) | 0.35 | 0.79 | ||||||
Diluted Earnings Per Common Share (a) | 0.34 | 0.78 | ||||||
Market Price Per Share-High (b) | 35.34 | 29.42 | ||||||
Market Price Per Share-Low (b) | 31.64 | 25.82 | ||||||
Second Quarter | ||||||||
Continuing Operations: | ||||||||
Net Sales | $ | 5,446 | $ | 5,313 | ||||
Gross Profit | 2,704 | 2,748 | ||||||
Earnings from Continuing Operations | 476 | 411 | ||||||
Basic Earnings per Common Share | 0.3 | 0.26 | ||||||
Diluted Earnings per Common Share | 0.3 | 0.26 | ||||||
Net Earnings | 476 | 1,725 | ||||||
Basic Earnings Per Common Share (a) | 0.3 | 1.09 | ||||||
Diluted Earnings Per Common Share (a) | 0.3 | 1.08 | ||||||
Market Price Per Share-High (b) | 38.77 | 30.85 | ||||||
Market Price Per Share-Low (b) | 34.69 | 28.25 | ||||||
Third Quarter | ||||||||
Continuing Operations: | ||||||||
Net Sales | $ | 5,369 | $ | 5,265 | ||||
Gross Profit | 2,722 | 2,581 | ||||||
Earnings from Continuing Operations | 773 | 339 | ||||||
Basic Earnings per Common Share | 0.5 | 0.21 | ||||||
Diluted Earnings per Common Share | 0.49 | 0.21 | ||||||
Net Earnings | 966 | 1,943 | ||||||
Basic Earnings Per Common Share (a) | 0.62 | 1.22 | ||||||
Diluted Earnings Per Common Share (a) | 0.61 | 1.21 | ||||||
Market Price Per Share-High (b) | 37.16 | 33.69 | ||||||
Market Price Per Share-Low (b) | 32.7 | 30.39 | ||||||
Fourth Quarter | ||||||||
Continuing Operations: | ||||||||
Net Sales | $ | 5,655 | $ | 5,632 | ||||
Gross Profit | 2,844 | 2,837 | ||||||
Earnings (loss)Â from Continuing Operations | 589 | (522 | ) | |||||
Basic Earnings per Common Share | 0.38 | (0.33 | ) | |||||
Diluted Earnings per Common Share | 0.37 | (0.33 | ) | |||||
Net Earnings | 589 | 1,053 | ||||||
Basic Earnings Per Common Share (a) | 0.38 | 0.66 | ||||||
Diluted Earnings Per Common Share (a) | 0.37 | 0.66 | ||||||
Market Price Per Share-High (b) | 38.81 | 34.67 | ||||||
Market Price Per Share-Low (b) | 32.75 | 29.96 | ||||||
(a) | ||||||||
The sum of the four quarters' of earnings per share for 2013 and 2012 may not add to the full year earnings per share amount due to rounding and/or the use of quarter-to-date weighted average shares to calculate the earnings per share amount in each respective quarter. | ||||||||
(b) | ||||||||
The 2012 market prices per share reflect historical share prices that have been adjusted to reflect the separation of AbbVie. | ||||||||
Summary_of_Significant_Account3
Summary of Significant Accounting Policies (Details) (USD $) | 12 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Basis of Presentation | ' | ' | ' |
Reporting period lag for consolidation of financial results | '1 month | ' | ' |
EARNINGS PER SHARE | ' | ' | ' |
Earnings from continuing operations allocated to common shares | $2,366 | $575 | $1,123 |
Net earnings allocated to common shares | $2,558 | $5,917 | $4,714 |
PENSION AND POST EMPLOYMENT BENEFITS | ' | ' | ' |
Amortization period of differences Between the expected long-term return on plan assets and the actual return | '5 years | ' | ' |
Model used to derive fair value | 'Discounted cash flow model or Black-Scholes model | ' | ' |
Buildings | Minimum | ' | ' | ' |
Property and equipment: | ' | ' | ' |
Estimated Useful Lives | '10 years | ' | ' |
Buildings | Maximum | ' | ' | ' |
Property and equipment: | ' | ' | ' |
Estimated Useful Lives | '50 years | ' | ' |
Buildings | Average | ' | ' | ' |
Property and equipment: | ' | ' | ' |
Estimated Useful Lives | '27 years | ' | ' |
Equipment | Minimum | ' | ' | ' |
Property and equipment: | ' | ' | ' |
Estimated Useful Lives | '3 years | ' | ' |
Equipment | Maximum | ' | ' | ' |
Property and equipment: | ' | ' | ' |
Estimated Useful Lives | '20 years | ' | ' |
Equipment | Average | ' | ' | ' |
Property and equipment: | ' | ' | ' |
Estimated Useful Lives | '11 years | ' | ' |
Summary_of_Significant_Account4
Summary of Significant Accounting Policies (Details 2) (USD $) | 12 Months Ended |
In Millions, unless otherwise specified | Dec. 31, 2011 |
Summary of Significant Accounting Policies | ' |
Charge recorded to other (income) expense | $137 |
Cumulative-effect adjustment related to discontinued operations | $137 |
Summary_of_Significant_Account5
Summary of Significant Accounting Policies (Details 3) (Trade receivables, Italy, Spain, Greece and Portugal) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Trade receivables | Italy, Spain, Greece and Portugal | ' | ' |
Concentration of Risk | ' | ' |
Trade receivables by principal customers (as a percent) | 12.00% | 16.00% |
Separation_of_AbbVie_Inc_Detai
Separation of AbbVie Inc. (Details) (USD $) | 0 Months Ended | 3 Months Ended | 12 Months Ended | |||||||
Jan. 02, 2013 | Mar. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Jan. 02, 2013 | Dec. 31, 2013 | |
AbbVie | AbbVie | Proprietary Pharmaceuticals Business | Proprietary Pharmaceuticals Business | Proprietary Pharmaceuticals Business | Proprietary Pharmaceuticals Business | Proprietary Pharmaceuticals Business Assets and Liabilities Held for Disposal | ||||
Maximum | AbbVie | AbbVie | AbbVie | AbbVie | AbbVie | |||||
Separation of AbbVie Inc. | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock distribution ratio | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' |
Assets: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cash and cash equivalents | ' | ' | ' | ' | ' | ' | ' | ' | $5,900,000,000 | ' |
Investments | ' | ' | ' | ' | ' | ' | ' | ' | 2,200,000,000 | ' |
Trade receivables, less allowances | ' | ' | ' | ' | ' | ' | ' | ' | 3,200,000,000 | 163,000,000 |
Inventories | ' | ' | ' | ' | ' | ' | ' | ' | 700,000,000 | 243,000,000 |
Prepaid expenses, deferred income taxes, and other current receivables | ' | ' | ' | ' | ' | ' | ' | ' | 2,900,000,000 | ' |
Net property and equipment | ' | ' | ' | ' | ' | ' | ' | ' | 2,200,000,000 | 28,000,000 |
Intangible assets, net of amortization | ' | ' | ' | ' | ' | ' | ' | ' | 2,300,000,000 | ' |
Goodwill | ' | ' | ' | ' | ' | ' | ' | ' | 6,100,000,000 | ' |
Deferred income taxes and other assets | ' | ' | ' | ' | ' | ' | ' | ' | 1,100,000,000 | ' |
Total assets | ' | ' | ' | ' | ' | ' | ' | ' | 26,600,000,000 | ' |
Liabilities: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Short-term borrowings | ' | ' | ' | ' | ' | ' | ' | ' | 1,000,000,000 | ' |
Trade accounts payable and other current liabilities | ' | ' | ' | ' | ' | ' | ' | ' | 5,200,000,000 | ' |
Long-term debt | ' | ' | ' | ' | ' | ' | ' | ' | 14,600,000,000 | ' |
Post-employment obligations, deferred income taxes and other long-term liabilities | ' | ' | ' | ' | ' | ' | ' | ' | 3,100,000,000 | ' |
Total liabilities | ' | ' | ' | ' | ' | ' | ' | ' | 23,900,000,000 | ' |
Net Assets Transferred to AbbVie Inc. | ' | ' | ' | ' | ' | ' | ' | ' | 2,700,000,000 | ' |
Additional disclosures | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accumulated other comprehensive losses, net of income taxes, primarily related to the pension and other benefit plan net liabilities as well as foreign translation | ' | ' | ' | ' | ' | ' | ' | ' | 1,000,000,000 | ' |
Favorable resolution of various tax positions | 103,000,000 | ' | 234,000,000 | ' | ' | 193,000,000 | ' | ' | ' | ' |
Financial information for discontinued operations | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net sales | ' | ' | ' | ' | ' | ' | 18,380,000,000 | 17,444,000,000 | ' | ' |
Earnings before taxes | ' | ' | ' | ' | ' | ' | 5,958,000,000 | 3,963,000,000 | ' | ' |
Taxes on earnings | ' | ' | ' | ' | ' | ' | 574,000,000 | 361,000,000 | ' | ' |
Net earnings | ' | ' | ' | ' | ' | ' | 5,384,000,000 | 3,602,000,000 | ' | ' |
Term for which transition services may be provided | ' | ' | ' | ' | '24 months | ' | ' | ' | ' | ' |
Term by which the transition services agreement can be extended | ' | ' | ' | '1 year | ' | ' | ' | ' | ' | ' |
Additional disclosures | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other current assets | ' | ' | ' | ' | ' | ' | ' | ' | ' | 32,000,000 |
Other assets | ' | ' | ' | ' | ' | ' | ' | ' | ' | 38,000,000 |
Trade accounts payable and accrued liabilities | ' | ' | ' | ' | ' | ' | ' | ' | ' | 386,000,000 |
Accrued liabilities | ' | ' | ' | ' | ' | ' | ' | ' | ' | 387,000,000 |
Other liabilities | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7,000,000 |
Obligation to transfer the net assets held for disposition included in other current liabilities | ' | ' | ' | ' | ' | ' | ' | ' | ' | $111,000,000 |
Supplemental_Financial_Informa2
Supplemental Financial Information (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | |
Supplemental Financial Information | ' | ' | ' |
Net loss on extinguishment of debt | $1,351,000,000 | ' | ' |
Redemption amount | 7,700,000,000 | ' | ' |
Premium paid and the write off of deferred financing costs | 1,830,000,000 | ' | ' |
Component of long-term investment | ' | ' | ' |
Charge recorded to other (income) expense | ' | 137,000,000 | ' |
Long-term Investment Securities | 274,000,000 | ' | 119,000,000 |
Gross unrecognized tax benefits | 2,257,000,000 | 2,123,000,000 | 1,965,000,000 |
Other Accrued Liabilities: | ' | ' | ' |
Accrued rebates payable to government agencies | 1,020,000,000 | ' | 136,000,000 |
Accrued other rebates | 1,079,000,000 | ' | 220,000,000 |
All other accrued liabilities | 4,689,000,000 | ' | 3,144,000,000 |
Other accrued liabilities, total | 6,788,000,000 | ' | 3,500,000,000 |
Accrued wholesaler chargeback rebates | 300,000,000 | ' | 90,000,000 |
Post-employment Obligations and Other Long-term Liabilities: | ' | ' | ' |
Defined benefit pension plans and post-employment medical and dental plans for significant plans | 4,871,000,000 | ' | 1,818,000,000 |
Deferred income taxes | 710,000,000 | ' | 466,000,000 |
All other | 3,476,000,000 | ' | 2,500,000,000 |
Post-employment Obligations and Other Long-term Liabilities | 9,057,000,000 | ' | 4,784,000,000 |
Designated as hedge | Fair value hedges | Interest rate swaps | ' | ' | ' |
Component of long-term investment | ' | ' | ' |
Gain related to the unwinding of interest rate swaps related a portion of the debt | 479,000,000 | ' | ' |
Other (income) expense | ' | ' | ' |
Component of long-term investment | ' | ' | ' |
Charge recorded to other (income) expense | ' | 100,000,000 | ' |
Other Accrued Liabilities: | Piramal Healthcare Limited's Healthcare Solutions business | ' | ' | ' |
Component of long-term investment | ' | ' | ' |
Contingent consideration | 400,000,000 | ' | 400,000,000 |
Post-employment Obligations and Other Long-term Liabilities: | ' | ' | ' |
Component of long-term investment | ' | ' | ' |
Gross unrecognized tax benefits | 1,400,000,000 | ' | 1,300,000,000 |
Post-employment Obligations and Other Long-term Liabilities: | Piramal Healthcare Limited's Healthcare Solutions business | ' | ' | ' |
Component of long-term investment | ' | ' | ' |
Contingent consideration | 385,000,000 | ' | 70,000,000 |
Equity securities | ' | ' | ' |
Component of long-term investment | ' | ' | ' |
Long-term Investment Securities | 213,000,000 | ' | 93,000,000 |
Other | ' | ' | ' |
Component of long-term investment | ' | ' | ' |
Long-term Investment Securities | $61,000,000 | ' | $26,000,000 |
Accumulated_Other_Comprehensiv2
Accumulated Other Comprehensive Income (Details) (USD $) | 12 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2011 | Dec. 31, 2010 |
Other comprehensive income from continuing operations, net of income taxes | ' | ' | ' |
Balance at the beginning of the period | ($3,594) | $212 | ($1,367) |
Separation of AbbVie | 1,010 | ' | ' |
Other comprehensive income (loss) before reclassifications | 531 | ' | ' |
Income (loss) amounts reclassified from accumulated other comprehensive income | 41 | ' | ' |
Net current period comprehensive income (loss) from continuing operations | 572 | ' | ' |
Balance at the end of the period | -2,012 | 212 | -1,367 |
Cumulative Foreign Currency Translation Adjustments | ' | ' | ' |
Other comprehensive income from continuing operations, net of income taxes | ' | ' | ' |
Balance at the beginning of the period | -79 | ' | ' |
Separation of AbbVie | -400 | ' | ' |
Other comprehensive income (loss) before reclassifications | -239 | ' | ' |
Net current period comprehensive income (loss) from continuing operations | -239 | ' | ' |
Balance at the end of the period | -718 | ' | ' |
Net Actuarial Losses and Prior Service Costs and Credits | ' | ' | ' |
Other comprehensive income from continuing operations, net of income taxes | ' | ' | ' |
Balance at the beginning of the period | -3,596 | ' | ' |
Separation of AbbVie | 1,402 | ' | ' |
Other comprehensive income (loss) before reclassifications | 771 | ' | ' |
Income (loss) amounts reclassified from accumulated other comprehensive income | 111 | ' | ' |
Net current period comprehensive income (loss) from continuing operations | 882 | ' | ' |
Balance at the end of the period | -1,312 | ' | ' |
Cumulative Unrealized Gains on Marketable Equity Securities | ' | ' | ' |
Other comprehensive income from continuing operations, net of income taxes | ' | ' | ' |
Balance at the beginning of the period | 31 | ' | ' |
Other comprehensive income (loss) before reclassifications | 22 | ' | ' |
Income (loss) amounts reclassified from accumulated other comprehensive income | -40 | ' | ' |
Net current period comprehensive income (loss) from continuing operations | -18 | ' | ' |
Balance at the end of the period | 13 | ' | ' |
Cumulative Gains on Derivative Instruments Designated as Cash Flow Hedges | ' | ' | ' |
Other comprehensive income from continuing operations, net of income taxes | ' | ' | ' |
Balance at the beginning of the period | 50 | ' | ' |
Separation of AbbVie | 8 | ' | ' |
Other comprehensive income (loss) before reclassifications | -23 | ' | ' |
Income (loss) amounts reclassified from accumulated other comprehensive income | -30 | ' | ' |
Net current period comprehensive income (loss) from continuing operations | -53 | ' | ' |
Balance at the end of the period | $5 | ' | ' |
Business_Acquisitions_Details
Business Acquisitions (Details) (USD $) | 12 Months Ended | 1 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Aug. 31, 2013 | Aug. 31, 2013 |
IDEV Technologies | OptiMedica | |||
Business acquisitions | ' | ' | ' | ' |
Percentage of voting interest acquired | ' | ' | 100.00% | 100.00% |
Cash paid for business acquisition | ' | ' | $310 | $260 |
Additional payments upon completion of certain development, regulatory and sales milestones | ' | ' | ' | 150 |
Non-deductible acquired in-process research and development | ' | ' | 170 | 60 |
Non-deductible definite-lived intangible assets | ' | ' | 66 | 160 |
Non-deductible goodwill | 9,772 | 15,774 | 123 | 151 |
Net deferred tax liabilities | ' | ' | 56 | 70 |
Contingent consideration | ' | ' | ' | $70 |
Amortization period of acquired intangible assets | '11 years | ' | '11 years | '18 years |
Goodwill_and_Intangible_Assets1
Goodwill and Intangible Assets (Details) (USD $) | 12 Months Ended | 0 Months Ended | 12 Months Ended | ||||||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Jan. 02, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | |
AbbVie | Established Pharmaceutical Products | Nutritional Products | Diagnostic Products | Vascular Products | IDEV Technologies and OptiMedica | ||||
Goodwill and intangible assets information | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Goodwill on acquisition | ' | ' | ' | ' | $2,900,000,000 | $286,000,000 | $444,000,000 | $3,100,000,000 | $274,000,000 |
Change in goodwill due to foreign currency translation and other adjustments | -168,000,000 | 69,000,000 | -225,000,000 | ' | ' | ' | ' | ' | ' |
Amount of goodwill transferred | ' | ' | ' | 6,100,000,000 | ' | ' | ' | ' | ' |
Amount of reductions of goodwill relating to the disposal of all or a portion of a business other than the effects of the separation of AbbVie | 0 | ' | ' | ' | ' | ' | ' | ' | ' |
Amount of reduction of goodwill relating to impairments | $0 | ' | ' | ' | ' | ' | ' | ' | ' |
Goodwill_and_Intangible_Assets2
Goodwill and Intangible Assets (Details 2) (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Goodwill and Intangible Assets | ' | ' | ' |
Gross amount of amortizable intangible assets | $12,200,000,000 | $17,600,000,000 | ' |
Accumulated amortization of intangible assets | 6,800,000,000 | 9,700,000,000 | ' |
Indefinite-lived intangible assets related to in-process research and development acquired in a business combination | 266,000,000 | 691,000,000 | ' |
Estimated annual amortization expense, intangible assets, 2014 | 711,000,000 | ' | ' |
Estimated annual amortization expense, intangible assets, 2015 | 652,000,000 | ' | ' |
Estimated annual amortization expense, intangible assets, 2016 | 636,000,000 | ' | ' |
Estimated annual amortization expense, intangible assets, 2017 | 635,000,000 | ' | ' |
Estimated annual amortization expense, intangible assets, 2018 | 505,000,000 | ' | ' |
Average amortization period, intangible assets | '11 years | ' | ' |
Impairment charges for certain research and development assets | ' | 69,000,000 | 125,000,000 |
Minimum | ' | ' | ' |
Goodwill and Intangible Assets | ' | ' | ' |
Average amortization period, intangible assets | '2 years | ' | ' |
Maximum | ' | ' | ' |
Goodwill and Intangible Assets | ' | ' | ' |
Average amortization period, intangible assets | '20 years | ' | ' |
AbbVie | ' | ' | ' |
Goodwill and Intangible Assets | ' | ' | ' |
Gross amount of amortizable intangible assets | 5,700,000,000 | ' | ' |
Accumulated amortization of intangible assets | 3,800,000,000 | ' | ' |
Indefinite-lived intangible assets related to in-process research and development acquired in a business combination | $417,000,000 | ' | ' |
Restructuring_Plans_Details
Restructuring Plans (Details) (USD $) | 12 Months Ended | |||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 |
Restructuring Plan 2012 | ' | ' | ' | ' |
Restructuring costs | ' | ' | ' | ' |
Employee related severance charges | $78 | $167 | ' | ' |
Asset impairments and contractual obligations in restructuring charges | 4 | 22 | ' | ' |
Restructuring charges | 78 | 167 | ' | ' |
Restructuring reserve | 148 | ' | ' | ' |
Restructuring Plan 2012 | Cost of products sold | ' | ' | ' | ' |
Restructuring costs | ' | ' | ' | ' |
Restructuring charges | 35 | 70 | ' | ' |
Restructuring Plan 2012 | Selling, general and administrative expense | ' | ' | ' | ' |
Restructuring costs | ' | ' | ' | ' |
Restructuring charges | 47 | 119 | ' | ' |
Restructuring Plan 2013 and Prior Years | ' | ' | ' | ' |
Restructuring costs | ' | ' | ' | ' |
Employee related severance charges | 11 | ' | ' | ' |
Restructuring charges | 11 | ' | 194 | ' |
Restructuring reserve | 20 | 129 | 177 | 77 |
Accelerated depreciation in restructuring charges | 41 | 110 | 25 | ' |
Restructuring Plan 2013 and Prior Years | AbbVie | ' | ' | ' | ' |
Restructuring costs | ' | ' | ' | ' |
Restructuring charges | ' | ' | 176 | ' |
Restructuring Plan 2013 and Prior Years | Cost of products sold | ' | ' | ' | ' |
Restructuring costs | ' | ' | ' | ' |
Restructuring charges | 11 | ' | 18 | ' |
Restructuring Plan 2012 and 2010 | ' | ' | ' | ' |
Restructuring costs | ' | ' | ' | ' |
Employee related severance charges | ' | 150 | ' | ' |
Restructuring reserve | 0 | ' | ' | ' |
Restructuring Plan 2012 and 2010 | AbbVie | ' | ' | ' | ' |
Restructuring costs | ' | ' | ' | ' |
Restructuring reserve | 0 | 115 | ' | ' |
Restructuring Plan 2011 and 2008 | ' | ' | ' | ' |
Restructuring costs | ' | ' | ' | ' |
Restructuring charges | ' | ' | 28 | ' |
Restructuring reserve | 41 | 56 | 79 | 88 |
Accelerated depreciation and product transfer costs | ' | 16 | 42 | ' |
Restructuring Plan 2011 and 2008 | Cost of products sold | ' | ' | ' | ' |
Restructuring costs | ' | ' | ' | ' |
Restructuring charges | ' | ' | $28 | ' |
Restructuring_Plans_Details_2
Restructuring Plans (Details 2) (USD $) | 12 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Restructuring Plan 2012 | ' | ' | ' |
Restructuring reserve activity | ' | ' | ' |
Restructuring charges | $78 | $167 | ' |
Payments, impairment and other adjustments | -97 | ' | ' |
Restructuring reserve, ending balance of the period | 148 | ' | ' |
Restructuring Plan 2013 and Prior Years | ' | ' | ' |
Restructuring reserve activity | ' | ' | ' |
Restructuring reserve, beginning balance of the period | 129 | 177 | 77 |
Restructuring charges | 11 | ' | 194 |
Transfer of liability to AbbVie | -62 | ' | ' |
Payments, impairment and other adjustments | -58 | -48 | -94 |
Restructuring reserve, ending balance of the period | 20 | 129 | 177 |
Restructuring Plan 2011 and 2008 | ' | ' | ' |
Restructuring reserve activity | ' | ' | ' |
Restructuring reserve, beginning balance of the period | 56 | 79 | 88 |
Restructuring charges | ' | ' | 28 |
Payments, impairment and other adjustments | -15 | -23 | -37 |
Restructuring reserve, ending balance of the period | $41 | $56 | $79 |
Incentive_Stock_Program_Detail
Incentive Stock Program (Details) (USD $) | 12 Months Ended | |||
In Millions, except Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Jan. 02, 2013 |
Share-based Compensation Arrangement by Share-based Payment Award | ' | ' | ' | ' |
Incentive stock programs, shares reserved for future grants | 130,000,000 | ' | ' | ' |
Incentive stock programs, reduction in shares reserved for future grants (in shares) | 22,000,000 | ' | ' | ' |
Stock options | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award | ' | ' | ' | ' |
Award vesting period | '3 years | ' | ' | ' |
Stock options outstanding, weighted-average remaining life | '4 years | '4 years | ' | ' |
Exercisable options, weighted-average remaining life | '3 years 1 month 6 days | '3 years 8 months 12 days | ' | ' |
Stock options outstanding during the period | ' | ' | ' | ' |
Stock options outstanding at the beginning of the period (in shares) | 48,685,273 | ' | ' | ' |
Stock options outstanding at the beginning of the period, weighted-average exercise price (in dollars per share) | $24.97 | ' | ' | ' |
Stock options granted during the period (in shares) | 5,652,197 | ' | ' | ' |
Stock options granted during the period, weighted-average exercise price (in dollars per share) | $34.91 | ' | ' | ' |
Stock options exercised during the period (in shares) | -11,370,121 | ' | ' | ' |
Stock options exercised during the period, weighted-average exercise price (in dollars per share) | $25.37 | ' | ' | ' |
Stock options lapsed during the period (in shares) | -210,009 | ' | ' | ' |
Stock options lapsed during the period, weighted-average exercise price (in dollars per share) | $31.82 | ' | ' | ' |
Stock options outstanding at the end of the period (in shares) | 42,757,340 | 48,685,273 | ' | ' |
Stock options outstanding at the end of the period, weighted-average exercise price (in dollars per share) | $26.15 | $24.97 | ' | ' |
Exercisable options outstanding at the beginning of the period (in shares) | 43,511,651 | ' | ' | ' |
Exercisable options outstanding at the end of the period (in shares) | 36,185,039 | 43,511,651 | ' | ' |
Exercisable options outstanding, weighted-average exercise price at the beginning of the period (in dollars per share) | $24.68 | ' | ' | ' |
Exercisable options outstanding, weighted-average exercise price at the end of the period (in dollars per share) | $25.02 | $24.68 | ' | ' |
Aggregate intrinsic value of options outstanding | $525 | ' | ' | ' |
Aggregate intrinsic value of options exercisable | 487 | ' | ' | ' |
Total intrinsic value of options exercised | 120 | 528 | 94 | ' |
Total unrecognized compensation cost | 153 | ' | ' | ' |
Total unrecognized compensation cost, recognition period | '3 years | ' | ' | ' |
Total non-cash compensation expense charged against income | 262 | 284 | 256 | ' |
Tax benefit recognized in total non-cash compensation expense | 84 | 87 | 71 | ' |
Fair value of an option granted (in dollars per share) | $5.77 | $6.80 | $6.23 | ' |
Fair value assumptions: | ' | ' | ' | ' |
Risk-free interest rate (as a percent) | 1.10% | 1.20% | 2.70% | ' |
Average life of options | '6 years | '6 years | '6 years | ' |
Volatility (as a percent) | 20.00% | 21.00% | 21.00% | ' |
Dividend yield (as a percent) | 1.60% | 3.60% | 4.10% | ' |
Stock options | Maximum | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award | ' | ' | ' | ' |
Maximum term of option | '10 years | ' | ' | ' |
Restricted stock awards and restricted stock units | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award | ' | ' | ' | ' |
Awards and units outstanding (in shares) | 14,385,221 | ' | ' | 15,728,503 |
Awards and units outstanding, weighted-average grant-date fair value (in dollars per share) | $30.13 | ' | ' | $25.51 |
Awards and units granted during period (in shares) | 7,261,541 | ' | ' | ' |
Awards and units granted during period, weighted-average grant-date fair value (in dollars per share) | $34.92 | ' | ' | ' |
Awards and units vested during period (in shares) | 7,821,999 | ' | ' | ' |
Awards and units vested during period, weighted-average grant-date fair value (in dollars per share) | $25.36 | ' | ' | ' |
Awards and units lapsed during period (in shares) | 782,824 | ' | ' | ' |
Awards and units lapsed during period, weighted-average grant-date fair value (in dollars per share) | $29.34 | ' | ' | ' |
Fair value of awards and units vested | $274 | $385 | $237 | ' |
Restricted stock awards | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award | ' | ' | ' | ' |
For awards with a term of five years, number of years in which no more than one-third of the award vests | '1 year | ' | ' | ' |
Portion of awards vesting in any one year for awards that vest over 5 years (as a percent) | 33.00% | ' | ' | ' |
Restricted stock awards | Minimum | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award | ' | ' | ' | ' |
Award vesting period | '3 years | ' | ' | ' |
Restricted stock awards | Maximum | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award | ' | ' | ' | ' |
Award vesting period | '5 years | ' | ' | ' |
Restricted stock units | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award | ' | ' | ' | ' |
Award vesting period | '3 years | ' | ' | ' |
Number of shares of common stock received for each vested restricted stock unit (in shares) | 1 | ' | ' | ' |
2009 Incentive Stock Program | Stock options | ' | ' | ' | ' |
Stock options outstanding during the period | ' | ' | ' | ' |
Stock options granted during the period (in shares) | 4,733,378 | ' | ' | ' |
2009 Incentive Stock Program | Replacement stock options | ' | ' | ' | ' |
Stock options outstanding during the period | ' | ' | ' | ' |
Stock options granted during the period (in shares) | 918,819 | ' | ' | ' |
2009 Incentive Stock Program | Restricted stock awards | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award | ' | ' | ' | ' |
Awards and units granted during period (in shares) | 848,674 | ' | ' | ' |
2009 Incentive Stock Program | Restricted stock units | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award | ' | ' | ' | ' |
Awards and units granted during period (in shares) | 6,412,867 | ' | ' | ' |
Debt_and_Lines_of_Credit_Detai
Debt and Lines of Credit (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2011 | |
Debt Instrument | ' | ' | ' |
Total, net of current maturities | $18,085,000,000 | $3,388,000,000 | ' |
Current portion of long-term debt | 309,000,000 | 9,000,000 | ' |
Total carrying amount | 18,394,000,000 | 3,397,000,000 | ' |
Redemption amount | 7,700,000,000 | ' | ' |
Net loss on extinguishment of debt | 1,351,000,000 | ' | ' |
Principal payments of long-term debt | ' | ' | ' |
Principal payments required in 2014 | ' | 9,000,000 | ' |
Principal payments required in 2015 | ' | 10,000,000 | ' |
Principal payments required in 2016 | ' | 3,000,000 | ' |
Principal payments required in 2017 | ' | 1,000,000 | ' |
Principal payments required in 2018 | ' | 1,000,000 | ' |
Principal payments required in 2019 and thereafter | ' | 3,300,000,000 | ' |
Unused lines of credit | ' | 5,000,000,000 | ' |
Weighted-average interest rate on short-term borrowings (as a percent) | 0.40% | 0.20% | 0.40% |
AbbVie | ' | ' | ' |
Debt Instrument | ' | ' | ' |
Long-term debt issued | 14,700,000,000 | ' | ' |
AbbVie | Minimum | ' | ' | ' |
Debt Instrument | ' | ' | ' |
Maturity period | '3 years | ' | ' |
AbbVie | Maximum | ' | ' | ' |
Debt Instrument | ' | ' | ' |
Maturity period | '30 years | ' | ' |
1.2% Notes, due 2015 | ' | ' | ' |
Debt Instrument | ' | ' | ' |
Total, net of current maturities | 3,500,000,000 | ' | ' |
Interest rate percentage | 1.20% | ' | ' |
Variable Rate Notes, due 2015 | ' | ' | ' |
Debt Instrument | ' | ' | ' |
Total, net of current maturities | 500,000,000 | ' | ' |
1.75% Notes, due 2017 | ' | ' | ' |
Debt Instrument | ' | ' | ' |
Total, net of current maturities | 4,000,000,000 | ' | ' |
Interest rate percentage | 1.75% | ' | ' |
2.0% Notes, due 2018 | ' | ' | ' |
Debt Instrument | ' | ' | ' |
Total, net of current maturities | 1,000,000,000 | ' | ' |
Interest rate percentage | 2.00% | ' | ' |
5.125% Notes, due 2019 | ' | ' | ' |
Debt Instrument | ' | ' | ' |
Total, net of current maturities | 947,000,000 | 947,000,000 | ' |
Interest rate percentage | 5.13% | 5.13% | ' |
4.125% Notes, due 2020 | ' | ' | ' |
Debt Instrument | ' | ' | ' |
Total, net of current maturities | 597,000,000 | 597,000,000 | ' |
Interest rate percentage | 4.13% | 4.13% | ' |
2.9% Notes, due 2022 | ' | ' | ' |
Debt Instrument | ' | ' | ' |
Total, net of current maturities | 3,100,000,000 | ' | ' |
Interest rate percentage | 2.90% | ' | ' |
6.15% Notes, due 2037 | ' | ' | ' |
Debt Instrument | ' | ' | ' |
Total, net of current maturities | 547,000,000 | 547,000,000 | ' |
Interest rate percentage | 6.15% | 6.15% | ' |
6.0% Notes, due 2039 | ' | ' | ' |
Debt Instrument | ' | ' | ' |
Total, net of current maturities | 515,000,000 | 515,000,000 | ' |
Interest rate percentage | 6.00% | 6.00% | ' |
5.3% Notes, due 2040 | ' | ' | ' |
Debt Instrument | ' | ' | ' |
Total, net of current maturities | 694,000,000 | 694,000,000 | ' |
Interest rate percentage | 5.30% | 5.30% | ' |
4.4% Notes, due 2042 | ' | ' | ' |
Debt Instrument | ' | ' | ' |
Total, net of current maturities | 2,600,000,000 | ' | ' |
Interest rate percentage | 4.40% | ' | ' |
Other, including fair value adjustments relating to interest rate hedge contracts designated as fair value hedges | ' | ' | ' |
Debt Instrument | ' | ' | ' |
Total, net of current maturities | $85,000,000 | $88,000,000 | ' |
Financial_Instruments_Derivati2
Financial Instruments, Derivatives and Fair Value Measures (Details) (USD $) | 12 Months Ended | |||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Jan. 02, 2013 | |
Derivative instruments, notional amount and fair value | ' | ' | ' | ' |
Gross unrealized holding gains on available-for-sale equity securities | $22,000,000 | $51,000,000 | $64,000,000 | ' |
Fair Value - Assets | 171,000,000 | 305,000,000 | ' | ' |
Fair Value - Liabilities | 580,000,000 | 841,000,000 | ' | ' |
Designated as hedging instrument | Short-term borrowings | Net investment hedges | ' | ' | ' | ' |
Derivative instruments, notional amount and fair value | ' | ' | ' | ' |
Fair Value - Liabilities | 505,000,000 | 615,000,000 | 680,000,000 | ' |
Designated as hedging instrument | Interest rate swaps | Fair value hedges | ' | ' | ' | ' |
Derivative instruments, notional amount and fair value | ' | ' | ' | ' |
Notional amount of cash flow hedge instruments | 1,500,000,000 | 9,500,000,000 | 6,800,000,000 | ' |
Contracts transferred to AbbVie | ' | ' | ' | 8,000,000,000 |
Amount of hedge ineffectiveness recorded in income | 0 | 0 | 0 | ' |
Designated as hedging instrument | Interest rate swaps | Deferred income taxes and other assets | Fair value hedges | ' | ' | ' | ' |
Derivative instruments, notional amount and fair value | ' | ' | ' | ' |
Fair Value - Assets | 87,000,000 | 185,000,000 | ' | ' |
Designated as hedging instrument | Interest rate swaps | Post-employment obligations, deferred income taxes and other long-term liabilities | Fair value hedges | ' | ' | ' | ' |
Derivative instruments, notional amount and fair value | ' | ' | ' | ' |
Fair Value - Liabilities | ' | 80,000,000 | ' | ' |
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | ' | ' | ' | ' |
Derivative instruments, notional amount and fair value | ' | ' | ' | ' |
Notional amount of cash flow hedge instruments | 137,000,000 | 1,600,000,000 | ' | ' |
Contracts transferred to AbbVie | ' | ' | ' | 1,000,000,000 |
Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold | '12 months | ' | ' | ' |
Designated as hedging instrument | Foreign currency forward exchange contracts | Prepaid expenses, deferred income taxes, and other receivables | ' | ' | ' | ' |
Derivative instruments, notional amount and fair value | ' | ' | ' | ' |
Fair Value - Assets | 14,000,000 | 22,000,000 | ' | ' |
Designated as hedging instrument | Foreign currency forward exchange contracts | Other accrued liabilities | ' | ' | ' | ' |
Derivative instruments, notional amount and fair value | ' | ' | ' | ' |
Fair Value - Liabilities | ' | 11,000,000 | ' | ' |
Not designated as hedging instrument | Foreign currency forward exchange contracts | ' | ' | ' | ' |
Derivative instruments, notional amount and fair value | ' | ' | ' | ' |
Notional amount of cash flow hedge instruments | 13,800,000,000 | 18,200,000,000 | 15,700,000,000 | ' |
Contracts transferred to AbbVie | ' | ' | ' | 4,300,000,000 |
Not designated as hedging instrument | Foreign currency forward exchange contracts | Prepaid expenses, deferred income taxes, and other receivables | ' | ' | ' | ' |
Derivative instruments, notional amount and fair value | ' | ' | ' | ' |
Fair Value - Assets | 70,000,000 | 98,000,000 | ' | ' |
Not designated as hedging instrument | Foreign currency forward exchange contracts | Other accrued liabilities | ' | ' | ' | ' |
Derivative instruments, notional amount and fair value | ' | ' | ' | ' |
Fair Value - Liabilities | $75,000,000 | $135,000,000 | ' | ' |
Financial_Instruments_Derivati3
Financial Instruments, Derivatives and Fair Value Measures (Details 2) (USD $) | 12 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Net investment hedges | Designated as hedging instrument | ' | ' | ' |
Gain (loss) on derivatives | ' | ' | ' |
Gain (loss) Recognized in Other Comprehensive Income (loss) | $110 | $65 | ($30) |
Interest rate swaps | Fair value hedges | Designated as hedging instrument | Interest expense | ' | ' | ' |
Gain (loss) on derivatives | ' | ' | ' |
Gain (loss) Reclassified into Income | -98 | 62 | 488 |
Foreign currency forward exchange contracts | Not designated as hedging instrument | Net foreign exchange loss (gain) | ' | ' | ' |
Gain (loss) on derivatives | ' | ' | ' |
Income (expense) | 88 | 131 | -41 |
Foreign currency forward exchange contracts | Cash flow hedges | Designated as hedging instrument | Cost of products sold | ' | ' | ' |
Gain (loss) on derivatives | ' | ' | ' |
Gain (loss) Recognized in Other Comprehensive Income (loss) | 35 | 13 | 67 |
Gain (loss) Reclassified into Income | $47 | $114 | ($44) |
Financial_Instruments_Derivati4
Financial Instruments, Derivatives and Fair Value Measures (Details 3) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Millions, unless otherwise specified | ||
Fair value, asset and liability measures | ' | ' |
Long-term Investment Securities | $119 | $274 |
Equity securities | ' | ' |
Fair value, asset and liability measures | ' | ' |
Long-term Investment Securities | 93 | 213 |
Carrying value | ' | ' |
Fair value, asset and liability measures | ' | ' |
Total long-term debt | -3,397 | -18,394 |
Foreign currency forward exchange contracts, receivable position | 84 | 120 |
Foreign currency forward exchange contracts, (payable) position | -75 | -146 |
Interest rate hedge contracts, receivable position | 87 | 185 |
Interest rate hedge contract, (payable) position | ' | -80 |
Carrying value | Equity securities | ' | ' |
Fair value, asset and liability measures | ' | ' |
Long-term Investment Securities | 93 | 213 |
Carrying value | Other | ' | ' |
Fair value, asset and liability measures | ' | ' |
Long-term Investment Securities | 26 | 61 |
Fair value | ' | ' |
Fair value, asset and liability measures | ' | ' |
Total long-term debt | -3,930 | -19,588 |
Foreign currency forward exchange contracts, receivable position | 84 | 120 |
Foreign currency forward exchange contracts, (payable) position | -75 | -146 |
Interest rate hedge contracts, receivable position | 87 | 185 |
Interest rate hedge contract, (payable) position | ' | -80 |
Fair value | Equity securities | ' | ' |
Fair value, asset and liability measures | ' | ' |
Long-term Investment Securities | 93 | 213 |
Fair value | Other | ' | ' |
Fair value, asset and liability measures | ' | ' |
Long-term Investment Securities | $24 | $56 |
Financial_Instruments_Derivati5
Financial Instruments, Derivatives and Fair Value Measures (Details 4) (Recurring, USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Millions, unless otherwise specified | ||
Fair value | ' | ' |
Fair value, asset and liability measures | ' | ' |
Equity securities | $26 | $76 |
Interest rate swap derivative financial instruments, assets | 87 | 185 |
Foreign currency forward exchange contracts, assets | 84 | 120 |
Total Assets | 197 | 381 |
Fair value of hedged long-term debt | 1,623 | 9,632 |
Interest rate swap derivative financial instruments, liabilities | ' | 80 |
Foreign currency forward exchange contracts, liabilities | 75 | 146 |
Contingent consideration related to business combinations | 208 | 323 |
Total Liabilities | 1,906 | 10,181 |
Quoted Prices in Active Markets | ' | ' |
Fair value, asset and liability measures | ' | ' |
Equity securities | 26 | 76 |
Total Assets | 26 | 76 |
Significant Other Observable Inputs | ' | ' |
Fair value, asset and liability measures | ' | ' |
Interest rate swap derivative financial instruments, assets | 87 | 185 |
Foreign currency forward exchange contracts, assets | 84 | 120 |
Total Assets | 171 | 305 |
Fair value of hedged long-term debt | 1,623 | 9,632 |
Interest rate swap derivative financial instruments, liabilities | ' | 80 |
Foreign currency forward exchange contracts, liabilities | 75 | 146 |
Total Liabilities | 1,698 | 9,858 |
Significant Unobservable Inputs | ' | ' |
Fair value, asset and liability measures | ' | ' |
Contingent consideration related to business combinations | 208 | 323 |
Total Liabilities | $208 | $323 |
Litigation_and_Environmental_M1
Litigation and Environmental Matters (Details) (USD $) | Dec. 31, 2013 |
In Millions, unless otherwise specified | |
Loss Contingencies | ' |
Maximum expected cleanup exposure for individual site | $4 |
Maximum expected cleanup exposure in aggregate | 15 |
Other legal proceedings and environmental exposures | ' |
Loss Contingencies | ' |
Other legal proceedings or environmental exposure, minimum | 70 |
Other legal proceedings or environmental exposure, maximum | 90 |
Recorded reserve balance for legal proceedings and exposures | $80 |
PostEmployment_Benefits_Detail
Post-Employment Benefits (Details) (USD $) | 12 Months Ended | 12 Months Ended | 12 Months Ended | ||||||||||||||||||||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2012 | Dec. 31, 2011 | Jan. 02, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
AbbVie | AbbVie | AbbVie | Defined Benefit Plans | Defined Benefit Plans | Defined Benefit Plans | Defined Benefit Plans | Defined Benefit Plans | Defined Benefit Plans | Defined Benefit Plans | Defined Benefit Plans | Medical and Dental Plans | Medical and Dental Plans | Medical and Dental Plans | Medical and Dental Plans | Medical and Dental Plans | Medical and Dental Plans | Medical and Dental Plans | Medical and Dental Plans | |||||
Discontinued operations | Discontinued operations | Continuing operations | Continuing operations | Continuing operations | Discontinued operations | Discontinued operations | Continuing operations | Continuing operations | Continuing operations | ||||||||||||||
Projected benefit obligations: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Projected benefit obligations, balance at the beginning of the period | ' | ' | ' | ' | ' | ' | ' | $11,322,000,000 | $9,212,000,000 | ' | ' | ' | ' | ' | ' | $1,889,000,000 | $1,657,000,000 | ' | ' | ' | ' | ' | ' |
Service cost - benefits earned during the year | ' | ' | ' | ' | ' | ' | ' | 303,000,000 | 389,000,000 | 332,000,000 | ' | ' | ' | ' | ' | 43,000,000 | 61,000,000 | 55,000,000 | ' | ' | ' | ' | ' |
Interest cost on projected benefit obligations | ' | ' | ' | ' | ' | ' | ' | 276,000,000 | 460,000,000 | 446,000,000 | ' | ' | ' | ' | ' | 59,000,000 | 81,000,000 | 88,000,000 | ' | ' | ' | ' | ' |
(Gains) losses, primarily changes in discount rates, plan design changes, law changes and differences between actual and estimated health care costs | ' | ' | ' | ' | ' | ' | ' | -650,000,000 | 1,461,000,000 | ' | ' | ' | ' | ' | ' | -156,000,000 | 148,000,000 | ' | ' | ' | ' | ' | ' |
Benefits paid | ' | ' | ' | ' | ' | ' | ' | -185,000,000 | -308,000,000 | ' | ' | ' | ' | ' | ' | -60,000,000 | -60,000,000 | ' | ' | ' | ' | ' | ' |
Separation of AbbVie Inc | ' | ' | ' | ' | ' | ' | ' | -4,654,000,000 | ' | ' | ' | ' | ' | ' | ' | -450,000,000 | ' | ' | ' | ' | ' | ' | ' |
Settlement | ' | ' | ' | ' | ' | ' | ' | ' | ' | 776,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other, including foreign currency translation | ' | ' | ' | ' | ' | ' | ' | 20,000,000 | 108,000,000 | ' | ' | ' | ' | ' | ' | -28,000,000 | 5,000,000 | ' | ' | ' | ' | ' | ' |
Projected benefit obligations, balance at the end of the period | ' | ' | ' | ' | ' | ' | ' | 6,432,000,000 | 11,322,000,000 | 9,212,000,000 | ' | ' | ' | ' | ' | 1,297,000,000 | 1,889,000,000 | 1,657,000,000 | ' | ' | ' | ' | ' |
Plan assets at fair value: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Plan assets at fair value, balance at the beginning of the period | ' | ' | ' | ' | ' | ' | ' | 7,949,000,000 | 6,961,000,000 | ' | ' | ' | ' | ' | ' | 417,000,000 | 389,000,000 | ' | ' | ' | ' | ' | ' |
Actual return on plans' assets | ' | ' | ' | ' | ' | ' | ' | 727,000,000 | 878,000,000 | ' | ' | ' | ' | ' | ' | 61,000,000 | 48,000,000 | ' | ' | ' | ' | ' | ' |
Company contributions | ' | ' | ' | ' | ' | ' | ' | 724,000,000 | 379,000,000 | ' | ' | ' | ' | ' | ' | 40,000,000 | 40,000,000 | ' | ' | ' | ' | ' | ' |
Benefits paid | ' | ' | ' | ' | ' | ' | ' | -185,000,000 | -308,000,000 | ' | ' | ' | ' | ' | ' | -60,000,000 | -60,000,000 | ' | ' | ' | ' | ' | ' |
Separation of AbbVie Inc | ' | ' | ' | ' | ' | ' | ' | -3,107,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Settlement | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' |
Other, primarily foreign currency translation | ' | ' | ' | ' | ' | ' | ' | 15,000,000 | 33,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Plan assets at fair value, balance at the end of the period | ' | ' | ' | ' | ' | ' | ' | 6,123,000,000 | 7,949,000,000 | 6,961,000,000 | ' | ' | ' | ' | ' | 462,000,000 | 417,000,000 | 389,000,000 | ' | ' | ' | ' | ' |
Projected benefit obligations greater than plan assets | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Projected benefit obligations greater than plan assets, December 31 | ' | ' | ' | ' | ' | ' | ' | -309,000,000 | -3,373,000,000 | ' | ' | ' | ' | ' | ' | -835,000,000 | -1,472,000,000 | ' | ' | ' | ' | ' | ' |
Long-term assets | ' | ' | ' | ' | ' | ' | ' | 685,000,000 | 69,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Short-term liabilities | ' | ' | ' | ' | ' | ' | ' | -11,000,000 | -43,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long-term liabilities | -1,818,000,000 | -4,871,000,000 | ' | ' | ' | ' | ' | -983,000,000 | -3,399,000,000 | ' | ' | ' | ' | ' | ' | -835,000,000 | -1,472,000,000 | ' | ' | ' | ' | ' | ' |
Net liability | ' | ' | ' | ' | ' | ' | ' | -309,000,000 | -3,373,000,000 | ' | ' | ' | ' | ' | ' | -835,000,000 | -1,472,000,000 | ' | ' | ' | ' | ' | ' |
Amounts Recognized in Accumulated Other Comprehensive Income (loss): | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Actuarial losses, net | ' | ' | ' | ' | ' | ' | ' | 1,791,000,000 | 4,923,000,000 | ' | ' | ' | ' | ' | ' | 334,000,000 | 701,000,000 | ' | ' | ' | ' | ' | ' |
Prior service cost (credits) | ' | ' | ' | ' | ' | ' | ' | 20,000,000 | 61,000,000 | ' | ' | ' | ' | ' | ' | -252,000,000 | -322,000,000 | ' | ' | ' | ' | ' | ' |
Total | ' | ' | ' | ' | ' | ' | ' | 1,811,000,000 | 4,984,000,000 | ' | ' | ' | ' | ' | ' | 82,000,000 | 379,000,000 | ' | ' | ' | ' | ' | ' |
Accumulated other comprehensive income (loss), net of income taxes | -2,012,000,000 | -3,594,000,000 | 212,000,000 | -1,367,000,000 | ' | ' | 1,400,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Projected benefit obligations | 2,000,000,000 | 3,100,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accumulated benefit obligations | 5,500,000,000 | 9,600,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
The aggregate accumulated benefit obligations, the projected benefit obligations and the aggregate plan assets | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accumulated benefit obligation | 408,000,000 | 8,100,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Projected benefit obligation | 505,000,000 | 9,619,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair value of plan assets | ' | 6,243,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Defined benefit plan net periodic benefit cost | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Service cost - benefits earned during the year | ' | ' | ' | ' | ' | ' | ' | 303,000,000 | 389,000,000 | 332,000,000 | ' | ' | ' | ' | ' | 43,000,000 | 61,000,000 | 55,000,000 | ' | ' | ' | ' | ' |
Interest cost on projected benefit obligations | ' | ' | ' | ' | ' | ' | ' | 276,000,000 | 460,000,000 | 446,000,000 | ' | ' | ' | ' | ' | 59,000,000 | 81,000,000 | 88,000,000 | ' | ' | ' | ' | ' |
Expected return on plans' assets | ' | ' | ' | ' | ' | ' | ' | -396,000,000 | -611,000,000 | -608,000,000 | ' | ' | ' | ' | ' | -36,000,000 | -33,000,000 | -34,000,000 | ' | ' | ' | ' | ' |
Settlement | ' | ' | ' | ' | ' | ' | ' | ' | ' | 40,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amortization of actuarial losses | ' | ' | ' | ' | ' | ' | ' | 169,000,000 | 244,000,000 | 163,000,000 | ' | ' | ' | ' | ' | 34,000,000 | 34,000,000 | 38,000,000 | ' | ' | ' | ' | ' |
Amortization of prior service cost (credits) | ' | ' | ' | ' | ' | ' | ' | 3,000,000 | 2,000,000 | 4,000,000 | ' | ' | ' | ' | ' | -35,000,000 | -42,000,000 | -42,000,000 | ' | ' | ' | ' | ' |
Total cost | ' | ' | ' | ' | ' | ' | ' | 355,000,000 | 484,000,000 | 377,000,000 | -206,000,000 | -176,000,000 | 355,000,000 | 278,000,000 | 201,000,000 | 65,000,000 | 101,000,000 | 105,000,000 | -48,000,000 | -49,000,000 | 65,000,000 | 53,000,000 | 56,000,000 |
Net actuarial gains and prior service credits | ' | ' | ' | ' | ' | ' | ' | 995,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net actuarial (gains) losses recognized in other comprehensive income | ' | ' | ' | ' | 167,000,000 | 19,000,000 | ' | ' | 1,200,000,000 | 1,100,000,000 | ' | ' | ' | ' | ' | 201,000,000 | 134,000,000 | -66,000,000 | ' | ' | ' | ' | ' |
Pretax amount included in accumulated other comprehensive income (loss), expected to be recognized in the net period benefit cost in 2014 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Pretax amount of actuarial losses expected to recognized in the net periodic benefit cost in 2014 | ' | ' | ' | ' | ' | ' | ' | -102,000,000 | ' | ' | ' | ' | ' | ' | ' | 37,000,000 | ' | ' | ' | ' | ' | ' | ' |
Pretax amount of prior service cost (credits) expected to recognized in the net periodic benefit cost in 2014 | ' | ' | ' | ' | ' | ' | ' | 2,000,000 | ' | ' | ' | ' | ' | ' | ' | 17,000,000 | ' | ' | ' | ' | ' | ' | ' |
Weighted-average assumptions used to determine benefit obligations | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Discount rate (as a percent) | ' | ' | ' | ' | ' | ' | ' | 4.90% | 4.30% | 5.00% | ' | ' | ' | ' | ' | 4.90% | 4.30% | 5.00% | ' | ' | ' | ' | ' |
Expected aggregate average long term change in compensation (as a percent) | ' | ' | ' | ' | ' | ' | ' | 5.00% | 5.30% | 5.30% | ' | ' | ' | ' | ' | 5.00% | 5.30% | 5.30% | ' | ' | ' | ' | ' |
Weighted average assumptions used to determine the net cost | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Discount rate (as a percent) | ' | ' | ' | ' | ' | ' | ' | 4.20% | 5.00% | 5.40% | ' | ' | ' | ' | ' | 4.20% | 5.00% | 5.40% | ' | ' | ' | ' | ' |
Expected return on plan assets (as a percent) | ' | ' | ' | ' | ' | ' | ' | 7.80% | 8.00% | 7.80% | ' | ' | ' | ' | ' | 7.80% | 8.00% | 7.80% | ' | ' | ' | ' | ' |
Expected aggregate average long-term change in compensation (as a percent) | ' | ' | ' | ' | ' | ' | ' | 5.00% | 5.30% | 5.10% | ' | ' | ' | ' | ' | 5.00% | 5.30% | 5.10% | ' | ' | ' | ' | ' |
Assumed health care cost trend rates | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Health care cost trend rate assumed for the next year (as a percent) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7.00% | 7.00% | 7.00% | ' | ' | ' | ' | ' |
Rate that the cost trend rate gradually declines to (as a percent) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5.00% | 5.00% | 5.00% | ' | ' | ' | ' | ' |
Year that rate reaches the assumed ultimate rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '2019 | '2019 | '2019 | ' | ' | ' | ' | ' |
A one percentage point increase / (decrease) in the assumed health care cost | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Increase in accumulated post employment benefit obligations due to a one percentage point increase in the assumed health care cost | 177,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Decrease in accumulated post employment benefit obligations due to a one percentage point decrease in the assumed health care cost | -146,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Increase in the total of service and interest cost components of net post employment health care cost due to a one percentage point increase in the assumed health care cost | 18,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Decrease in the total of service and interest cost components of net post employment health care cost due to a one percentage point decrease in the assumed health care cost | ($14,000,000) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
PostEmployment_Benefits_Detail1
Post-Employment Benefits (Details 2) (USD $) | 12 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Total benefit payments expected to be paid to participants | ' | ' | ' |
Contribution to Abbott Stock Retirement Plan, defined contribution plan | $86 | $150 | $151 |
Defined Benefit Plans | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 6,123 | 7,949 | 6,961 |
Domestic pension plans funded during the year | 724 | 379 | ' |
Defined benefit plan, expected contributions in future | 400 | ' | ' |
Total benefit payments expected to be paid to participants | ' | ' | ' |
2014 | 186 | ' | ' |
2015 | 198 | ' | ' |
2016 | 213 | ' | ' |
2017 | 229 | ' | ' |
2018 | 249 | ' | ' |
2019 to 2023 | 1,578 | ' | ' |
Domestic defined benefit plan | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plan, expected contributions in future | 300 | ' | ' |
Medical and Dental Plans | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 462 | 417 | 389 |
Domestic pension plans funded during the year | 40 | 40 | ' |
Total benefit payments expected to be paid to participants | ' | ' | ' |
2014 | 71 | ' | ' |
2015 | 73 | ' | ' |
2016 | 74 | ' | ' |
2017 | 76 | ' | ' |
2018 | 77 | ' | ' |
2019 to 2023 | 417 | ' | ' |
U.S. large cap | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
A mix of index funds that track S and P 500 (as a percent) | 60.00% | 50.00% | ' |
Separate actively managed securities that are benchmarked to russell 1000 (as a percent) | 40.00% | 50.00% | ' |
U.S. mid cap | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Mix of index funds investments (as a percent) | 70.00% | 75.00% | ' |
Separate actively managed securities that track and are benchmarked to S and P 400 mid-cap Index (as a percent) | 30.00% | 25.00% | ' |
U.S. government securities | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
A mix of index funds not actively managed (as a percent) | 50.00% | 50.00% | ' |
Separate actively managed accounts (as a percentage) | 50.00% | 50.00% | ' |
Corporate debt instruments | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
A mix of index funds not actively managed (as a percent) | 40.00% | 20.00% | ' |
Separate actively managed accounts (as a percentage) | 60.00% | 80.00% | ' |
Quoted Prices in Active Markets | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 2,378 | 2,661 | ' |
Quoted Prices in Active Markets | U.S. large cap | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 741 | 1,058 | ' |
Quoted Prices in Active Markets | U.S. mid cap | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 134 | 133 | ' |
Quoted Prices in Active Markets | International | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 608 | 657 | ' |
Quoted Prices in Active Markets | U.S. government securities | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 61 | 172 | ' |
Quoted Prices in Active Markets | Corporate debt instruments | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 108 | 355 | ' |
Quoted Prices in Active Markets | Non U.S. government securities | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 305 | 83 | ' |
Quoted Prices in Active Markets | Other, | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 69 | ' | ' |
Quoted Prices in Active Markets | Absolute return funds | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 197 | 85 | ' |
Quoted Prices in Active Markets | Commodities | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 6 | 9 | ' |
Quoted Prices in Active Markets | Other. | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 149 | 109 | ' |
Significant Other Observable Inputs | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 3,652 | 4,922 | ' |
Significant Other Observable Inputs | U.S. large cap | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 877 | 773 | ' |
Significant Other Observable Inputs | U.S. mid cap | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 275 | 358 | ' |
Significant Other Observable Inputs | International | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 711 | 950 | ' |
Significant Other Observable Inputs | U.S. government securities | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 392 | 727 | ' |
Significant Other Observable Inputs | Corporate debt instruments | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 270 | 381 | ' |
Significant Other Observable Inputs | Non U.S. government securities | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 231 | 291 | ' |
Significant Other Observable Inputs | Other, | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 8 | 24 | ' |
Significant Other Observable Inputs | Absolute return funds | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 791 | 1,246 | ' |
Significant Other Observable Inputs | Commodities | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 97 | 172 | ' |
Significant Unobservable Inputs | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 555 | 783 | 682 |
Significant Unobservable Inputs | Absolute return funds | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 486 | 739 | ' |
Significant Unobservable Inputs | Commodities | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 67 | 41 | ' |
Significant Unobservable Inputs | Other. | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 2 | 3 | ' |
Fair value | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 6,585 | 8,366 | ' |
Fair value | U.S. large cap | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 1,618 | 1,831 | ' |
Fair value | U.S. mid cap | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 409 | 491 | ' |
Fair value | International | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 1,319 | 1,607 | ' |
Fair value | U.S. government securities | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 453 | 899 | ' |
Fair value | Corporate debt instruments | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 378 | 736 | ' |
Fair value | Non U.S. government securities | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 536 | 374 | ' |
Fair value | Other, | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 77 | 24 | ' |
Fair value | Absolute return funds | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 1,474 | 2,070 | ' |
Fair value | Commodities | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | 170 | 222 | ' |
Fair value | Other. | ' | ' | ' |
Bases used to measure defined benefit plans assets at fair value | ' | ' | ' |
Defined benefit plans' assets at fair value | $151 | $112 | ' |
PostEmployment_Benefits_Detail2
Post-Employment Benefits (Details 3) (Significant Unobservable Inputs, USD $) | 12 Months Ended | |
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 |
Significant Unobservable Inputs | ' | ' |
Retirement Plans | ' | ' |
Defined benefit plans' assets at fair value | $555 | $783 |
Change in value of assets that are measured using significant unobservable inputs | ' | ' |
Plan assets at fair value, balance at the beginning of the period | 783 | 682 |
Transfers in (out of) from other categories | 6 | 6 |
Separation of AbbVie, Inc. | -165 | ' |
Actual return on plan assets: | ' | ' |
Assets on hand at year end | 29 | 59 |
Assets sold during the year | 51 | -4 |
Purchases, sales and settlements, net | -149 | 40 |
Plan assets at fair value, balance at the end of the period | $555 | $783 |
Taxes_on_Earnings_from_Continu2
Taxes on Earnings from Continuing Operations (Details) (USD $) | 0 Months Ended | 12 Months Ended |
In Millions, unless otherwise specified | Jan. 02, 2013 | Dec. 31, 2013 |
Taxes on Earnings | ' | ' |
Favorable resolution of various tax positions and other unusual provision items | $103 | $234 |
Discontinued operations | AbbVie | ' | ' |
Taxes on Earnings | ' | ' |
Favorable resolution of various tax positions and other unusual provision items | ' | $193 |
Taxes_on_Earnings_from_Continu3
Taxes on Earnings from Continuing Operations (Details 2) (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
item | |||
Taxes on Earnings from Continuing Operations | ' | ' | ' |
Impact of debt extinguishment on domestic loss before taxes | ' | $1,290,000,000 | ' |
Number of items which are not settled in the U.S. | 3 | ' | ' |
Undistributed earnings reinvested indefinitely in foreign subsidiaries | 24,000,000,000 | ' | ' |
Earnings (Loss) From Continuing Operations Before Taxes: | ' | ' | ' |
Domestic | 529,000,000 | -1,515,000,000 | -593,000,000 |
Foreign | 1,992,000,000 | 1,820,000,000 | 1,829,000,000 |
Earnings from Continuing Operations Before Taxes | 2,521,000,000 | 305,000,000 | 1,236,000,000 |
Current: | ' | ' | ' |
Domestic | 16,000,000 | -21,000,000 | -888,000,000 |
Foreign, current tax | 555,000,000 | 979,000,000 | 797,000,000 |
Total current taxes | 571,000,000 | 958,000,000 | -91,000,000 |
Deferred: | ' | ' | ' |
Domestic, deferred tax | -308,000,000 | -572,000,000 | 360,000,000 |
Foreign, deferred tax | -125,000,000 | -660,000,000 | -159,000,000 |
Total deferred taxes | -433,000,000 | -1,232,000,000 | 201,000,000 |
Total Taxes on Earnings from Continuing Operations | 138,000,000 | -274,000,000 | 110,000,000 |
Differences between the effective income tax rate and the U.S. statutory tax rate: | ' | ' | ' |
Statutory tax rate on earnings from continuing operations (as a percent) | 35.00% | 35.00% | 35.00% |
Benefit of lower tax rates and tax exemptions on foreign income (as a percent) | -18.00% | -75.70% | -14.90% |
Resolution of certain tax positions pertaining to prior years (as a percent) | -9.30% | -69.40% | -14.00% |
Effect of retroactive legislation (as a percent) | -4.10% | ' | ' |
State taxes, net of federal benefit (as a percent) | 1.70% | 3.40% | -0.30% |
All other, net (as a percent) | 0.20% | 17.00% | 3.10% |
Effective tax rate on earnings from continuing operations (as a percent) | 5.50% | -89.70% | 8.90% |
Deferred tax assets: | ' | ' | ' |
Compensation and employee benefits | 862,000,000 | 1,936,000,000 | ' |
Other, primarily reserves not currently deductible, and NOL's and credit carryforwards | 2,908,000,000 | 3,278,000,000 | ' |
Trade receivable reserves | 155,000,000 | 557,000,000 | ' |
Inventory reserves | 137,000,000 | 211,000,000 | ' |
Deferred intercompany profit | 274,000,000 | 1,095,000,000 | ' |
State income taxes | 196,000,000 | 197,000,000 | ' |
Total deferred tax assets | 4,532,000,000 | 7,274,000,000 | ' |
Deferred tax liabilities: | ' | ' | ' |
Depreciation | -72,000,000 | -75,000,000 | ' |
Other, primarily the excess of book basis over tax basis of intangible assets | -1,774,000,000 | -2,447,000,000 | ' |
Total deferred tax liabilities | -1,846,000,000 | -2,522,000,000 | ' |
Total net deferred tax assets | 2,686,000,000 | 4,752,000,000 | ' |
Reconciliation of Unrecognized Tax Benefits | ' | ' | ' |
Balance at the beginning of the period | 2,257,000,000 | 2,123,000,000 | ' |
Increase due to current year tax positions | 244,000,000 | 673,000,000 | ' |
Increase due to prior year tax positions | 152,000,000 | 62,000,000 | ' |
Decrease due to prior year tax positions | -541,000,000 | -438,000,000 | ' |
Lapse of statute | -23,000,000 | ' | ' |
Settlements | -124,000,000 | -163,000,000 | ' |
Balance at the end of the period | 1,965,000,000 | 2,257,000,000 | 2,123,000,000 |
Unrecognized tax benefits that would impact effective tax rate | 1,700,000,000 | ' | ' |
Decrease in gross unrecognized tax benefits, lower bound | 350,000,000 | ' | ' |
Decrease in gross unrecognized tax benefits, upper bound | $425,000,000 | ' | ' |
Segment_and_Geographic_Area_In2
Segment and Geographic Area Information (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Millions, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | $5,655 | $5,369 | $5,446 | $5,378 | $5,632 | $5,265 | $5,313 | $5,284 | $21,848 | $21,494 | $21,407 |
Operating Earnings | ' | ' | ' | ' | ' | ' | ' | ' | 2,521 | 305 | 1,236 |
Depreciation | ' | ' | ' | ' | ' | ' | ' | ' | 928 | 1,363 | 1,395 |
Additions to Long-term Assets | ' | ' | ' | ' | ' | ' | ' | ' | 1,906 | 1,985 | 1,675 |
Total Assets | 42,953 | ' | ' | ' | 67,235 | ' | ' | ' | 42,953 | 67,235 | 60,277 |
Other | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 2,577 | 2,549 | 2,604 |
Depreciation | ' | ' | ' | ' | ' | ' | ' | ' | 164 | 661 | 647 |
Additions to Long-term Assets | ' | ' | ' | ' | ' | ' | ' | ' | 982 | 902 | 845 |
Total Assets | 1,181 | ' | ' | ' | 1,167 | ' | ' | ' | 1,181 | 1,167 | 1,148 |
Total Reportable Segments | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 19,271 | 18,945 | 18,803 |
Operating Earnings | ' | ' | ' | ' | ' | ' | ' | ' | 4,415 | 4,102 | 3,951 |
Depreciation | ' | ' | ' | ' | ' | ' | ' | ' | 764 | 702 | 748 |
Additions to Long-term Assets | ' | ' | ' | ' | ' | ' | ' | ' | 924 | 1,083 | 830 |
Total Assets | 11,178 | ' | ' | ' | 11,136 | ' | ' | ' | 11,178 | 11,136 | 11,905 |
Total Reportable Segments | Established Pharmaceutical Products | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 4,974 | 5,121 | 5,355 |
Operating Earnings | ' | ' | ' | ' | ' | ' | ' | ' | 1,182 | 1,237 | 1,254 |
Depreciation | ' | ' | ' | ' | ' | ' | ' | ' | 84 | 156 | 169 |
Additions to Long-term Assets | ' | ' | ' | ' | ' | ' | ' | ' | 128 | 237 | 122 |
Total Assets | 2,637 | ' | ' | ' | 2,805 | ' | ' | ' | 2,637 | 2,805 | 4,348 |
Total Reportable Segments | Nutritional Products | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 6,740 | 6,461 | 5,989 |
Operating Earnings | ' | ' | ' | ' | ' | ' | ' | ' | 1,263 | 1,020 | 792 |
Depreciation | ' | ' | ' | ' | ' | ' | ' | ' | 190 | 175 | 167 |
Additions to Long-term Assets | ' | ' | ' | ' | ' | ' | ' | ' | 340 | 428 | 205 |
Total Assets | 3,518 | ' | ' | ' | 3,211 | ' | ' | ' | 3,518 | 3,211 | 2,939 |
Total Reportable Segments | Diagnostic Products | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 4,545 | 4,292 | 4,126 |
Operating Earnings | ' | ' | ' | ' | ' | ' | ' | ' | 1,008 | 825 | 794 |
Depreciation | ' | ' | ' | ' | ' | ' | ' | ' | 368 | 295 | 313 |
Additions to Long-term Assets | ' | ' | ' | ' | ' | ' | ' | ' | 394 | 349 | 394 |
Total Assets | 3,312 | ' | ' | ' | 3,286 | ' | ' | ' | 3,312 | 3,286 | 3,218 |
Total Reportable Segments | Vascular Products | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 3,012 | 3,071 | 3,333 |
Operating Earnings | ' | ' | ' | ' | ' | ' | ' | ' | 962 | 1,020 | 1,111 |
Depreciation | ' | ' | ' | ' | ' | ' | ' | ' | 122 | 76 | 99 |
Additions to Long-term Assets | ' | ' | ' | ' | ' | ' | ' | ' | 62 | 69 | 109 |
Total Assets | $1,711 | ' | ' | ' | $1,834 | ' | ' | ' | $1,711 | $1,834 | $1,400 |
Segment_and_Geographic_Area_In3
Segment and Geographic Area Information (Details 2) (USD $) | 12 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Segment Reporting Information | ' | ' | ' |
Operating Earnings | $2,629 | $1,894 | $1,629 |
Net loss on extinguishment of debt | ' | -1,351 | ' |
Amortization of intangible assets | -791 | -795 | -884 |
Earnings from Continuing Operations Before Taxes | 2,521 | 305 | 1,236 |
Segment assets: | ' | ' | ' |
Current deferred income taxes | 2,528 | 2,986 | 2,701 |
Total Assets | 42,953 | 67,235 | 60,277 |
Total Reportable Segments | ' | ' | ' |
Segment Reporting Information | ' | ' | ' |
Operating Earnings | 4,415 | 4,102 | 3,951 |
Earnings from Continuing Operations Before Taxes | 4,415 | 4,102 | 3,951 |
Segment assets: | ' | ' | ' |
Total Assets | 11,178 | 11,136 | 11,905 |
Corporate functions | ' | ' | ' |
Segment Reporting Information | ' | ' | ' |
Corporate functions and benefit plans costs | -514 | -598 | -529 |
Reconciling items | ' | ' | ' |
Segment Reporting Information | ' | ' | ' |
Operating Earnings | 423 | 443 | 457 |
Net interest expense | -90 | -288 | -294 |
Net loss on extinguishment of debt | ' | -1,351 | ' |
Share-based compensation | -262 | -284 | -256 |
Amortization of intangible assets | -791 | -795 | -884 |
Other, net | -660 | -924 | -1,209 |
Separation related costs and cost reduction initiatives and integration | 350 | 430 | 240 |
Segment assets: | ' | ' | ' |
Cash, investments and restricted funds | 8,217 | 15,448 | 8,476 |
Current deferred income taxes | 2,528 | 2,986 | 2,701 |
Goodwill and intangible assets | 15,507 | 24,362 | 25,695 |
All other | $4,342 | $12,136 | $10,352 |
Segment_and_Geographic_Area_In4
Segment and Geographic Area Information (Details 3) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Millions, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | $5,655 | $5,369 | $5,446 | $5,378 | $5,632 | $5,265 | $5,313 | $5,284 | $21,848 | $21,494 | $21,407 |
Long-term Assets | 23,705 | ' | ' | ' | 35,912 | ' | ' | ' | 23,705 | 35,912 | 36,508 |
United States | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 6,269 | 6,349 | 6,302 |
Long-term Assets | 7,884 | ' | ' | ' | 15,244 | ' | ' | ' | 7,884 | 15,244 | 15,867 |
Japan | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 1,442 | 1,723 | 1,726 |
Long-term Assets | 902 | ' | ' | ' | 1,169 | ' | ' | ' | 902 | 1,169 | 1,225 |
Germany | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 1,070 | 984 | 1,058 |
Long-term Assets | 1,040 | ' | ' | ' | 6,173 | ' | ' | ' | 1,040 | 6,173 | 5,909 |
The Netherlands | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 960 | 1,107 | 1,204 |
Long-term Assets | 560 | ' | ' | ' | 532 | ' | ' | ' | 560 | 532 | 462 |
China | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 1,083 | 859 | 625 |
Long-term Assets | 356 | ' | ' | ' | 259 | ' | ' | ' | 356 | 259 | 127 |
India | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 922 | 919 | 917 |
Long-term Assets | 3,080 | ' | ' | ' | 3,467 | ' | ' | ' | 3,080 | 3,467 | 3,160 |
Brazil | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 470 | 448 | 470 |
Long-term Assets | 216 | ' | ' | ' | 200 | ' | ' | ' | 216 | 200 | 186 |
Switzerland | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 792 | 693 | 591 |
Long-term Assets | 1,117 | ' | ' | ' | 1,214 | ' | ' | ' | 1,117 | 1,214 | 1,045 |
Canada | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 734 | 753 | 652 |
Long-term Assets | 368 | ' | ' | ' | 352 | ' | ' | ' | 368 | 352 | 237 |
Italy | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 726 | 719 | 761 |
Long-term Assets | 100 | ' | ' | ' | 222 | ' | ' | ' | 100 | 222 | 229 |
France | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 680 | 667 | 781 |
Long-term Assets | 213 | ' | ' | ' | 220 | ' | ' | ' | 213 | 220 | 214 |
Russia | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 525 | 485 | 427 |
Long-term Assets | 30 | ' | ' | ' | 37 | ' | ' | ' | 30 | 37 | 21 |
Spain | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 413 | 417 | 447 |
Long-term Assets | 326 | ' | ' | ' | 314 | ' | ' | ' | 326 | 314 | 293 |
United Kingdom | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 479 | 497 | 4,751 |
Long-term Assets | 1,380 | ' | ' | ' | 1,345 | ' | ' | ' | 1,380 | 1,345 | 1,273 |
All Other Countries | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales to External Customers | ' | ' | ' | ' | ' | ' | ' | ' | 5,283 | 4,874 | 4,971 |
Long-term Assets | $6,133 | ' | ' | ' | $5,164 | ' | ' | ' | $6,133 | $5,164 | $6,260 |
Quarterly_Results_Unaudited_De
Quarterly Results (Unaudited) (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Millions, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Quarterly Results (Unaudited) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Sales | $5,655 | $5,369 | $5,446 | $5,378 | $5,632 | $5,265 | $5,313 | $5,284 | $21,848 | $21,494 | $21,407 |
Gross Profit | 2,844 | 2,722 | 2,704 | 2,747 | 2,837 | 2,581 | 2,748 | 2,716 | ' | ' | ' |
Earnings (loss) from Continuing Operations | 589 | 773 | 476 | 545 | -522 | 339 | 411 | 351 | 2,383 | 579 | 1,126 |
Basic Earnings per Common Share | $0.38 | $0.50 | $0.30 | $0.35 | ($0.33) | $0.21 | $0.26 | $0.22 | $1.52 | $0.36 | $0.72 |
Diluted Earnings per Common Share | $0.37 | $0.49 | $0.30 | $0.34 | ($0.33) | $0.21 | $0.26 | $0.22 | $1.50 | $0.36 | $0.72 |
Net Earnings | $589 | $966 | $476 | $545 | $1,053 | $1,943 | $1,725 | $1,242 | $2,576 | $5,963 | $4,728 |
Basic Earnings Per Common Share (in dollars per share) | $0.38 | $0.62 | $0.30 | $0.35 | $0.66 | $1.22 | $1.09 | $0.79 | $1.64 | $3.76 | $3.03 |
Diluted Earnings Per Common Share (in dollars per share) | $0.37 | $0.61 | $0.30 | $0.34 | $0.66 | $1.21 | $1.08 | $0.78 | $1.62 | $3.72 | $3.01 |
Low | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Quarterly Results | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Market Price Per Share | $32.75 | $32.70 | $34.69 | $31.64 | $29.96 | $30.39 | $28.25 | $25.82 | $32.75 | $29.96 | ' |
High | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Quarterly Results | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Market Price Per Share | $38.81 | $37.16 | $38.77 | $35.34 | $34.67 | $33.69 | $30.85 | $29.42 | $38.81 | $34.67 | ' |
Recovered_Sheet1
Schedule II Valuation and Qualifying Accounts (Details) (Allowance for Doubtful Accounts, USD $) | 12 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Allowances for Doubtful Accounts | ' | ' | ' |
Balance at Beginning of Year | $406 | $421 | $389 |
Provisions/Charges to Income | 163 | 343 | 430 |
Amounts Charged Off and Other Deductions | -257 | -358 | -398 |
Balance at End of Year | 312 | 406 | 421 |
AbbVie | ' | ' | ' |
Allowances for Doubtful Accounts | ' | ' | ' |
Amounts Charged Off and Other Deductions | ($178) | ' | ' |